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Chronic low back pain is a global socioeconomic crisis compounded by an
absence of reliable, curative treatments. The predominant pathology associated with
chronic low back pain is degeneration of intervertebral discs in the lumbar spine. During
degeneration, nerves can sprout into the intervertebral disc tissue and be chronically
subjected to inflammatory and mechanical stimuli, resulting in pain. Pain arising from the
intervertebral disc, or disc-associated pain, is a complex, multi-faceted disorder which
necessitates valid animal models to screen therapeutics and study pathomechanisms of
pain.
While many research teams have created animal models of disc degeneration, the
translation of these platforms to disc-associated pain models has been limited by an
absence of chronic pain-like behavior. Further, the few models which measure discassociated pain-like phenotypes have been established in mice, which are not amenable to
surgical treatment procedures due to their small size. This deficiency drives the need for a
new model of disc-associated pain where pain-like behavior is measurable and
intervertebral discs are large enough for surgical procedures. These criteria promote rats
as the optimal platform for a disc-associated model of chronic low back pain.

Herein, a rat model of disc-associated pain is described that displays chronic painlike behavior, overt disc degeneration, and nerve sprouting in the intervertebral disc. In
addition to the model, a novel method for measuring disc degeneration real-time, noninvasively, is delineated which exhibits remarkable precision and accuracy. Finally, a
next generation treatment, derived from decellularized, porcine nucleus pulposus tissue is
described which is injectable, thermally fibrillogenic, and cytocompatible. In the rat
model of disc-associated pain, this biomaterial restores degenerated disc volume and
dramatically decreases pain-like behavior.
In summary, this dissertation describes the development of a method for
quantifying degeneration real-time, establishes a rat model of disc-associated pain, and
successfully treats disc-associated pain in this model with a next-generation biomaterial.
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CHAPTER 1: Introduction
1.1 Preface
This dissertation describes the development of an animal model and therapeutic
for disc-associated low back pain. To motivate and contextualize this work, the
introduction begins with pain, as pain is the salient factor that drives the need for a
therapy. Without pain, no patient would enter the clinic seeking a treatment.

1.2 Pain
The International Association for the Study of Pain (IASP) defines pain as an
unpleasant sensory and emotional experience associated with, or resembling that
associated with, actual or potential tissue damage [4]. Pain is part of the human
experience and assists in weighing, alerting, avoiding and correcting actions that can lead
to harm. Despite being variable and individualized, pain duration is diagnostically broken
into two categories: acute and chronic. Acute pain is directly linked with tissue damage,
inflammation, and the wound healing process [5]. This type of pain is essential for
evolutionary survival to avoid danger and facilitate healing.

1.3 Chronic Pain
Chronic pain, or pain which outlasts the wound healing window, contains little
evolutionary value, and can be viewed as a disease itself [5]. While there is not complete
consensus, generally, pain that exists past the expected healing period (~three months in
humans) is categorized as chronic pain [5]. Chronic pain afflicts 20% of people
worldwide, imposing a tremendous burden on humankind [5]. In 2010, it was estimated
that chronic pain costs the United States $560 - $635 billion each year due to health care
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expenditures, days of work missed, hours of work lost, and lower wages [6]. This
immense cost exceeds the economic burden of cancer and heart disease combined [7]. A
partial explanation for the immense cost is that chronic pain encompasses a myriad of
disorders ranging from irritable bowel syndrome to chronic low back pain [5]. However,
the majority of pain burden resides in a few top contributors.

1.4 Chronic Low Back Pain
For the last three decades, chronic low back pain (cLBP) has been the leading
cause of chronic pain [8-10]. Additionally, cLBP accounts for the greatest number of
years lived with disability across all diseases according to the US Burden of Disease
Collaborators [11]. Chronic low back pain is defined as pain and discomfort, localized
between the bottom of the ribs and the crease of the buttocks, with or without leg pain,
that persists beyond three months [12, 13]. This type of chronic pain can range in
intensity from a mild nuisance to complete debilitation. The pain and debilitation of those
who suffer cLBP imposes costs on society at the individual and economic level.

1.5 Costs of Chronic Low Back Pain
The economic cost of cLBP cannot be understated, with estimates ranging from
$19.6 - $118.8 billion a year in direct and indirect costs [6]. Direct costs of cLBP include,
physician services, medical devices, medications, hospital services, diagnostic testing,
etc. Indirect costs of cLBP include all costs that do not involve monetary transactions but
are a result of the cLBP. Examples of indirect costs include work absenteeism, decreased
productivity, household caretaking, etc. [14].
Also not to be understated, is the burden of cLBP on those afflicted. A study
performed in 2013 indicates patients which develop chronic low back pain display
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remarkable increases in self-reported anxiety, depression, and stress [15]. Furthermore,
those suffering cLBP report harmful effects on their exercise, sex life, social life, work
relationships, and family relationships [16, 17]. Many studies have also reported
tangential findings including decreased sleep quality and increased suicide in patients
with cLBP [18-21].
Altogether, cLBP imposes costs on society that must be remedied. Part of the
difficulty in treating patients with cLBP is that the pain can arise from multiple sources in
the low back. This multifactorial nature of cLBP has led researchers to further explore
low back skeletal structures in hopes of finding reoccurring sources of pain.

1.6 Etiology of Chronic Low Back Pain
In theory, any innervated structure of the low back is a potential source of cLBP.
This knowledge has led research teams to identify fundamental structural sources of pain
in hopes of developing therapies for each unique etiology. In the past 20 years,
considerable effort has discovered that cLBP in humans arises from pathologies in three
types of joints: intervertebral discs (IVDs),
facet joints, and sacroiliac joints (Fig. 1) [22].
According to these studies, IVDs, facet joint,
and sacroiliac joints account for 39%, 15-32%,
and 13-18.5% of cLBP prevalence, respectively

Figure 1. Sources of low back
pain

[23-25]. Observing that the IVD is the strongest
associative factor with cLBP, it also represents
the therapeutic target with largest potential
impact if addressed.

Figure 1. Sources of chronic low back pain

4

1.7 Disc-associated Pain
CLBP arising from the IVD is associated with many research and clinical terms.
These terms include, discogenic pain, degenerative disc disease, painful IVD
degeneration (IDD), and disc-associated pain. For the purpose of this dissertation, chronic
pain associated with changes in, or arising from, the IVD will be referred to as discassociated pain.
In humans, disc-associated pain is notoriously
difficult to diagnose. Clinically it can manifest in a few
different phenotypes. The three primary manifestations
of disc-associated pain are radicular, non-specific, and
axial cLBP (Fig. 2) [26].

Figure 2. Types of
chronic low back pain

Radicular cLBP is the most debilitating form
and can involve motor deficits [27]. In most cases,
radicular cLBP is caused by nerve root compression
as a consequence of IVD degeneration [28].

Figure 2. Types of chronic low back
pain

Non-specific cLBP is cLBP that cannot be attributed to a recognizable pathology
[29]. This type of pain is the most difficult to address through a causal approach because
it occurs in variable regions of the body and can diminish and increase in intensity.
Despite this definition, research groups have reported that disc degeneration increases the
odds of presenting with non-specific cLBP by 2.18 [30]. Further, some patients that
exhibit non-specific low back pain respond to procedures which alter the IVD, suggesting
the IVD can be a source [31, 32].
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Axial low back pain is the most common type of cLBP and is defined by pain that
only localizes to the low back and occurs in a patient identifiable region on the body [33].
Axial pain is easier to treat than non-specific cLBP because pain production is
localizable, and the cause can often be estimated. This type of pain worsens with certain
activities like running and even at rest if an incorrect postural position is maintained [34].
Research involving 3097 individuals has indicated that disc degeneration, as measured by
magnetic resonance imaging (MRI), increases the odds of self-reported low back pain by
2.24, implicating the IVD as a reoccurring source of pain [35].
The aforementioned pain conditions comprise the three main clinical
manifestations of disc-associated low back pain. It should again be noted that these
clinical manifestations can be indicative of disc-associated pain but are not guaranteed to
be. For example, radicular low back pain can be caused by zygapophyseal joint damage,
non-specific pain by osteoporosis, and axial pain by ligament tears [22, 23].
The work detailed in this dissertation focuses on axial low back pain which
originates in IVD tissue. This type of disc-associated pain is thought to arise from
nerve fibers which aberrantly sprout into degenerated IVD tissue. It should also be
noted that the term “disc-associated pain” is not used clinically but rather is a
scientific term used as a descriptor of the pain source, rather than the clinical pain
phenotype.

1.8 How Disc-associated Pain is Diagnosed
Disc-associated low back pain was first described in 1970 by H.V. Crock [36]. In
this seminal work, Crock described clinical features like deep-seated and dull aching
back pain, referred pain, decreased physical activity, and restricted spinal movement as
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characteristics of disc-associated pain. These observations hold true today and are often
first line indicators a patient is experiencing disc-associated cLBP.
Today, patients which enter the clinic complaining of low back pain may be asked
to complete various pain, functional and IVD morphological assessments to ascertain a
diagnosis. The first and most important data collected at the clinic are body maps which
allow a patient to describe the location and duration of pain. Body maps have become
increasingly important in the last few years with the emphasis on individualized treatment
[37]. Additionally, cLBP patients may be asked to complete questionnaires which
measure various impacts of cLBP [38, 39]. These questionnaires assess both the intensity
and location of pain and how the pain affects life activities like socialization,
employment, etc. Functional tests employ static and dynamic measures of trunk muscle
activation during movement to quantify trunk strength, flexibility, and endurance. These
aspects of the trunk are measured because they are known to be impaired for many
people with chronic low back pain [40-42]. The most widely used method for evaluating
patient IVD morphology in the clinic is imaging via MRI [35]. This assessment is
performed to determine if spinal changes, especially IVD degeneration, are present and
could be a source of pain. MRI images are used to determine degenerative changes in the
IVD by identifying abnormalities like a loss of nuclear signal, decreased disc height,
high-intensity zones, and changes in disc contours. Interestingly, not all patients that
exhibit overt signs of disc degeneration suffer cLBP [35]. This simple fact makes a
diagnosis of disc-associated pain based on functional, self-reported, and IVD
morphological data clinically inadequate.
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Should patients screen positively across functional, self-reported, and IVD
morphological measures of cLBP, further diagnosis may be pursued to determine if the
IVD is the source of pain. Four associations have created diagnostic criteria for discassociated pain [43]. All associations require intradiscal provocation for a diagnosis
except for the IASP which permits anesthetization of the target disc as an alternate means
of identifying the disc as the pain source. Intradiscal provocation requires insertion of a
probe into the disc and injection of a contrast or pressure inducing agent to evoke pain
concordant with the patient experienced low back pain. However, in recent years, this
method has come under increased scrutiny because it introduces an annular tear, which is
known to disrupt the function of the disc and may accelerate IVD degeneration [44, 45].
Thus, the majority of patients who experience chronic pain caused by IVD degeneration
are diagnosed with axial or non-specific low back pain rather than disc-associated pain
because the source cannot be directly identified.

1.9 How Disc-associated Pain is Treated
For patients diagnosed with disc-associated pain and those suffering chronic low
back pain suspected to be disc-associated, four different treatment modalities can be used
to alleviate suffering. These four interventions come in the form of non-steroidal antiinflammatory drugs (NSAIDs), non-pharmacological treatments, opioids, and surgery.
NSAIDs are the first-line drug option for patients suffering disc-associated pain
because of their low potential for abuse, tolerability, and cost [46]. Further, these drugs
work systemically, increasing the chance they have to affect the patient pain state should
the pain be non-specific. NSAIDs are anti-inflammatory drugs that exert their effect by
inhibiting cyclooxygenase-1 and/or 2 (COX-1 and COX-2) [47]. In the context of disc-
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associated pain, NSAIDs indirectly suppress the activation thresholds of pain-sensing
nerve fibers in and around the degenerated IVD. For acute alleviation of low back pain,
over-the-counter drugs like aspirin, and acetaminophen are commonly recommended
[48]. Should these NSAIDs fail, selective COX-2 inhibitors like diclofenac, piroxicam,
meloxicam, and celecoxib can be prescribed [49]. COX-2 inhibitors can be administered
at higher effective doses than unselective NSAIDs because they pose less risk for
gastrointestinal bleeding and other side effects. Unfortunately, all NSAIDs are palliative
fixes for low back pain and eventually result in gastrointestinal toxicity when chronically
administered. Due to this limitation, NSAIDs are recommended only for short treatment
and at the lowest dose possible.
Non-pharmacological treatments may also be employed as first-line treatments for
chronic low back pain. Non-pharmacological treatments for cLBP include acupuncture,
exercise therapy, back schools, massages, behavioral management, physical therapy, and
more [50]. Unfortunately, systematic reviews have indicated that only highly managed,
combinatorial non-pharmacological treatments, like biopsychosocial rehabilitation can
have any effect on the management of low back pain [51, 52]. However, because these
treatments are non-invasive, cheap and have shown efficacy in combination with drug
treatments like NSAIDs, they are still recommended as a first course of treatment [53].
If pain persists despite non-pharmacological and NSAID treatments, opioids may
also be prescribed for cLBP. This class of drug has the most powerful analgesic capacity
and is widely used for treatment of severe pain [54]. Opioids include morphine, fentanyl,
oxycodone, hydrocodone, and more. All opioids exert their effect by acting on G proteincoupled receptors in the central and peripheral nervous system [55]. In this manner,
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opioids act as pain signal modulators rather than direct actors like NSAIDs [56]. Opioids
can be effective in treating disc-associated low back pain in the short-term, allowing
patients to experience immediate alleviation after treatment [57, 58]. However, like
NSAIDs, opioids are not recommended for long term treatment of pain. Opioid
prescription is avoided because these drugs have high potential for abuse and are the
single cause of the opioid crisis, which has plagued the United States for the last two
decades. In 2015 alone, 30,000 U.S. citizens died from opioid overdose [59]. For this
reason, physicians have become increasingly wary of prescribing opioids for any type of
chronic pain, especially low back pain.
The last-line option for patients suffering disc-associated cLBP is surgical
intervention and is particularly common for disc-associated radicular cLBP. The
predominant surgical procedure applied to treat disc-associated low back pain is surgical
fusion [50, 60, 61]. In 2014 alone, 347,102 spinal fusions surgeries were completed [62].
Fusion surgeries operate on two paradigms, either inducing spinal fusion between spinal
facets using autologous bone or by removing degenerated IVD tissue and fusing the IVD
space with a spacer and autologous bone [63]. Both options are highly invasive and
ramifications include fusion failure, increased chronic pain, adjacent spinal segment
degeneration, infection, etc. [64]. Despite potential complications, interbody fusions have
risen as the gold standard for treating chronic disc-associated pain that does not respond
to other therapies [50].
In summary, treatments for disc-associated pain that are non-invasive are
inadequate long-term and invasive treatments predispose patients to a myriad of surgical
complications and do not consistently alleviate pain. With this knowledge, a new
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generation of therapeutics will be necessary for effective long-term treatment of this
disorder. To understand what treatments could be viable, it is crucial to understand the
anatomy of the IVD in a healthy and degenerated state.

1.10 Anatomy of the Intervertebral Disc
The IVD is a tripartite organ composed of a nucleus pulposus, annulus fibrosus
and two end plates (Fig. 3). The nucleus pulposus (NP) sits at the core of the IVD and is
circumferentially enwrapped by the annulus fibrosus (AF), both of which interface with
adjacent vertebral bodies on the top and bottom through cartilaginous end plates (CEPs).
The interplay between these constituents allows the IVD to function as a dynamically
responsive viscoelastic spacer between vertebral bodies, providing rotational and
translational freedom to the spine.
The core of the disc, the
nucleus pulposus, forms from the

Figure 3. Overview of a healthy IVD

notochord during embryogenesis and
in a healthy state is entirely aneural
and avascular [65]. At birth, the NP
is highly cellularized, but by late

Figure 3. Overview of a healthy IVD

adulthood the NP exhibits sparce cellularity [65]. The low cell density is thought to result
from an absence of vasculature in the NP, which limits nutrient and oxygen abundance as
the tissue grows [66]. In fact, adult NP cells contain few mitochondria, implying they rely
almost entirely on anaerobic pathways to generate energy [67]. To maintain the structure
of the NP, resident NP cells produce proteoglycans rich with glycosaminoglycans
(GAGs), and collagen I and II [65]. Attached to a core protein backbone,
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glycosaminoglycans (GAGs) like chondroitin sulfate, dermatan sulfate, heparan sulfate,
and keratan sulfate comprise 30-50% of the NP dry weight [65]. These GAGs attract
water into the NP matrix because they are strongly polar and negatively charged. This
characteristic of GAGs causes immense swelling pressure in the NP allowing it to retain
water and resist compressive loading [68, 69]. Furthermore, GAGs in the NP, like
chondroitin sulfate, impart neuroinhibitory properties, disallowing nerves to aberrantly
grow into the NP tissue [70]. In addition to GAGs, the NP contains collagen II along with
lesser amounts of collagen IX and XI. Collagenous proteins account for 20% of the NP
dry weight [65]. These proteins form the basis of the NP extracellular matrix and provide
anchoring points for proteoglycans.
The annulus fibrosus compliments the NP by exhibiting remarkable elasticity and
resistance against radial expansion. The AF is a highly organized structure, containing
concentric rings of collagen that alternate at 30-degree angles to form a cylindrical-like
ply structure that enwraps the NP [65]. The AF can be functionally split into two regions,
the inner and the outer AF. The inner AF has large amounts of collagen I and II and
interfaces with the NP and cartilaginous endplates. During compressive loading, the inner
AF is predominantly subjected to compressive loads [65]. The outer AF is mainly
composed of collagen I and is innervated and vascularized in its outermost layers [71]
Under compressive loading, the inner AF is subjected to radial tensile stress as the NP
and inner AF expand within its boundaries [65]. In a relaxed state, collagenous fibers in
the outer AF appear as wavy or crimped and provide little resistance to motion [65].
However, in a strained state, collagenous fibers of the outer AF straighten and resist
further displacement. This characteristic of the outer annulus fibrosus imparts
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extraordinary rotational freedom while robustly disallowing motion that would be
damaging.
The IVD is capped on the caudal and cephalic ends by cartilaginous end plates.
The CEPs are thin sheets of hyaline cartilage that interface the NP and inner AF with
vertebral bone [65]. The CEPs are cellularized by chondrocytes which maintain the
collagen II and aggrecan-rich extracellular matrix [65]. At birth, blood vessels may
traverse from the adjacent vertebra into the CEPs, providing a heavy supply of nutrients
[65]. With age, these vessels disappear which has led researchers to hypothesize that this
change is involved with the dramatic decline in NP cellularity with age [72]. With or
without the presence of vasculature, the core function of the CEP is to permit diffusion of
nutrients to the NP through channels in its central region.

1.11 Mechanics of the Intervertebral Disc
The primary function of the IVD is to provide
rotational and translational degrees of freedom to the
spine. In a relaxed state, the abundant GAGs in the NP
impart a continuous swelling pressure which produces
axial and radial strain which must be countered by the
AF to maintain function [73]. In the simplest sense, the

Figure 4. Overview of spinal mobility
permitted by the IVD

NP can be thought of as a partially squeezed sponge in a
sink of water and the AF as rubber bands which wrap the
sponge and keep it from completely rehydrating.
As part of loading, the IVD is subjected to

Figure 4. Overview of spinal mobility
permitted by the IVD.

compression, flexion, extension, and torsion (Fig. 4). The IVD experiences significant
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compressive pressure in all upright activities [74]. During a compression event, the NP is
pressurized and immediately expands radially. As a compensatory mechanism for the
expanding NP, the outer AF then bulges outward and the collagen fibers in the lamellae
sheets straighten and align to provide equal and opposite resistance. When loading is
prolonged and exceeds the swelling pressure of the NP, water may gradually exude from
the NP. As the NP depressurizes due to water loss, it loses its ability to bear load,
subjecting the AF to compressive forces which can be deleterious [65]. However, some
NP depressurization is part of the healthy functioning of the IVD as it facilitates diurnal
nutrient cycling by allowing the NP to pull in nutrient laden water at rest, during sleep
[65].
IVDs of the spine are subjected to flexion and extension any time the spine is not
in a neutral, well-aligned, position [65]. Contrasting pure compressive loading, where the
AF expands radially to resist the expansion of the NP, flexion and extension result in
asymmetric AF loading patterns. For example, during an exercise that involves spinal
extension, the posterior AF is compressed while the anterior AF is in tension. Likewise,
during lateral bending, the side of AF in the direction of the bending is subjected to
compressive pressures while the side opposite to the bending is subjected to tension. It
should be acknowledged that the IVD exhibits a remarkable capacity to bear spinal
loading in these abnormal states. For instance, in the case of a moderate deadlift (200 –
350 lbs.), lumbar IVD are subjected to axial compressive loading in excess of 1,500
pounds, shear loading in excess of 330 pounds, and internal pressures which can exceed
2000 pounds per square inch i.e., commensurate with a pressure washer [75-77].
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The final important mechanical characteristic of the IVD is its rotational freedom
[65]. Torsion is imparted on the IVD during twisting motion of the trunk. When
quantifying torsional mechanics of the spine, it is easier to understand when speaking
about spinal motion segments, i.e., the IVD and two adjacent vertebral bodies. The
maximum rotational freedom of individual motion segments is 1°–3° [65]. While this
may not seem sufficient to allow the trunk rotational freedom experienced by most
humans, the presence of multiple motion segments at the cervical, thoracic, and lumbar
spinal levels endow the spine with significant overall rotational freedom [78]. Similar to
compressive loading, the annulus fibrosus is ultimately responsible for resisting normal
and deleterious strains via alignment and elongation of collagenous fibers in the lamellae.
In summary, healthy IVDs display incredible mechanical properties, permitting
compression, flexion, extension, and torsion of the spine. Without IVDs, the spine would
be completely rigid and would be incompatible with essentially all movement associated
with natural human mobility. However, spinal stability and mobility are not maintained
by the presence of IVD tissue alone. Ample nerve supply in the outer AF and surrounding
ligaments is required for coordinating musculature control over the spine and monitoring
the health of the disc.

1.12 Innervation of the Intervertebral Disc
In general, the IVD is described as both avascular and aneural [65]. In reality
however, the healthy IVD is innervated and vascularized in the outermost rings of the AF
[71]. The majority of nerves in the disc are nociceptive, i.e., they are nociceptors, which
means they are responsible for initiating signals to the brain which manifest as pain [79].
To understand how disc-associated pain develops, it is vital to understand where nerves
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in the disc originate from, how they behave, how they can change, and how nociception
becomes pain.

1.13 Neuroanatomy of Dorsal Root Ganglia
Nerves in the IVD predominantly originate from dorsal root ganglia [80, 81].
Dorsal root ganglia (DRG) are spherical clusters of neuronal and support cells which
exist bilaterally at each level of the spine [82]. These clusters represent the junction
between the central and peripheral nervous system. The core function of the DRG is to
transmit and modulate sensory information from the periphery to the central nervous
system where it is further processed and propagated to the brain [82]. The predominant
type of neuron found in the DRG is a pseudounipolar sensory neuron, meaning a single
axon extends from the cell body and bifurcates into a dendritic end, which extends to a
peripheral site, and
an axonic end,
which inserts into

Figure 5. Overview of DRG anatomy and innveration

the dorsal horn of
the spinal cord

Figure 5. Overview of DRG anatomy and innervation

(Fig. 5) [83]. In general, all DRG sensory neurons functionally behave according to the
same paradigm. In this paradigm, the dendritic end exists in a peripheral site where it can
detect a specific set of stimulants like chemicals, heat, vibration etc. When a stimulant
exceeds a certain threshold, an action potential is initiated and propagates to the axonic
end where it is detected by interneurons in the spinal cord [84]. This all or nothing
response allows neurons to effectively transmit sensory information from peripheral
tissue to the central nervous system. DRG neurons can come in multiple phenotypes,
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tailored for detecting different types of sensory information. These phenotypes include
large neurons, intermediate neurons, small non-peptodergic neurons, and small
peptodergic neurons [79].
Large neurons facilitate conscious and subconscious processing of joint
positioning or proprioception [85]. For the spine, this perception is critical to coordinate
proper musculature control.
Intermediate neurons are a subset of DRG neurons that are mechanosensitive [79].
While generally only responsive to vibration and touch, in the disc these neurons serve as
pain sensing fibers for harmful mechanical stimuli that can result in permanent tissue
damage [86]. Additionally, these fibers have demonstrated capacity to phenotypically
switch and express substance P (SP), which can contribute to inflammatory pain
hypersensitivity [87].
Small non-peptodergic neurons are a subset of sensory neurons that respond to
noxious chemical and mechanical stimuli, especially under inflammatory conditions [79,
88, 89]. These neurons are primarily responsive to mechanical stimuli although they have
been shown to increase their responsiveness by 4-fold to noxious chemical stimuli after
inflammation is induced [88, 90]. Also, the presence of P2X purinoceptor 3 (P2X3), a
receptor for adenosine triphosphate (ATP), on these neurons implicates them in the
sensation of tissue damage because cells release physiologically high concentrations of
ATP under acute and inflammatory stress [91].
Small peptodergic neurons, which utilize small signaling peptides like calcitonin
gene-related peptide (CGRP) and substance P (SP), comprise the majority of nociceptors
that involve pain signaling as well as the majority of nociceptors in the IVD [79]. These
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nociceptors can be responsive to either heat, cold, mechanical, chemical or a combination
of stimulants [92]. In the IVD, peptodergic neurons are the primary source of
inflammatory pain because they dynamically interact with the inflammatory milieu [93].
Additionally, the peptides released by this neuronal subclass are known to act as
inflammatory agents implicating them as part of the causal loop in disc-associated cLBP
[94, 95].
In sum, nerve fibers in the disc which contribute to disc-associated pain are small
diameter fubers, especially small diameter peptodergic neurons. These nerve fibers can
be activated by a wide range of stimulants and their signaling can be further augmented
by a phenomenon known as sensitization.

1.14 Sensitization of Dorsal Root Ganglia Neurons
Regardless of the neuronal subclass, all sensory neurons can have their activity
modulated by a phenomenon called sensitization [96, 97]. Under the sensitization
paradigm, neurons break from “same stimulus-same response” behavior and dramatically
alter their activity. When sensitized, nociceptive neurons may lower firing thresholds,
increase receptive fields, phenotypically switch their stimulant response profiles,
spontaneously activate, and increase firing amplitude [96, 97]. The primary factors which
drive sensitization are chemical mediators released by cells around neuronal fibers and
cell bodies. These mediators include, but are not limited to, ATP, PGE2, nerve growth
factor (NGF), macrophage colony stimulating factor (M-CSF), interleukin-6 (IL-6),
interleukin-1β (IL-1β), tumor necrosis factor alpha (TNF-α), CGRP, and SP [97].
Sensitization via these factors can occur in various manners including phosphorylation of
signal amplifier molecules, increasing ion channel transcription, and increasing ion
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channel externalization [98]. Regardless of the way which sensitization is produced, the
end result is a dramatic increase in responsiveness to stimulants. Nociceptor
hypersensitivity caused by sensitization is thought to be a key source of chronic pain
[99].

1.15 How Nociception and Sensitization Produce Pain
As defined by the IASP, pain requires emotional processing. For this reason, pain
and nociception are distinct from each other. Nociception strictly relates to the neural
detection of a stimulus that, if eventually passed into the brain, would result in pain.
Similarly, sensitization does not indicate an amplified pain state. The analogous verbiage
for cognitively manifested sensitization is pain hypersensitivity. For disc-associated axial
cLBP, pain is thought to arise from sensitized nociceptors in and around degenerated disc
tissue.

1.16 Degeneration of Intervertebral Discs
In a healthy state, IVDs are not sources of nociception nor pain due to their sparse
innervation. Unfortunately, in all humans, IVDs do not remain in a healthy state over the
course of life. Intrinsic healing mechanisms like the innate immune response are illequipped at repairing such a complex and isolated tissue like the IVD [100]. On account
of this, IVDs, especially those in the low back, suffer overt degeneration over the human
life span (Fig. 6).
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1.17 Pathophysiology of Intervertebral Disc Degeneration
IVD degeneration onset can
result from natural aging or trauma and
can be accelerated by environmental and
genetic factors like smoking and
collagen gene polymorphisms,

Figure 6. Overview of a healthy and degenerated
IVD

respectively [101-103]. Irrespective of
the exact cause, degeneration onset is
typified by metabolic and mechanical
stresses on disc cells, incompatible with
tissue homeostasis that result in
inflammation. Evaluation of human IVD
tissue throughout the human lifespan

Figure 6. Overview of a healthy and degenerated IVD

has implicated TNF-α to be the primary initiator of disc degeneration [104]. This
canonical pro-inflammatory cytokine and its cognate receptors are expressed in healthy
IVD tissue and are upregulated with age and degree of degeneration [105]. Interestingly,
multiple research groups have suggested that TNF-α is not the key cytokine in
degenerative signaling but rather stimulates the production of IL-1β which is the master
regulator of IVD catabolism [104, 106-108]. IL-1β facilitates production of inflammatory
cytokines like IL-6, interleukin-17 (IL-17), interleukin-8 (IL-8), interleukin-2 (IL-2), and
interferon gamma (IFN-γ). These factors in turn stimulate the creation of growth factors
like nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and
transforming growth factor beta (TGF-β) to combat the ongoing catabolism [109].
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Furthermore, this inflammatory soup drives the translation of chemotactic proteins like
chemokine ligand 2 (CCL2), chemokine ligand 7 (CCL7), chemokine ligand 5 (CCL5),
and chemokine ligand 8 (CXCL8) which recruit innate and adaptive immune cells like
macrophages and T-cells, respectively [108, 110]. Additionally, two main classes of
matrix degrading enzymes are produced, disintegrin and metalloproteinase with
thrombospondin motifs 5s (ADAMTSs) and matrix metalloproteinases (MMPs).
ADAMTSs like ADAMTS-5 are increased in response to the production of cytokines like
IL-1β and degrade proteoglycans in the extracellular matrix, particularly in the NP [111].
Proteoglycan loss decreases the ability of the NP to retain water and thus resist
compressive loading. Further, MMPs like MMP-2 are increased in response to production
of cytokines like IL-1α and TNF-α and hydrolyze collagen in the extracellular matrix
[112]. TNF-α and high amounts of TGF-β also shift NP cells to produce collagen I and
decrease collagen II leading to net fibrosis. Through the concerted action of ADAMTSs
and MMPs, tissue properties may decline to the point at which the disc cannot sustain
loading, leading to NP herniation and annular tears. Overall, this catabolic process can
persist for decades leading to aberrant nerve sprouting, and altered disc mechanics,
ultimately culminating in chronic low back pain.

1.18 Innervation of Degenerated Intervertebral Discs
Amid the degenerative process, three factors enable ingrowth of nociceptive nerve
fibers deep into the IVD. These factors are, a loss of neuroinhibitory GAGs, formation of
annular fissures, and the production of neuronal growth factors [95, 103, 113]. The loss
of neuroinhibitory GAGs like chondroitin sulfate results from the activity of catabolic
enzymes, like ADAMTSs, which breakdown GAG-containing proteoglycans [106, 111,
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114]. Annular fissures provide a route of minimal resistance for nerves to sprout and
elongate. In fact, in humans, a preponderance of nerves is routinely observed in
degenerated IVD tissue around sites of granulation and fissure [115, 116]. Finally, factors
which stimulate nerve ingrowth, like NGF and BDNF, are constitutively expressed by
human IVD cells amidst degeneration [117]. These factors strongly promote growth of
nerves up the growth factor gradient, causing nerve fibers to penetrate the disc.
Evidence of aberrant nerve penetration has been observed repeatedly in IVD
samples taken from human donors [115, 116, 118-122]. Shinohara et al. were first to
visualize nerves within human degenerated disc tissue [122]. In this seminal work, nerve
fibers were observed deep within the annulus fibrosus tissue, particularly around
granulation tissue deposited within annular fissures. These findings have since been
replicated by a number of independent research teams [118, 120, 121]. Additionally,
biopsies taken from painful and non-painful IVDs exhibit significantly more nerve fibers,
suggesting the aberrant penetration of fibers into degenerated tissue is the basis of discassociated pain [120]. More recently, the type of nerve fiber within the disc has been
interrogated using immunohistochemistry. This analysis has discovered that most
aberrantly penetrating fibers are of the small peptodergic type [93]. However, despite a
large body of literature demonstrating nerve fibers in degenerated IVD tissue, consensus
that this pathology drives disc-associated pain has not been reached. For this reason,
more work must be accomplished to elucidate the relationship between aberrant disc
innervation and the presence and intensity of disc-associated pain.
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1.19 Mechanical Properties of Degenerated Intervertebral Discs
Motion segments containing degenerative IVDs present with mechanical
properties distinct from healthy segments, namely, neutral zone expansion and decreased
torsional resistance [123]. The neutral zone is the range of displacement a motion
segment can pass with minimal resistance and can be quantified in all planes and
rotationally. Evidence in the literature indicates that neutral zone expansion may be due
to a breakdown of the interconnected collagen lamellae in the annulus fibrosis [124].
Decreased resistance to torsional strain also results from compromise of the collagenous
AF macrostructure. Due to tissue catabolism, hoop stresses are not passed uniformly
through the rings of collagen, leading to tissue destruction and ultimately disconnection
[125]. This compromise of macrostructure results in a feedback loop where increasing
tissue destruction causes the remaining healthy tissue to bear a higher load, resulting in
mechanical overload [125]. These facets of IVD degenerative mechanics along with an
understanding of the irregular innervation of degenerated discs draw attention to the
contribution of altered disc mechanics in pain generation.

1.20 Nociceptive Sources of Disc-associated Pain
Curiously, not all patients who present with clinical signs of disc degeneration
experience chronic low back pain [35]. This fact has led researchers to further explore the
pathogenesis of disc-associated pain. Fundamentally, disc-associated pain can manifest
from three sources: nerve root compression, inflammatory factors, and mechanical
factors.
Nerve root compression results in neuropathic pain [126]. The primary source of
neuropathy in context of disc-associated pain is nerve root compression due to disc height
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loss, which manifests clinically as radicular pain [28]. Nerve root compression can be
surgically addressed by removing bone around the intervertebral foramen to alleviate
compression [127]. Interestingly, nerve root compression may be treatable with a
therapeutic which restores disc volume, although this concept is largely unproven.
Inflammatory factors are abundant in the degenerative process and act on nonpeptodergic and peptodergic nerve fibers. For example, molecules like ATP, produced by
inflammatory cells, bind purinergic receptors on non-peptodergic nerves leading to
nociception [91]. Further, CGRP, which increases in abundance during degeneration, can
bind receptors on peptodergic nerve fibers also leading to nociception [128]. Activation
of these nerve fibers is thought to drive the dull chronic aching pain reported by discassociated pain patients [129]. Supporting this notion, systemic treatment with antiinflammatory drugs, like NSAIDs, can prove effective short-term in treating discassociated pain [46, 130].
Evidence of the role of mechanical factors in disc-associated pain can be observed
in the outcomes of current treatments. The treatment for disc-associated pain with highest
success rate short-term is surgical fusion [60, 61, 131, 132]. Surgical fusions are routinely
performed by rigidly adjoining adjacent vertebral bodies thereby introducing stability to a
degenerated motion segment. In select cases, fusion patients report excellent results after
surgery implying that stabilization alone can be sufficient in alleviating disc-associated
pain [133]. Another, albeit less effective, treatment for low back pain are spinal stability
exercises. Exercise increases the strength of core muscles like the multifidus and
transverse abdominus imparting more musculature control over spinal movements.
Studies have demonstrated significant pain remission short term with exercise regimes
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focused on increasing multifidus cross-sectional area indicating muscular stabilization of
the spine can reduce pain and disability [134, 135]. This evidence in combination with
localization of aberrant sprouting along fissures provides ample evidence that altered
spinal mechanics drives at least part of pain emergence in those suffering disc-associated
low back pain.
These data support inflammation and altered disc mechanics as the primary
contributors to disc nociception and in turn, chronic disc-associated low back pain.
Knowing this, a therapeutic which addresses one or both factors stand to improve discassociated pain through causal mechanisms. To date, the only therapies which get close
to this level of efficacy are highly invasive surgical procedures. The purpose of the work
described in this dissertation was to engineer a minimally invasive therapy for low back
pain that was causally targeted. To accomplish this goal, a method for monitoring disc
degeneration real-time was established, an animal model of disc-associated pain was
created, a therapeutic was engineered, and finally, the therapeutic was evaluated in vitro
and in vivo.

CHAPTER 2: Motivation
Treatments for spinal disorders have been in development since as early as the
1890s. One of the first procedures ever described was by W.T. Wilkins who removed a
hernia and fused two vertebrae using carbolized silk suture [136]. Since this time, spinal
procedures have been refined and today, the gold standard, spinal fusion, uses patient
tissue and metal alloys to accomplish spinal fusion. In light of the drawbacks of surgical
fusions and inadequacy of other treatments, research teams around the world have been
working to create alternative next generation therapeutics like antibody therapies, gene
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therapies, injectable biomaterials, etc. [50]. However, because these treatments are not
simply constrained to inert metal alloys for fabrication, they pose more severe risk for
side effects. To this end, animal models of disc degeneration and disc-associated pain
have become increasingly important to evaluate the pathogenesis of disc-associated pain
and screen treatments.

2.1 Models of Intervertebral Disc Degeneration
The earliest model of disc degeneration was described in 1932 and entailed an
annulotomy in New Zealand white rabbits [137]. Since this time, animal models of disc
degeneration have been created in mice, rats, pigs, chondrodystrophic dogs, nonchondrodystrophic dogs, goats, sheep, cows, macaques, baboons, and rhesus monkeys
[138]. The induction method for disc degeneration is also highly varied including both
spontaneous and induced approaches. Spontaneous mechanisms for creating disc
degeneration include natural aging, specific diets, transgenic secreted protein acidic and
cysteine rich (SPARC) null breeding, genetic knockout of collagen genes, and transgenic
induction of HLA-B27 and human β2m genes [138]. Methods for inducing disc
degeneration in animal models include, stab incision, tail bending, facet removal, cyclic
compression, chronic compression, NP aspiration, chemonucleolysis, nucleotomy,
cytokine injection, complete Freund’s adjuvant (CFA) injection, annulotomy and more
[138-140]. However, these models are only useful for elucidating pathomechanisms of
disc degeneration because they do not quantify pain.

2.2 Models of Disc-associated Pain
All models of disc degeneration have pros and cons, but a massive limitation to
most models is the inability to assess pain. In humans, pain, i.e., nociception
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contextualized with emotional processing, can only be measured via cognitive
communication. Because animals are incapable of communicating in sophisticated ways,
researchers must be wary when describing pain in animals [141]. For this reason, human
recognizable signs of pain in animals are referred to as pain-like behaviors. This careful
terminology avoids anthropomorphizing animal behavior in an attempt to be more
scientifically sound. Likewise, therapies administered to animals cannot be described as
analgesics but rather must be denoted as anti-nociceptive, because analgesia relates to the
suppression of pain.
Primates are the most ideal animal for studying disc-associated pain because their
anatomy and physiology is closely analogous to humans and their high cognitive ability
permits means for robust pain-like behavior evaluation [142-144]. Unfortunately,
primates are expensive, and their cognitive abilities raise ethical questions as to the
degree of suffering that is reasonable to induce in animals for the purpose of researching
therapies to alleviate human suffering [145]. For this reason, primates are reserved for
evaluating therapeutics that have proven effective in lower order species.
Less cognitively evolved animals, like rabbits, pigs, and goats have provided
excellent utility for studying the molecular and morphological pathogenesis of disc
degeneration but have failed to provide reliable measures of disc-associated pain [143,
146-149]. A partial explanation is that the aforementioned animals are prey animals
which are known to exhibit pain-masking as part of evolutionary behavior to avoid
predation [150]. Additionally, these animals can be difficult to handle, meaning that
measures of pain-like behavior are limited to observational metrics which are notoriously
noisy and require high animal numbers to provide enough statistical power to detect
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differences [151]. Fortunately, since the inception of biomedical sciences, researchers
have poured considerable effort into developing pain-like behavior assays in rodents that
are robust and reliable [141].
Rodents are excellent for pre-clinical models because of their accelerated aging,
well-defined behavioral assays, size, and cost [141]. It may be reasoned pronograde
animals like rodents cannot represent the spinal loading of orthograde animals like
humans. Interestingly, research suggests the orientation of the spine, whether parallel or
perpendicular to gravity, does not largely impact discal pressures [75, 77, 152]. This lack
of difference is further supported by the similarity of disc rheological properties among
rodents, pigs, rabbits, sheep, baboons, and humans [153-156]. For models aimed at
evaluating early stage therapeutics, rats are a stronger candidate than mice because rat
discs are around ten times larger and thus are more amenable for injection procedures
[157].

2.3 Outcomes in Rat Models of Disc-associated Pain
In rat models of disc-associated pain, success can be measured by a few key
pathologies associated with IVD degeneration in humans. These metrics are gross IVD
morphological decline, IVD biomechanical decline, IVD inflammation, and above all,
pain-like behavior.

2.4 Measuring Gross Morphology of Rat IVDs
Gross IVD morphology can be approximated using non-invasive procedures and
directly measured using tissue processing techniques. The most common analysis used to
measure disc degeneration real-time is the disc height index (DHI) [158]. The DHI is a
combination of measurements that normalizes the IVD height to adjacent vertebral
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bodies. As described earlier, when the disc degenerates, it loses water content, leading to
a decrease in height which is detected by the DHI. This metric can be quantified using
any imaging modality that can contrast bony and soft tissue. In practice, X-ray images
provide an easy way to repeatedly collect this information throughout the course of an
animal study. However, this method is limited by observer bias and sample orientation
because the location of measurements involved in collecting the DHI are not clear nor
consistent. The poor accuracy and precision of this method has created a need to innovate
new methods for evaluating the disc state real-time. The widely accepted method for
evaluating IVDs after they are collected at the end of an animal study is histological
analysis [159]. Staining with hematoxylin and eosin (H&E) is the gold standard for
grading disc degeneration semi-quantitatively [160]. Research methods for grading
degenerated IVDs are extensively established and described in detail for all major animal
model species and humans [160-163]. H&E grading invariably involves evaluating predefined disc morphologies, like NP cell number, AF organization, etc., on a point scale.
These grades are then summed to get a total measure of IVD degeneration. Other
histological stains like fast green, Alcian blue, Safranin-O, tartrazine, toluidine blue, and
picrosirius red are less commonly utilized but can be valuable if questions about specific
matrix constituent like collagen and proteoglycans are of interest [164, 165]. In sum,
numerous methods for non-invasive and terminal state assessment of IVDs have been
described, each with their own advantages and disadvantages.

2.5 Measuring Mechanical Properties of Rat IVDs
In many rat models of disc degeneration and disc-associated pain, mechanical
properties of healthy and degenerated disc are collected [2, 147, 166, 167]. To
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accomplish this, IVDs are excised and fixed to devices called pots that interface with
mechanical assessment apparatuses. Torsional and compressive mechanics are the two
properties of IVDs routinely measured [156, 168-170]. Torsional mechanics are assessed
using rheometers which apply predefined angular displacements on the disc and collect
torsional resistance values. Compression mechanics are collected using systems like the
ElectroForce 3300, and entail measuring the resistance to compressive displacement.
Results from rat IVDs suggests degenerated discs are stiffer and exhibit expanded neutral
zones although these effects are not consistently observed in all rat models [167, 171,
172]. Part of the problem in collecting robust mechanical data in rats is the small size of
the IVDs, which makes potting and attachment a difficult process. Overall, outcomes of
mechanical testing have been hindered by inter and intra experimental variability.
However, the consistent decline of mechanical properties in degenerated IVDs suggests
there is valuable data to be collected if the systems can be refined.

2.6 Measuring Inflammation in Rat IVDs
Inflammation of the IVD is measured as part of post-processing at the conclusion
of many animal studies [173, 174]. Inflammation can be quantified using an array of
techniques including, immunohistochemistry (IHC), western blots, polymerase chain
reaction (PCR), reverse-transcriptase polymerase chain reaction (rt-PCR), and more.
Widely used cytokine targets for quantifying inflammation include IL-1β, TNF-α and IL6. The presence of these targets or their transcripts is ubiquitous across rodent models of
disc degeneration albeit less data exists for disc-associated pain models [175-177].
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2.7 Measuring Pain-like Behavior in Rats
Measuring pain-like behavior is essential in rat models of disc-associated pain.
Without a pain-like phenotype, disc-associated pain models are simply models of disc
degeneration. Fortuitously, many assays have been described which measure pain-like
behavior in rats [146]. These assays can be broken into two core groups: evoked and
spontaneous pain-like behavior (Fig. 7). Evoked pain-like behavior assays entail direct
manipulation of the
animal by an observer
and bias towards
collecting measures of

Figure 7. Breakout of pain assays used to measure
pain-like behavior in animal models of discassociated cLBP

acute pain. Examples
of evoked assays in
rat models of disc-

Figure 7. Breakout of pain and assays used to measure pain-like behavior
in animal models of disc-associated cLBP

associated pain are pressure algometry, grip strength, von Frey, cold plate, acetone
withdraw, hot plate, tail flick, and Hargreave’s [146]. Pressure algometry and grip
strength are the only assays in this list which directly perturb the degenerated IVD,
making them the most useful and determinative in detecting disc-associated pain. All
other assays listed measure signs of increased distal hypersensitivity to either tactile
stimulus, heat or cold [151, 178]. Hypersensitivity to stimuli at sites distinct from the
IVD can be caused by sensitization of DRG neurons and/or centrally acting interneurons
and cerebral pain-related neurons [96]. Primarily, distal hypersensitivity is thought to
manifest after disc degeneration because DRG which innervate the distal location also
innervate the degenerated disc tissue [179, 180]. This phenomenon is known as cross-
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sensitization [181, 182]. Under the cross-sensitization paradigm, inflammatory factors in
one tissue or organ phenotypically alter the entire DRG, leading to hypersensitivity in all
tissue sites innervated by a single DRG body [183-185]. For example, IVD inflammation
may sensitize the L5 DRG, which also innervates the hindpaw footpad, resulting in
hindpaw hypersensitivity. However, assays which do not directly provoke the disc are not
always indicative of disc-associated nociception nor inflammation. Large differences,
especially in assays which measure thermal hypersensitivity, can be indicative of a
neuropathy [186, 187]. Thus, due to human confounds and extraneous factors, the ideal
method for assessing pain in animals is through pure observational methods like those
involved in spontaneous pain-like behavior assays.
Spontaneous pain-like behavior assays do not require animal manipulation but
rather rely on observing changes in voluntary action. These assays include the open field
test, rotarod, gait, weight bearing, grimace, vocalization, and operant conditioning [141,
144, 188]. Measuring significant changes in spontaneous pain behavior assays is ideal
because these assays entirely abrogate the effects of human involvement and are strongly
indicative of chronic pain. However, spontaneous assays of pain are more sensitive to
confounding factors than evoked pain-like behavior assays. For example, the Open Field
Test can be powerfully confounded by environmental variables like, illumination, size,
white noise, abrupt noise, room odors, handler odors, how an animal is transferred, etc.
[189]. Scientists have drawn attention to details like these because they are known to
interact with outcomes, leading to inter-lab outcome variability and replicability
problems. Furthermore, confounds may have larger effect sizes on animal behavior than a
given treatment, severely limiting the ability to detect differences. Despite these
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limitations, measuring significant differences in spontaneous pain-like behavior assays is
considered a more robust and translatable measurement of a pain-like condition than
evoked measures [151].

2.8 Types of Rat Disc-associated Pain Models
Current rat models of disc-associated pain fall into two categories: spinal
destabilization and direct IVD damage.
Spinal destabilization procedures like facet removal are generally paired with
mild damage to the disc like annular incisions to induce disc degeneration and discassociated pain [149, 190, 191]. The rationale behind these models is that deleterious
loading can be the fundamental initiator of disc degeneration. Supporting this notion,
multiple researchers have reported increased mechanical and thermal hypersensitivity
after lumbar facet removal paired with annular damage [176, 192]. Additionally, these
models have demonstrated overt degeneration and increases of IL-1β, TNF-α, IL-6, and
SP, in the IVD tissue indicating human markers of disc degeneration are replicated [175,
176]. However, the validity of these models as pure disc-associated pain is questionable
because spinal features like the facets, which are known to be sources of low back pain in
humans, are also damaged [191, 193]. On account of this, spinal destabilization models
of disc-associated pain are not adequate as pure models of human disc-associated cLBP.
Most rat models of disc-associated pain involve direct damage to the IVD [148,
149]. In rats, the L5-L6 IVD is the lowest lumbar IVD, analogous to the human L4-L5
IVD, the most common site of human disc degeneration [194]. Therefore, the L5-L6 disc
is a common target for single level procedures in rats. The repeated IVD puncture model
is the most typical model employed to create a disc-associated pain-like phenotype in rats
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[173, 188, 195-198]. These models induce degeneration by repeatedly puncturing the
IVD with syringe needles ranging from 18-gauge to 33-gauge. This model paradigm has
yielded fair results with one model demonstrating spontaneous pain-like behavior and
several demonstrating evoked pain-like behavior. Using a 10X puncture model of the L5L6, Leimer et al., have been the only group to measure spontaneous pain-like behavior
changes. In this model, animals that were injured spent less time traveling in the Open
Field Test and exhibited preference for forelimbs in stride frequency as part of a gait
analysis [173]. Lai et al., Muralidharan et al, Li et al, and Isa et al., have all performed
puncture models and measured differences in evoked pain-like behavior like deep
pressure hypersensitivity, hindpaw tactile hypersensitivity, and tail thermal
hypersensitivity [176, 199-201]. However, pain-like phenotypes in these models suffer
inter-study variability and repeated puncture of the disc with a syringe needle cores the
tissue resulting in pathologies dissimilar from humans. More severe models of discassociated pain utilize triple level injury of the lumbar spine, damaging the L3-L4, L4L5, and L5-L6 IVDs and may inject inflammatory agents like cytokines or CFA into the
IVD [2, 139, 199, 202, 203]. Iterations of this model have been repeatedly employed and
display robust mechanical hypersensitivity indicative of disc-associated pain [2, 139, 167,
199, 203]. The Iatridis lab has utilized variations of a triple-level puncture with cytokine
injection model in more than four publications, with all iterations displaying robust
hindpaw tactile hypersensitivity and a minority displaying other signs of pain-like
behavior like thermal hypersensitivity, increased grooming, etc. [2, 139, 167, 204].
However, these models apply a severe injury and an injection volume that represents a
significant fraction of the entire disc volume and apply supraphysiological levels of
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inflammatory cytokines [157, 205-208]. Furthermore, pain-like behavior has failed to
manifest in female animals in dual sex studies implicating other mechanisms than IVD
degeneration are at play in the production of pain-like hypersensitivity [2]. These factors
implicate potential inflammatory cytokine leakage and sensitization of nervous tissue
around the disc as behavioral confounds. More models have been described but these are
greatly limited by factors such as relatively large needle size, spinal damage, inconsistent
behavioral shifts, and inappropriate inflammatory agents [173, 176, 198, 209, 210].
In summary, numerous models of disc-associated pain have been outlined, but
translatability has been limited by inconsistent pain-like behavior, severe injury, spinal
damage, supraphysiological inflammatory agents, sex differences, and more. There is a
need for an animal model of disc-associated pain induced through pure, single-level,
mechanical injury that manifests mild pain-like behavior in evoked and spontaneous
pain-like behavioral assays.

2.9 Treatments in Rat Disc-associated Pain Models
To date, numerous research groups have treated disc degeneration in rodent
models with varying degrees of success. These treatments have included cell
transplantation, in situ gene therapy, and bioactive factors [202, 211-218]. The vast
majority of models are limited by the administration of treatments prophylactic or
concomitant with the initiation of degeneration. Further, the majority of publications that
evaluate treatments for disc degeneration fail to quantify pain-like behavior [219].
Clinically, patients do not seek treatment for disc degeneration unless the degeneration
causes pain. This simple fact brings into question the validity of prior work because
treatments are administered prior to pain-like manifestation which does not replicate how
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human patients are treated. As of 2021, no treatment in over 100 animal model
publications has achieved approval by the Food and Drug Administration (FDA) for the
treatment of degenerative disc disease providing strong evidence that the prophylactic
and concomitant treatment paradigms are inadequate [219]. There is a strong need to shift
the treatment paradigm to that of rescue treatment, which above all replicates how
humans are treated at the clinic.
Nevertheless, there is growing evidence from in vitro and in vivo work that
injectable treatments for disc-associated pain have therapeutic potential [220, 221].
Specifically, focus has shifted to biomaterials as platforms for composing injectable
therapies with tunable properties. These candidate materials have demonstrated
promising properties on the benchtop but have yet to make an impact in an animal model
of disc-associated pain.

2.10 Biomaterials for Treating Disc-Associated Pain
Hydrogel biomaterials are ideal therapeutics for IVD tissue replacement and
repair due to their tunable, injectable, and conformable properties. As evidence of their
profound utility, the global biomaterials market has grown to an estimated $106.5 billion
as of 2019 [222]. Hydrogel biomaterials can be broken into two major classes – natural
and synthetic. Synthetic biomaterials, like polyethylene glycol (PEG) and polyacrylic
(PAA) hydrogels are recognized as foreign bodies by the immune system making them
unideal for long term solutions [223-225]. Natural biomaterials, like collagen or
hyaluronic acid hydrogels, employ native structural moieties and ligands making them
more readily received by hosts.
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Natural biomaterials derived from decellularized tissue have more recently
entered the therapeutic arena due to several advantages [226-228]. Foremost of these
advantages is their intrinsic biomimicry. When fabricated from analogous tissue sources
and carefully processed, decellularized tissues maintain native proteins,
microarchitecture, and immunomodulatory factors like matrix bound vesicles [229-231].
In the context of disc degeneration repair, decellularized tissues convey another
advantage in that they can be enzymatically digested to create an injectable solution
which is thermally fibrillogenic.
In the last decade, several research teams have developed decellularized
biomaterials for treating IVD degeneration [230, 232-235]. Using methods that involve
detergents, ultrasonication, freeze-thaw cycles, nucleases, and trypsin digestion, these
teams have removed cellular material and other antigens from IVD tissue to create ECM
scaffolds. More recently, decellularized methods have been paired with enzymatic
digestion to yield solutions composed of ECM constituents [235, 236]. Because a major
component of these ECM solutions is collagen, they spontaneously form collagenous
hydrogels when brought to 37 °C [237]. This thermal gelation allows these formulations
to be delivered to IVDs, in vivo, via minimally invasive injection. In fact, a decellularized
biomaterial composite has proven effective at decreasing disc degeneration in a rabbit
model of IVD degeneration [238]. However, the capacity of a decellularized biomaterial
to alleviate disc-associated pain has not been determined. Considering disc-associated
pain is driven by nociception in the disc, which may be exacerbated by mechanical
instability, a minimally invasive, injectable, thermally curing biomaterial may be able to
percolate into tissue defects, restore mechanics, and alleviate pain.
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In order to accomplish biomaterial-tissue integration and promote long term
viability of a biomaterial implant, native cells must be present to facilitate cross-linking
of tissue extracellular matrix with delivered extracellular matrix components or moieties,
like collagen or aldehyde groups [226]. Unfortunately, degenerated discs are
characterized by their hypocellularity making cell-mediated integration slow if not nonexistent [239]. To remedy this problem, chemical cross-linkers have entered the realm of
biomaterial engineering as potent solutions for robust tissue integration. In the past,
covalent bonding of biomaterials doped with crosslinking agents has been studied as part
of the development of bioadhesives likes Gelatine-Resorcine-Formaline (GRF) glue
[240]. Classical crosslinking agents like glutaraldehyde and carbodiimide, have been
used to cross-link collagenous tissues to prevent degradation and promote integration of
implants like PeriGuard, a bovine pericardial patch [241-243]. These crosslinking agents
work by creating covalent linkages between and within collagen fibrils resulting in
increased interconnectivity [241, 244]. In addition to making biomaterials more resistant
to degradation, chemical cross-linkers can also dramatically increase the mechanical
properties of tissues. However, the current broad guidance for adding chemical
crosslinking agents to biomaterials is that of caution because cross-linkers are known to
have potent cytotoxic effects and can result in biomaterial failure [245].
More recently, a naturally derived chemical crosslinking agent, genipin, has
entered realm of biomaterials [246-248]. This agent, derived from the fruiting bodies of
Gardenia Jasminoides, exhibits remarkably minimal cytotoxicity at concentrations which
increase the mechanical properties of biomaterials by more than double [168, 246, 247,
249-251]. In the context of collagen, free genipin covalently bonds with lysine molecules
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via nucleophilic attack. When two genipin molecules interact after each having bound
with a lysine, they condense into a single covalent bridge between the two lysine residues
and form an aromatic ring [251]. This structural reformation results in a blue color which
can be readily observed by the naked eye. Additionally, genipin has proven
cytocompatible as part of bioadhesives used to repair annular defects in IVDs. In this
context the genipin crosslinked biomaterial, FibGen, exhibits superior reparative
properties compared to commercially available products like BioGlue [252]. A
decellularized biomaterial, doped with genipin, could dramatically improve the
mechanical function and integrity of a degenerated disc, decreasing inflammation and
nociceptor activation, thereby alleviating disc-associated low back pain.
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CHAPTER 3: Context for Project Chapters
The primary goal of this dissertation was to engineer a therapeutic for discassociated low back pain. Prior to any evaluation of a treatment, two systems had to be
established. The first was a means to quantify disc degeneration real-time and the second
was an animal model of disc-associated pain.
The first goal, described in Chapter 4, was motivated by the inadequacy of the
DHI method as a real-time proxy for disc degeneration. At the outset of all animal work,
it was quickly realized that the DHI method required too many subjective choices by the
experimenter and could not be relied on as a robust metric for gauging degeneration
longitudinally. To remedy this problem, a method for processing three-dimensional data
from uCT scans to create three-dimensional renderings of the intervertebral discs was
created. This system was used to non-invasively measure changes in disc volume of
degenerating discs because it was known that damaging the disc would decrease the
water content and volume. This method was extremely sensitive in detecting changes of
the IVD and provided a state of the art means to monitor disc degeneration real time.
The second goal, described in Chapter 5, was to create novel and robust model of
disc-associated pain. The problem with established models of disc-associated pain was
that they either were too mild to manifest a replicable pain-like phenotype, or they were
far too severe to be categorized as a model of pure disc-associated pain. Additionally,
essentially all models had been created in male animals, despite cLBP being far more
prevalent in women [10]. To address this deficit, a model of disc-associated pain using
only mechanical injury of the L5-L6 IVD in female Sprague Dawley rats was established.
This model manifested consistent and increasing chronic axial hypersensitivity and deep
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pressure hypersensitivity at the L5-L6 level. Furthermore, this was the first rat model to
demonstrate nerve fibers penetrating deep into degenerated disc tissue. The presence of
pain-like behavior across two assays in concert with aberrant nerve sprouting solidified
this model as a leader in the field of biomedical research.
The final goal, described in Chapter 6, outlines the engineering of a biomaterial
derived from decellularized, healthy NP tissue, supplemented with collagen and genipin.
After testing in vitro, this biomaterial was injected into animals which had been
experiencing disc degeneration for 8-weeks. The novel biomaterial therapy increased
exploratory behavior in the open field test, decreased axial hypersensitivity, and
prevented the development of deep pressure hypersensitivity. Additionally, immediately
after treatment, disc volumes in treated animals returned to baseline and remained at
baseline for the remainder of the study, suggesting complete tissue-biomaterial
integration.
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CHAPTER 4: Application of microcomputed tomography to
calculate rat intervertebral disc volume as a surrogate measure
of degeneration
4.1 Introduction
Low back pain (LBP) is the leading cause of disability worldwide [253]. 84% of
people who suffer an episode of LBP will recover, but for 16%, the pain will become
chronic and disabling [254]. Chronic LBP increases risk of unemployment, depression,
insomnia, suicide and costs the United States more than $100 billion each year [255-257].
Despite the immense socioeconomic burden of chronic LBP, elucidation of the causal
drivers of pain remains incomplete. The most strongly associated factor with chronic
LBP is intervertebral disc (IVD) degeneration [22].
The IVD is a viscoelastic organ that sits between vertebral bodies, providing
spinal damping and flexibility. The IVD has three components: the cartilaginous end
plates, the annulus fibrosus (AF), and the nucleus pulposus (NP) [258]. The AF, high in
elastic collagen I fibers, circumferentially enwraps the NP which is rich in
glycosaminoglycans and collagen II. The AF and the NP together form a thick disc which
is capped on both ends by cartilaginous end plates which allow nutrient diffusion from
adjacent vertebral bodies[258]. In a healthy state, negatively charged GAGs in the NP
make it energetically favorable for the NP to imbibe and maintain 75% of its weight in
water [68]. Maintenance of water in the NP is essential for the IVD to resist compressive
loads and to dynamically cycle nutrients throughout the tissue. The tradeoff for the
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phenomenal mechanics of this organ is an absence of nerves, blood vessels, and
immunological access which predisposes the IVD to degeneration.
In humans, the primary causes of IVD degeneration are age, environmental
factors, and trauma [102]. These factors serve to decrease nutrient flow to the IVD,
triggering cellular senescence and apoptosis, creating a catabolic feedback loop resulting
in IVD degeneration [259]. Two hallmarks of IVD degeneration measured regularly to
diagnose disc degeneration are disc water loss and height loss. Disc water content is
usually measured using MRI and quantified using defined grading schemes like the
Pfirman grading system [260]. Disc height loss is thought to result from compromise of
the AF which acts as a hydrostatic barrier between the hydrated NP and surrounding
tissue[261]. Clinically, disc height loss is measured using X-ray imaging using a process
that normalizes the IVD space to the length of adjacent vertebral bodies. This
measurement, known as the disc height index (DHI), is the gold standard for assessing
IVD degeneration real time using X-ray imaging [262]. While this metric is useful in
humans, X-ray imaging exhibits poor spatial resolution in the sub millimeter range,
limiting the utility of the DHI in rodent models, where IVDs heights range from 100 µm
– 1600 µm [263-265]. Additionally, measuring DHI using radiographs is limited by error
introduced by subjective choices made by experimenters concerning sample orientation,
measurement selection, measurement location, etc. [158]. Despite these limitations, the
DHI is widely used in rat and mouse models because no other robust method has been
established [138].
Microcomputed tomography (µCT) is a relatively new imaging technique which
has been developed over the past several decades [266, 267]. Unlike X-ray imaging,
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which collects data from a single imaging plane, µCT employs a rotating scanner that
collects data from a myriad of reference frames, permitting 3D reconstructions with high
spatial resolution. This 3D imaging method is fundamentally like MRI with the caveat
that µCT uses X-rays which deliver greater resolving power compared to the radio waves
used in MRI. Modern µCT are capable of high-resolution scanning with spatial
resolutions as low as 9 µm which vastly outperforms state of the art small animal X-ray
scanners with spatial resolutions of 143 µm [268]. These µCT scans can be used to
evaluate DHI through measurements in a single slice plane, but this option is suboptimal
because it requires observer discernment for slice selection and disregards most of the
data set. In recent years, contrast enhanced µCT has been used to precisely measure
volumetric changes in degenerated IVDs in rodents, but the use of a contrast agent
increases cost and time [157, 263]. Due to the limitations of using the DHI or contrast
agents in small animal models of IVD degeneration, the purpose of this work was to
evaluate if non-contrast enhanced µCT could be used to generate a metric of volume to
assess degeneration real time in rodents.
The objective of this study was twofold: 1) develop a novel technique for
quantifying IVD volume in vivo using µCT without the use of a contrast agent and 2)
determine the ability of this technique to measure changes in IVD volume in real time in
an animal model of IVD injury and degeneration. The data presented herein confirm that
IVD volume as measured by µCT imaging is a reliable, precise, and sensitive metric for
quantifying IVD degeneration in rodents in vivo.
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4.2 Materials and Methods
Animals: 24 female, 15-week-old, Sprague Dawley rats were purchased from Envigo and
housed with a 12-hour light/dark cycle and ad libitum access to food and water. All
animal procedures were in accordance with the National Institute of Health guidelines
following PHS Policy on Humane Care and Use of Laboratory Animals and approved by
the Institutional Animal Care and Use Committee and the University of Nebraska –
Lincoln.
µCT Data Collection: Scans of the L5-L6 IVD were collected using a Quantum GX2
µCT Imaging System. The rat lumbar spine was radiographed by placing anesthetized
animals in the scanning bed in the supine position and scanning for 2-minutes with 90 kV
power, 88 µA tube current, 72 mm FOV, 144 µm isotropic voxel size, and a Cu .06 + Al
.05 X-ray filter. The resulting VOX files were renamed according to respective animal
ID’s and transferred to an external hard drive to be processed. All baseline values, week
0, were collected in a single day. Animals were also scanned at 2, 8 and 18 weeks after
injury.
Disc Height Index: The disc height index was quantified according to previously
described methods[167, 269, 270]. In brief, the mid-coronal disc slice image was
determined by selecting the midpoint slice between the most dorsal and ventral slice that
contained the disc. The IVD height was calculated using three measurements of disc
height (two lateral and one midline) and six measurements of adjacent vertebral body
length (two lateral and one midline x two vertebral bodies) (Fig. 2A). DHI = (2 x (D + E
+ F)) / (A + B + C + D + E + F).
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IVD Injury Surgery: This injury method applied herein is based on an established model
of disc degeneration developed by our lab (under review). On the day of surgery, the
animals were split into two groups of equal size (n = 12): sham and injured. Rats were
anesthetized, and the lumbar spine was approached ventrally by dissecting through the
abdominal cavity and retroperitoneum. The iliac crest was used as a landmark to reliably
dissect down to the L5-L6 IVD. For injured animals, the L5-L6 IVD was punctured
bilaterally with a strong point dissecting needle (Roboz, RS-6066) with an O.D. of 0.5
mm set to a length of 3 mm. The exact needle length was predetermined based on µCT
data to ensure that the needle length did not exceed the diameter of the smallest L5-L6
IVD in all animals. While the needle was within the IVD, it was swept back and forth
along a 90o arc six times in the transverse plane to disrupt the dorsal and lateral aspects of
the IVD for injured animals. A simple continuous and subcutaneous suture pattern were
used to close the abdominal wall and the skin respectively. Buprenorphine SR (1 mg/kg)
was administered once post-op for pain and animals were rested for two weeks following
surgery. At the study conclusion, a total of two animals were excluded from the study
(sham: n = 12 and injured: n = 10) due to mis-puncture confirmed by IVD volume and
H&E (data not shown).
Statistical analysis: All data is presented as mean ± standard deviation. Data were
analyzed using GraphPad Prism 9. Normality was assessed using a Shapiro-Wilk test.
IVD volume and DHI data were analyzed using a one-way ANOVA with Dunnett’s post
hoc. Results were considered statistically different when p < 0.05.
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4.3 Results
The first objective of this work was to use µCT data to create a new method for
assessing the IVD non-invasively and without the use of a contrast agent. IVD volume
was identified as a potential measurement primarily because it incorporated as much data
from the µCT scan as possible into the outcome, unlike the DHI method which used only
a single slice plane. To establish this method, Sprague Dawley rats were acquired to
collect lumbosacral µCT data to create a protocol for quantifying IVD volume. Data
collection was completed by anesthetizing rats using isoflurane, placing them on the
scanning bed in the supine position, and scanning the lumbosacral spine using a Quantum
GX2 µCT (Fig. 8A). Once data was collected, the VOX files were loaded into Analyze
14.0 (Analyze Direct), a proprietary software associated with Quantum imaging devices.
All VOX files were loaded in as float files (Fig. 8B). A chosen file was then opened
using the segment tool and the L5-L6 IVD was located using the iliac crest as a landmark
(Fig. 8C&D.) The ventral most slice of the L5-L6 IVD space can be seen in Fig. 8E. The
vertebral column was then made into an object using the semi-automatic tool for
thresholding bony objects (Fig. 8F). The threshold intensity used for bone in this work
was 700 Hounsfield unites (HU) [271, 272]. The bony spine object was then locked, and
a new object for the IVD space was created. Starting at the ventral most slice of the L5L6 IVD space, where both adjacent vertebral bodies can be visualized, the IVD space
object was drawn using the manual draw tool (Fig. 8G). Making sure the vertebral body
object was locked was important during this drawing to prevent unwanted overlap (Fig.
8H). The edge of the disc space, i.e., the width boundary, was approximated by a line of
shortest length between the edges of the L5 and L6 vertebral body. The manual drawing
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was continued through all slices of the L5-L6 IVD space until the dorsal edge of the spine
was reached, and the vertebral bodies began to recede. The middle slice can be seen in
Fig. 1I, and the last slice can be seen in Fig 8J. Finally, the semi-automatic tools for
coronal and propagating objects, with smoothing enabled, were performed to smooth out
the objects and reduce variability caused by imprecise drawing (Fig. 8K). The object
maps were then saved, and the segment tool was closed. The same sample was next
opened using the measure tool and the corresponding object map was loaded (Fig. 8L).
After, the sample enabled objects tool under the 3-D tab was performed to generate the
volume for object 3 which corresponds to the volume of the IVD space (Fig. 8M). This
process was performed on twenty-four animals as a proof-of-concept. The average disc
volume in this cohort was 4.69 mm3 ± .58 mm3 (Fig. 8O). These data indicated the disc
volume method was a viable tool for quantitatively assessing the IVD, non-invasively, in
real time, and without the use of a contrast agent.
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Figure 8. Overview of disc volume quantification. (A) Animals are scanned in the supine position for 2minutes with 90 kV power, 88 µA tube current, 72 mm FOV, 144 µm voxel size, and a Cu .06 + Al .05 Xray filter. (B) VOX files are loaded into Analyze 14.0 and output as a float data type. (C) Loaded VOX
files within the main workspace are opened in the segment tool. (D) Loaded samples within the segment
tool. (E) Zoomed image of the ventral most portion of the lumbosacral spine. The ventral start of the L5L6 is in the center of the frame. The arrowhead points to the iliac crest (F) The bony tissue of the spine is
defined as an object using the semi-automatic tool with a threshold set to 700 HU. (G) The bony tissue
object is locked, and a new object is defined for the IVD space. The IVD object is painted in manually in
the space between the L5 and L6 vertebral bodies. The bright green indicates the region being actively
painted. (H) Locking the bony tissue object prevents overlap between this object and the IVD object. (I)
The IVD object is continually painted in all frames where both adjacent vertebral bodies are present. (J)
The IVD object finishes where the vertebral bodies visually rapidly separate from one another. (K) The
object maps are propagated through all frames and smoothed using the semi-automatic tools “propagate
objects” and “coronal” with the smoothing box checked. The final object map is saved, and the segment
tool is closed. (L) The sample is opened in the measure tool and the relevant object map is loaded. (M)
Within the measure tool, the sample enabled objects is selected under the 3-D tab, and the volume for the
IVD space is output. (N) 24 L5-L6 IVD volumes were quantified from 24 female Sprague Dawley rats.
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The second objective of this work was to test the ability of the IVD volume
method to detect changes due to injury of the IVD. In this work, the DHI was used as a
benchmark comparator against the disc volume method (Fig 9A-C). A commonly applied
procedure for inducing IVD degeneration in animal models is mechanical trauma [167,
200]. To this end, the L5-L6 IVD was punctured in twelve of the twenty-four animals
from the same cohort used to establish the process. The injury entailed using a microdissecting needle to perforate the AF and compromise the hydrostatic barrier of the IVD.
It was expected the compromised AF barrier would result in immediate water loss and in
turn height and volume loss. Confirming this notion, at two weeks post-op the IVD height
index in injured animals significantly dropped from 0.098 ± 0.005 to 0.087 ± 0.011. The
average DHI of injured animals was significantly different from sham at 2-weeks and 8weeks post injury but not at week 18 (Fig. 9D). Likewise, the disc volume decreased
substantially after injury from 4.90 mm3 ± 0.423 mm3 to 3.47 ± 0.612 mm3 and this
decline was significant compared to sham at 2-weeks and 8-weeks. However, like the
DHI method, disc volume did not measure a significant difference at week 18. The
outcomes of this assessment revealed a 30% drop in volume and 11% drop for the DHI at
2-weeks post-injury (Fig. 9D, 9F). The disparity in these outcomes in context of
proportionately equal standard deviation indicated the DHI method had less power to
detect changes in the IVD compared to the volume method. Because the DHI method
intrinsically includes a normalization step by involving adjacent vertebral body lengths
into the calculation, it was then asked if further normalization to pre-surgery, especially
for IVD volume, could increase the statistical power. Normalization of the DHI data
reduced the power, resulting in no significant differences detected between sham and
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injured animals at any time point (Fig. 9E). Conversely, normalization of IVD volume
increased the power, resulting in larger differences between sham and injured animals. At
all-time points after injury, the calculated p-value was less than .0001 which was orders
of magnitude more significant than non-normalized data (Fig. 9G). These data indicate
that the IVD volume method imparted greater statistical power than the DHI method in
determining changes in the IVD state due to mechanical injury although both could detect
changes.
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Figure. 9. Validation of the disc volume method after disc puncture. (A) Measurements and equation
used to determine the disc height index. (B) IVD space painted in a single slice during the disc volume
measurement. (C) Three-dimensional rendering of the IVD volume after all paint slices are concatenated
into a single object map. The IVD is colored in teal. (D) Disc height index data measured at baseline, week
0, and post-injury at weeks 2, 8 and 18. The disc height index method measured a significant decrease in
injured animals compared to sham in weeks 2 and 8. (E) Normalized disc height index data pre-op and
post-op. When normalized, the disc height index method failed to detect a significant change in injured
animals compared to sham. (F) IVD volume data at baseline, week 0, and post-injury at weeks 2, 8 and 18.
The IVD volume method measured a highly significant volume decrease in injured animals compared to
sham in weeks 2 and 8. (G) Normalized IVD volume data pre-op and post-op. When normalized, the IVD
volume method detected a highly significant decrease in injured animal IVD volume compared to sham in
weeks 2, 8 and 18. Data is shown as mean with standard deviation (n = 10-12 per group). Significant
differences between groups were assessed using a one-way ANOVA with Dunnett's post hoc. * = P < .05
sham vs. injured. *** = P < .001 sham vs. injured. **** = P < .0001 sham vs. injured.
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4.4 Discussion
The objective of this study was twofold: 1) develop a novel technique for
quantifying IVD volume in vivo using µCT without the use of a contrast agent and (2)
determine the ability of this technique to measure changes in the IVD real time in an
animal model of IVD degeneration. The Analyze 12.0 software in combination with
highly spatially resolved data collected from µCT provided a means to develop a novel
technique for quantifying IVD volume. This method proved sensitive at detecting
changes two weeks after injury to the IVD. The application of this method in rodents in
vivo provides a new tool for researchers to measure IVD degeneration longitudinally in a
manner more precise and reliable than the DHI method and with reduced cost and time
yet equal precision compared to contrast enhanced uCT.
The impetus for this work resulted from difficulties measuring DHI using µCT
data in a pilot animal model of IVD degeneration of ours. During these measurements,
we noted that the selected slice used to measure DHI had a large impact on the outcome.
This variability was due to naturally occurring changes in IVD height across the disc.
IVD height variability based on location is well characterized in literature which has used
contrast enhanced µCT to show the IVD height can range from 0.4 mm to 1.6 mm
depending on the location within the IVD, an increase of 400% from smallest to
largest[265]. Another major drawback of the DHI method was that it used a single slice
plane from the µCT data, disregarding 95% of the data set which contained the IVD.
Statistically, it is generally better to sample as much of an experimental unit as possible
to increase the accuracy of the ground truth approximation. Knowing the IVD was the
experimental unit we were seeking to quantify, we hypothesized incorporating all slices
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of the IVD into a single measurement would increase the power of the metric. We
determined the best way to do this was by assessing the volume of the IVD because this
outcome involved all slices that contained the IVD abrogating the effect of sampling
location. A major decision at the outset of data collection was to scan all animals using a
voxel size of 144 µm. This voxel size was chosen because we aimed to create a method
that could be performed rapidly and repeatedly, bringing into consideration the total x-ray
dosing. Despite the voxel size being relatively large compared to what the system was
capable of, the extra spatial dimension alone proved efficacious in increasing the power
of the volumetric method compared to the DHI. If necessary, the precision of our method
could be increased in future work by increasing scan time, shrinking the FOV and
reducing the voxel size. Further, the volume method was unaffected by differences in
animal position evidenced by the consistency in measurements between the first study,
where animals were placed in the prone position and the second study, where animals
were scanned in the supine position. Understanding the relatively utility of both methods,
we then questioned further about the sources and degree of error for each measurement.
Error in the DHI method can be accounted primarily by slice selection and
measurement location, assuming all other parameters like imaging settings are
standardized. Using µCT data, the slice selection error alone was sufficient to shift the
outcome. In our work, DHI values could shift by 20% between slices indicating a large
potential for single measurement interobserver variability. On the other hand, error in the
volume method can be accounted primarily by selection of the start and end slice of the
IVD space. Error introduced by painting within each slice was not a considerable concern
because smoothed object propagation interpolated the edges of all objects and served to
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normalize this variability across all samples. In our work, the first slice was defined as
the slice in which 10 pixels of each vertebral body, defined by the bony spine object, was
visually present. The final slice was defined as the slice in which vertebral bodies began
to diverge. In our data sets, the IVD generally spanned 20 slices meaning incorrect
selection of the start and end slice by one slice could introduce around 10% error, half of
the DHI method. Of note, the start and end slice contained a fraction of the of the IVD
space compared to interior slices suggesting this 10% error rate is an upper bound. These
estimates of error terms indicate the DHI method is more prone to error introduced
through experimenter subjectivity via slice selection and intrinsic process variability
compared to the IVD volume method.
Another foundational principle of statistics is that error is normally distributed
within data sets given a sufficiently large sample size. This phenomenon is readily
observed in our data sets because both DHI and IVD volume sham animal averages at
post-op closely matched pre-op averages despite having compositionally different error
terms. The fact that IVD volume had drastically increased power in detecting differences
due to injury suggests outcomes from this method were less diluted by error intrinsic to
the process (Fig 9E&F). We believe this decrease in the dilutionary effect of error was a
direct result of sampling the entire experimental unit i.e., the IVD, in the volume method.
A limitation of the volume method is that it is directly affected by radial IVD expansion,
a phenomenon known to occur with degeneration [273]. The DHI method is not directly
affected by this problem because no measurements of width are incorporated into the
DHI outcome. Although the DHI method does not measure width, radial expansion might
indirectly impact the location of lateral height measurements, potentially skewing
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degenerated IVD values. Work will need to be done in the future to determine how much
of a dilutionary effect radial expansion has on the outcome because data in this area is
lacking.
Considerable work has been performed over the past decade using contrastenhanced µCT to characterize and measure various aspects of rodent IVDs to provide
insight into the pathobiology of IVD degeneration [157, 263, 265, 274]. Contrast agents
leverage the anionic charge of small molecules of in combination with the anionic charge
of GAGs to imbue contrast proportional to the concentration of GAGs in the IVD.
Unfortunately, these contrast agents are costly, exceeding $1,000/50 mg in the case of
Ioversol (Sigma), require infusion, and take time to clear the system making them unideal
for repeated use. For simple measurements of disc volume, the high contrast afforded by
contrast-enhanced µCT is not necessary because contrast is only required along the
margins of the disc, between bone and soft tissue. For this reason, we speculated the disc
volume could be measured with similar precision to that observed in prior work without
the use of contrast enhancement. In both of our studies the standard deviation was 14% of
the average which is lower than prior contrast enhanced work [275]. The consistent lower
proportion of error in our data suggests our method is equally reliable and precise
compared to methods which use contrast enhanced µCT.
In summary, we have developed a method that uses µCT data to compute IVD
volume to assess IVD state changes in real time, non-invasively, and without the use of a
contrast agent. The head-to-head comparison of the volumetric method with the DHI
which is the gold standard for quantifying IVD state changes, suggests our method was
more sensitive at detecting differences after injury to the IVD in live animals. Future
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work is needed to evaluate the utility of this metric longitudinally and to assess if the
contribution of radial IVD expansion significantly affects measure outcomes. We hope
this method will be a useful tool for researchers that have a need to assess IVD state in
vivo.

The work described in Chapter 4, constitutes a scientific paper which is currently
under review in Computer Methods in Biomechanics and Biomedical Engineering:
Imaging & Visualization.
DJ. Lillyman, F. Lee, EC. Barnett, TJ. Miller, RA. Wachs. Application of
microcomputed tomography to calculate rat intervertebral disc volume as a surrogate
measure of degeneration. Computer Methods in Biomechanics and Biomedical
Engineering: Imaging & Visualization
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CHAPTER 5: Axial hypersensitivity is associated with
aberrant nerve sprouting in a novel model of disc degeneration
in female Sprague Dawley rats
5.1 Introduction
Low back pain (LBP) is the leading cause of disability worldwide [253]. 84% of
people who suffer an episode of LBP will recover, but for 16%, the pain will become
chronic and disabling [254]. Chronic LBP (cLBP) increases risk of unemployment,
depression, insomnia, suicide and costs the United States more than $100 billion each
year [255-257]. Despite the immense socioeconomic burden of cLBP, elucidation of the
causal drivers of pain remains incomplete. The most strongly associated factor with
chronic LBP is intervertebral disc degeneration, known as disc-associated pain [22].
Unfortunately, treatments for disc-associated cLBP exhibit poor long-term efficacy [61,
276, 277]. The failure of current treatments can be attributed to a poor understanding of
the pathobiology underpinning disc-associated pain and a lack of pre-clinical animal
models to screen therapeutics.
In a subset of human patients with disc-associated pain, pathological changes in
the disc are thought to drive nociception and in turn pain. In these patients, degenerated
discs exhibit four important characteristics: 1) extracellular matrix (ECM) breakdown, 2)
hypocellularity, 3) aberrant nerve sprouting and 4) inflammation [79, 113, 114, 116, 118,
205, 278, 279]. ECM breakdown and hypocellularity result from deleterious nutrient
deficiency and altered biomechanics incompatible with tissue homeostasis [259]. CLBP
disc samples also exhibit high levels of pro-inflammatory mediators and a preponderance
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of nerves suggesting inflammation and nerve sprouting are involved in LBP genesis [116,
118, 280]. These four factors provide empirical targets for an animal model of painful
disc degeneration.
To be successful, animal models of pain must achieve three criteria: construct
validity, face validity, and predictive validity [281-283]. Construct and face validity
relate to the replicative accuracy of disease induction and phenotype respectively.
Predictive validity describes how well treatment efficacy in a model translates to human
efficacy. For a disc-associated LBP model, construct and face validity require pain
genesis to relate to pathological shifts in the disc, like nerve sprouting, and for the
phenotype to manifest similar to the disability and pain observed in humans. In theory,
accurate construct and face validity endow a model with degeneration analogous to the
human disease state, making treatments translatable, thereby imparting predictive
validity. It is vital these criteria are achieved in animal models that seek to provide insight
for human disease mechanisms and treatments.
Rodents are excellent for pre-clinical models because of their accelerated aging,
well-defined behavioral assays, size, and cost [141]. It may be reasoned pronograde
animals like rodents cannot represent the spinal loading of orthograde animals like
humans. Interestingly, research suggests the orientation of the spine, whether parallel or
perpendicular to gravity, does not largely impact discal pressures [75, 77, 152]. This lack
of difference is further supported by the similarity of disc rheological properties among
rodents, pigs, rabbits, sheep, baboons, and humans [153-156]. For a model aimed at
evaluating early stage therapeutics, rats are a stronger candidate than mice because rat
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discs are around ten times larger and thus are more amenable for injection procedures
[157].
In efforts to create a model of disc-associated cLBP in rats, various research
groups have induced disc degeneration with methods such as multi-level injury, cytokine
injection, spinal destabilization, and large gauge needle puncture, but the transition from
a model of degeneration to a model of chronic LBP has been limited by acute time
frames, absence of pain-like behavior, animal sex variability, animal age, and
confounding secondary effects [173, 176, 198, 200, 203, 209, 210]. Given the state of
cLBP research, there is a need for a valid rat model of disc-associated pain that is
analogous to human disease progression, nociception, pain-like behavior, chronicity, and
disc degeneration phenotype.
The objective of this work was to develop a novel rodent model of LBP that
comprehensively recapitulates the underpinning pathobiology of disc degeneration and
the emergence of pain observed in humans. Due to the similarity between our data and
the clinical presentation of disc-associated cLBP, this model provides value as a platform
for evaluating treatments and exploring the pathobiology of disc-associated cLBP.

5.2 materials and Methods
Animals: 36 female, 15-week-old, Sprague Dawley rats were purchased from Envigo
and housed with a 12-hour light/dark cycle and ad libitum access to food and water. On
the day of surgery, the animals were split into three groups of equal size (n = 12): sham,
1-scrape and 6-scrape. After surgery, all animals were weighed and assessed on a weekly
basis for overall health. Sample sizes were chosen to ensure sufficient power to detect a
30% decrease in grip strength in injured animals compared to sham animals assuming a
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standard deviation that was 26% of the mean. At the study conclusion, a total of 3
animals were excluded from the study (sham: n = 12, 1-scrape: n = 11, 6-scrape: n = 10)
due to mis-puncture confirmed by disc volume and H&E data. All animal procedures and
assays were in accordance with the National Institute of Health guidelines following PHS
Policy on Humane Care and Use of Laboratory Animals and approved by the Institutional
Animal Care and Use Committee and the University of Nebraska – Lincoln.
Surgical Procedure and Injury: On the day of surgery, rats were anesthetized, and the
lumbar spine was approached ventrally by dissecting through the abdominal cavity and
retroperitoneum. The iliac crest was used as a landmark to reliably dissect down to the
L5-L6 disc. For sham animals, the L5-L6 was visualized only, and the surgical site was
closed in the same manner as injured animals outlined below. For injured animals, the
L5-L6 lumbar disc was punctured bilaterally with a strong point dissecting needle
(Roboz, RS-6066) with an O.D. of 0.5 mm set to a length of 3 mm. The exact needle
length was predetermined based on µCT data to ensure that the needle length did not
exceed the diameter of the smallest L5-L6 disc in all animals. While the needle was
within the disc, it was swept back and forth along a 90o arc once or six times in the
transverse plane for 1-scrape and 6-scrape animals respectively. A simple continuous and
subcutaneous suture pattern were used to close the abdominal wall and the skin
respectively. Buprenorphine SR (.75 mg/kg) was administered once post-op for pain and
animals were rested for two weeks following surgery to enable healing. All animals
displayed mild pica behavior, i.e., bedding consumption, after surgery but this behavior
resolved within 72 hours.
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Disc volume: The L5-L6 disc volume was quantified using the Quantum GX2 µCT
Imaging System and Analyze 13.0 (Analyze Direct). In short, the rat lumbar spine was
radiographed by placing anesthetized animals in the supine position and scanning for 2minutes with 90 kV power, 88 µA tube current, 72 mm FOV, 144 um voxel size, and a
Cu .06 + Al .05 X-ray filter. VOX files were then removed from the µCT computer and
analyzed in Analyze 13.0. To begin processing, raw VOX files from the µCT scans were
processed using a high pass threshold to remove all non-bony signal. After the scans were
reduced to only bony tissue using the software filter, the intervertebral disc space was
colored in every coronal plane where the adjacent vertebral bodies were present using a
manual draw tool. The slices of colored intervertebral disc space between the L5 and L6
vertebral bodies were then concatenated, smoothed using a built-in function and saved as
an object map. The volume of the object map of these concatenated colored planes was
quantified using a built-in software analysis. This quantification was based on a
previously established method developed in our lab (under review).
Behavioral tests: For all behavioral tests, animals were acclimated prior to the study
commencement to the assay apparatuses and experimenters over the course of three
weeks with at least 1 hour of acclimation to each assay apparatus prior to any data
collection. All assays except grip strength were performed under red light to minimize
animal stress. No more than two behavioral assays were performed on a given day.
Experimenters were blinded to animal treatment and all animals were assigned to groups
by an unblinded observer.
Von Frey mechanical hypersensitivity: Hypersensitivity to punctate mechanical
stimulation in both hind paws was quantified using an electronic von Frey aesthesiometer
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(IITC, 2391) with a rigid tip with an outer diameter of 0.8 mm. Briefly, four animals at a
time were allowed to acclimate for 15 minutes in clear acrylic chambers placed on a
metal grid (IITC, 410). Withdraw threshold was assessed bilaterally by sequentially
applying the probe to the right hind paw of all animals followed by the left hind paw of
all animals. This process was performed 5 times with approximately 5 minutes of rest
between each test for a total of 10 values (5 left, 5 right). The withdraw threshold was
calculated by taking the combined left and right average of the final 4 measurements (8
subsamples for each animal). All withdraw thresholds were log transformed to achieve
normality and then normalized to baseline to reduce variability.
Grip strength axial hypersensitivity: Hypersensitivity to axial strain was quantified
using a grip strength apparatus (Columbus Instruments, 1027SR). All animals were
allowed to acclimate to the testing room for 15 minutes prior to testing. Animals were
picked up by grasping the hind quarter and then allowed to grip a metal wire mesh
attached to the grip strength force sensor. The experimenter’s grip was then transitioned
to the base of the tail and the animal was gently pulled backward until it released the
metal wire mesh. This process was repeated three times and the average max force (N)
was used as the grip strength. All withdraw grip strength thresholds were log transformed
to achieve normality and then normalized to baseline to reduce variability.
Pressure algometry deep tissue hypersensitivity: Hypersensitivity around the L5-L6
motion segment was measured using an electronic von Frey aesthesiometer (IITC, 2391)
with a blunt tip. All animals were allowed to acclimate to the testing room for 15 minutes
prior to testing. Each animal was sequentially hooded inside a clean cotton t-shirt such
that the entire animal was covered. The animal was then loosely constrained by one
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experimenter while another experimenter applied the blunt probe to the dorsal L5-L6 skin
and slowly increased the pressure until the animal exhibited a nocifensive response. The
L5-L6 skin area was ascertained by palpating along the caudal spinal curvature to locate
the area of skin directly superficial to the spinous processes just caudal of the iliac crest.
Positive responses included rolling, rapid movement, and vocalization. Two
measurements were collected for each animal and the average was used as the deep tissue
pressure threshold. All animal thresholds were normalized to baselines to reduce
variability.
Open field test: Spontaneous pain-like behavior was evaluated using the open field test
with custom built acrylic 2’x2’x2’ black, opaque arenas. All animals were allowed to
acclimate to the testing room for 15 minutes prior to testing. Animals were individually
placed in arenas illuminated by overhead red lighting and allowed to explore for 30
minutes while recorded by an overhead low-light camera (ALPCAM). The middle 20
minutes of each video was analyzed using Ethovision (Noldus) for total distance traveled,
time spent rearing unsupported, time spent rearing supported, time spent grooming, max
velocity, average turn angle, and max turn angle. All data were normalized to baselines to
reduce variability.
Motion segment processing: At the study conclusion, L5-L6 discs were resected, fixed,
decalcified, embedded, and sectioned to provide motion segment sections for histological
and immunohistochemical processing. In brief, animals were euthanized using CO2
overdose with cardiac puncture as a secondary measure, and the lumbar spine was
resected, and cleaned using bone cutters. The L5-L6 motion segment was isolated from
the cleaned spine using a fine-tooth hand saw. After, motion segments were placed in a 6-
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well plate with 5 mL of 4% paraformaldehyde (PFA) at room temperature for 24 hours
with agitation. After fixation, motion segments were washed 3 x 15 minutes with 1X PBS
and decalcified for 18 hours in 3 mL of Immunocal (StatLab 1414-32) at room
temperature on an orbital shaker plate at 250 RPM. Decalcified segments were then
washed 3 x 15 minutes with 1X PBS and cryoprotected using an overnight 30% sucrose
soak. Finally, sections were embedded in Optimal Cutting Temperature Compound
(Tissue-Tek) and sectioned in the sagittal plane at 15 µm and 40 µm thicknesses.
Histological processing: 15 µm sections from L5-L6 motion segments were processed
using H&E according to standard protocols. In short, sections were post fixed for 15
minutes with 4% PFA, washed with 1X PBS, and stained with hematoxylin. Following
hematoxylin staining, sections were washed with 1X PBS, differentiated using acid
alcohol, blued with a sodium acetate solution, dehydrated using an alcohol gradient,
counterstained with eosin, dehydrated with xylenes and mounted using Permount (Fisher
Scientific SP15-100). Three motion segment sections from each animal were stained
using the aforementioned process and each motion segment was imaged by collecting and
stitching two images taken with a 10X objective on a Zeiss Axio Observer A1 Inverted
Microscope (Carl Zeiss Microscopy, Inc.).
Immunohistochemistry: 15 µm and 40 µm sections from L5-L6 motion segments were
processed using IHC to visualize inflammatory cytokines and nerve fibers respectively.
Both assessments employed the same IHC protocol but used different primary and
secondary antibodies. Sections were post-fixed with 4% PFA for 15 minutes, washed 2 x
5 minutes with 1X PBS, 2 x 5 minutes with PBST (1X PBS + 0.01% Tween-20), blocked
for one hour with blocking buffer (1X PBS + 3% goat serum + 0.3% Triton X-100), and
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incubated in blocking buffer with either 1:100 mouse-derived anti-rat TNF-α (Santa Cruz
SC-52746) or 1:500 mouse-derived anti-rat NF-H (Abcam ab528399), 1:100 rabbitderived anti-rat PGP9.5 (Abcam Ab108896), and 1:1000 chicken-derived anti-rat
peripherin (Novus NBP1-05423) for 16 hours. After primary incubation, sections were
washed 3 x 15 minutes with PBST and incubated in blocking buffer for one hour with
1:500 goat-derived anti-mouse AF488 (Abcam Ab150177) and, in the case of nerve IHC,
anti-rabbit AF555 (Abcam B150086) and anti-chicken AF647 (ThermoFisher A21449).
Following secondary incubation, sections were washed 3 x 15 minutes in PBST and
incubated with DAPI (ThermoFisher D1306) 1:1000 in PBS for 15 minutes followed by a
3 x 5-minute wash in 1X PBS and then mounted using Prolong Gold (ThermoFisher
P36930). Three motion segment sections from each L5-L6 disc were processed using the
aforementioned method and the entire motion segment images were created by stitching 6
tiles collected on a Cytation 5 (BioTek) at 4X magnification in the following channels or
emission/excitations: brightfield, 377/447 (DAPI), 445/510 (AF488), 531/593 (AF555),
and 628/685 (AF647).
Image Analysis: H&E, nerve fiber IHC, inflammatory cytokine IHC, and cellularity
outcomes were evaluated on three sections from each animal for a total of ~99 images for
each process. Three blinded observers were employed for H&E and nerve fiber scoring.
H&E sections were graded according to a rubric delineated by Lai et al. 2021 excepting
NP cell morphology [160]. To accomplish this process, disc morphology was broken into
NP shape, NP area, NP cell number, NP cell morphology, NP-AF border appearance, AF
lamellar organization, AF tears/fissure/disruptions and endplate
disruptions/microfractures/ossification. Each of these sub criteria was evaluated on a 0-2
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basis, with 0 implying a healthy tissue and 2 implying a degenerated tissue. Observers
were trained on example H&E images until the interobserver agreement exceeded 75%.
For nerve fiber and inflammatory cytokine IHC, the disc was split into 7 zones: dorsal
ligament, dorsal AF, NP, ventral AF inner two thirds, ventral AF outer one third,
granulation, and ventral ligament (Fig 10.). These zones are outlined in Fig. 1. For nerve
fiber IHC, each zone was scored a 0, 1 or 2 based on the presence of 0, 1-3, and 4+ nerve
fibers respectively. For nerve IHC scoring, nerve fibers within the ligamentous tissue
served as ground truths for immunopositivity. A fiber was recognized as either a cross
section, represented by a circular area of intense immunopositivity, or a longitudinal
section, defined by a tract of immunopositivity. Further, for nerve IHC grading, graders
were asked to verify immunopositivity observed in PGP9.5 by comparing to NF-H and
peripherin immunopositivity. All images were individually scored on a high dynamic
range IPS display by three blinded evaluators and each final animal score was calculated
by taking an average of all three motion segments across the three observers. Cell
counting for cellularity and inflammatory cytokine IHC analyses were processed by a
single blinded observer using ImageJ. DAPI images were processed in ImageJ according
to standard methods to approximate number of cells [284]. For inflammatory cytokine
IHC, total number of cells and area of each zone was quantified using ImageJ using the
same method as DAPI counting with two exceptions. For inflammation quantification,
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the particle maximum area set to 200 µm2 and the intensity threshold for 8-bit image
conversion was set to 50-infinity.

Figure 10. Disc breakout by regions. Region specific quantification for IHC analysis was accomplished
by breaking the disc into seven regions. These regions are overlaid on the brightfield image: a = dorsal
ligament, b = dorsal AF, c = NP, d = ventral AF inner 2/3, e = ventral AF outer 1/3, f = granulation, g =
ventral ligament. Scale bar = 1 mm. [3]

Figure 10. Disc breakout by regions
Correlation and Principal Component Analysis: The Pearson correlation analysis and
principal component analysis (PCA) were performed in GraphPad Prism 9. For both
analyses, week 18 µCT and behavioral data were used. The data used from the H&E, disc
nerve, and disc cellularity were the disc only values, i.e., the combination of the AF and
NP values (Fig 5E, 6E, 7E). The disc inflammation data was composed only of the
average number of TNF-α positive cells in the AF (Fig 8E). The ligament cellularity was
composed of the ventral and dorsal ligament cell number average. A visual overview of
the data used can be seen in Table 1. For the grip strength vs. nerve score analysis, week
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16 and week 18 grip strength data was average to get a better approximation of the mean
and this data was correlated to the disc (NP + AF) nerve score. All animals from all
treatments were included in both the correlation and PCA data. The data across the three
treatments represented a spectrum of degeneration and thus associative analyses like the
Pearson correlation and PCA were particularly useful in identifying what consequences
of disc injury related to one another at the 18-week time point.

Table 1. Overview of the data included in the Pearson correlation and PCA. [3]

T

Statistical analysis: All data is presented as mean ± standard deviation. Data were
analyzed using GraphPad Prism 9. Normality was assessed using a Shapiro-Wilk test.
Behavioral and disc volume data were analyzed using a two-way ANOVA with
Dunnett’s post hoc. Each region in cellularity and inflammation data was analyzed using
a one-way ANOVA with a Dunnett’s post hoc. H&E and nerve IHC was analyzed using a
Kruskal-Wallis test with a Dunn’s post hoc. Results were considered statistically different
when p < 0.05.

5.3 Results
Model overview
Sprague-Dawley rats were selected because of their outbred genetics, and well
characterized assays for pain-like behavior assessment [146]. To date, the overwhelming
majority of rodent models of disc degeneration and LBP have been created in male
animals [146, 285]. In contrast, female animals were chosen for this study because LBP
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is 30% more prevalent in aged women than men [286]. Animals were injured at 18-weeks
of age to ensure all animals had reached osseous maturity such that growth related bony
remodeling would not confound the model [287]. In humans, disc degeneration rarely
occurs prior to osseous maturity emphasizing the importance of a correct skeletal growth
state. This study entailed three weeks of acclimation and baseline data collection,
surgery, and 18 weeks of observation (Fig. 11A). During surgery, the L5-L6 disc was
visualized in all animals via a ventral approach after dissecting through the abdominal
wall and retroperitoneum (Fig. 11B). The L5-L6 disc was the target for injury because it
is analogous to the L4-L5 disc in humans which is the most common level of disc
degeneration [194]. For injured animals, a hard point micro-dissecting needle was used to
bilaterally puncture and disrupt the macrostructure of the disc (Fig. 11C). The needle was
rotated along a 90-degree arc in the transverse plane once for animals in the 1-scrape
injury and six times for animals in the 6-scrape injury. This injury resulted in bilateral,
complete annular fissures along with internal macrostructure disruption from the scraping
motion. Annular fissures have been described as major contributors and predictors of
progressive lumbar disc degeneration and LBP in humans [101].
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Figure 11. Animal study overview

Figure. 11. Animal study overview. (A) Timeline of the study. Animals were acclimated for 3 weeks
before collecting baselines. Behavior testing was done every other week and µCT was performed on
weeks 0, 2, 4, 8, 12, and 18. (B) Graphic of the surgical process. The L5-L6 intervertebral disc was
approached ventrally through the abdomen. (C) Graphic of the important aspects of the injury process.
The needle was inserted to a depth of 3 mm and swept back and forth in the transverse plane along a 90°
arc – this process was performed bilaterally. The transparent needle represents the contralateral location
of needle insertion. One animal from the 1-scrape and two animals from the 6-scrape group were
excluded from the study due to mis-puncture. Final animal number per group is shown in bold in
parenthesis. [3]
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Injury results in disc volume loss
To evaluate disc degeneration in real time, microcomputed tomography (µCT)
was used to calculate the L5-L6 disc volume at 0, 2, 4, 8, 12, and 18 weeks. This method
entailed masking the intervertebral disc space between the L5 and L6 vertebral bodies to
create a 3D reconstruction of the disc for which the volume was calculated (Fig.
12A&B). Disc volume in both 1-scrape and 6-scrape groups drastically dropped after
surgery and remained significantly decreased compared to sham at all measured time
points up to week 18 (Fig. 12C). The disc volume method detected highly significant
differences between sham and injured animals at weeks 2, 4, 8 and 12 (p < 0.0001 0.0097). These data confirmed the 1-scrape and 6-scrape injury compromised the
hydrostatic equilibrium the disc, resulting in persistent decreased disc volume.

Figure 12. Disc volume significantly decreases after injury

Figure. 12. Disc volume significantly decreases after injury. (A) 2D rendering with the L5-L6
intervertebral disc space colored in blue. Approximately 20 of these colored slices were concatenated to
make the final object map for which the volume was determined. (B) 3D rendering of the rat lumbosacral
spine with the L5-L6 disc object map colored in blue. (C) Normalized L5-L6 disc volume of all animal
groups. Both injured groups displayed significantly decreased disc volumes compared to sham through
week 12. Significant differences were not observed in week 18 due to the gradual increase of disc volume
in injured animals occurring after week 2. Data is shown as mean with standard deviation (n = 10-12 per
group). # = p < 0.05 sham vs. 1-scrape. * = p < 0.05 sham vs. 6-scrape. [3]
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Injury produces hypersensitivity in evoked pain-like behavior
A battery of pain-like behavior assessments was performed on a biweekly basis to
assess the impact of disc injury on animal function. Grip strength, pressure algometry,
and von Frey assays measured evoked pain-like behavior, entailing direct manipulation of
the animal by an experimenter whereas the open field test measured spontaneous painlike behavior, involving only observation.
The grip strength assay specifically assessed grip strength impairment mediated
by axial strain hypersensitivity (Fig. 13A) [288]. Of note, axial hypersensitivity is
commonly observed in patients suffering disc-associated LBP and has been observed in
mouse models of spontaneous and induced disc degeneration [289-292]. 1-scrape animals
exhibited significantly greater hypersensitivity compared to sham only in weeks 12 and
16 whereas 6-scrape animals exhibited increased hypersensitivity in week 6 and at all
time points from week 10 to 18 (Fig. 13B). The differences observed in grip strength
demonstrated axial strain in injured animals resulted in increased axial pain-like behavior.
Hypersensitivity to deep pressure was determined using a modified pressure
algometry assay (Fig. 13C) [293]. This assay was employed because deep pressure
hypersensitivity has been previously described as highly determinative of LBP in humans
and has been used in another model of painful disc degeneration [200, 294]. Weeks 2 and
4 data were not included because animals displayed strong aversive responses to the
assay in these weeks. Injured animals exhibited significantly increased hypersensitivity
compared to sham animals only at week 10 for 1-scrape and in week 16 (week 18 p =
0.052) for 6-scrape animals (Fig. 13D). This assay was successful in detecting

73

differences between the sham and injured animals but the failure of sham to return to
baseline indicated the measurement was influenced by both surgery and injury.
The von Frey assay was performed to measure referred hypersensitivity and to
rule out radiculopathy confounds (Fig. 13E). Radiculopathy development was a concern
because the needle used to injure the disc could have errantly damaged spinal roots.
Fortunately, unilateral differences in withdraw threshold were not observed indicating the
model was not confounded by spinal root lesions. Referred hypersensitivity in the hind
paw was anticipated in this model because L5 DRG neurons innervate the hind paw
footpad and the dorsal and dorsolateral outer AF, implicating cross-sensitization as a
contributor to pain-like behavior [179, 181, 182, 295, 296]. Sham animals consistently
had higher withdraw thresholds than injured animals, but these differences failed to reach
significance at all time points except for week 14 between sham and 1-scrape. These data
indicated referred hypersensitivity in the hind-paw did not develop after disc injury,
complementing and contrasting prior models in female and male rats, respectively [2,
139].
The open field test was performed to evaluate changes in spontaneous pain-like
behavior (Fig. 13G). LBP increases movement disability in humans so it was presumed
animals suffering disc-associated pain may exhibit similar changes [297]. No significant
differences were observed at any time point in all quantifications including total distance
traveled, time spent rearing unsupported, time spent rearing supported, time spent
grooming, max velocity, average turn angle and max turn angle (Fig. 13H & data not
shown). During analysis, it was determined that a slight difference in box illumination
due to the arenas not being symmetrically arranged under the overhead lighting affected
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the roaming behavior (Fig. 13G). The data collected from this assay could be improved
in the future by addressing this confound.
These pain-like behavior data indicate the 1-scrape and 6-scrape injury resulted in
hypersensitivity to axial strain and pressure but did not result in detectable changes in
referred hypersensitivity, radiculopathy, nor changes in spontaneous open field behavior.
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Figure 13. Disc injury results in evoked pain-like behavior hypersensitivity
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Figure. 13. Disc injury results in evoked pain-like behavior hypersensitivity. Evoked pain-like
behavior assays: grip strength (A&B), pressure algometry (C&D) von Frey (E&F). (B) Normalized grip
strength data. 6-scrape animals developed significant hypersensitivity compared to sham animals that
persisted for 8 weeks. 1-scrape animals displayed hypersensitivity compared to sham in weeks 12 and 16.
(D) Normalized pressure algometry data. 6-scrape animals exhibited significant deep pressure
hypersensitivity compared to sham animals in weeks 16 but not week 18 (p < .052). 1-scrape animals
exhibited significant hypersensitivity in week 10 compared to sham. (F) Normalized combined left and
right hind-paw von Frey data. The average injured animal thresholds were consistently lower than sham
animals but failed to reach significance except in week 14 compared to 1-scrape. (G) Screen capture of
animal spontaneous pain-like behavior measured in the open field test. (H) Total distance traveled by the
animals in the open field. No significant differences were observed. Data is shown as mean with standard
deviation (n = 10-12 per group). # = p < 0.05 sham vs. 1-scrape. * = p < 0.05 sham vs. 6-scrape. [3]

Injury results in disc degeneration and ECM breakdown
At the study conclusion, all animals were euthanized, and motion segment
sections were stained with hematoxylin and eosin (H&E) to grade morphological signs of
disc degeneration according to a previously established method [160]. NP cell
morphology was omitted from the criteria outline by Lai et al. because section thickness
(15 µm) made grading this feature unfeasible. Sham animal discs contained healthy,
GAG rich NPs and AFs with regularly spaced, uniform lamellae (Fig. 14A). All animals
displayed signs of end plate ossification highlighted by the arrowhead in box II,
presumably due to natural aging (Fig. 14A-II). Both 1-scrape and 6-scrape animals
exhibited less hematoxylin staining in the NP compared to sham, indicating a loss of
glycosaminoglycans and cell nuclei (Fig. 14B&C). Hypertrophic cells identified by
enlarged nuclei were visible in the AF of injured animals close to hypocellular tissue
around the needle tract (Fig. 14B-III arrowhead & Fig. 14C-V). All degenerated discs
contained granulation tissue between the ventral margin of the disc and ventral ligament
(Fig. 14B & Fig. 14C-V arrowhead). Interestingly, multiple animal motion segments
across both injury groups contained ongoing herniations, one of which can be seen in box
IV (Fig. 14B-IV). To score each section, NP shape, NP area, NP cell number, NP border
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appearance, AF lamellar organization, AF tears/fissure/disruptions and endplate
ossification were graded on a 3-point scale. Individual criteria for H&E scores measured
significantly increased degeneration in all criteria between injured and sham animals
except the end plate (Fig. 14D). Summated scores also confirmed significantly increased
overall degeneration in injured animals (Fig. 14E). In summary, the H&E data
demonstrated the 1-scrape and 6-scrape injury induced disc degeneration as measured by
an established semi-quantitative protocol.
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Figure 14. Injury to the disc results in disc degeneration.

79
Figure. 14. Injury to the disc results in disc degeneration. Representative H&E images from the sham
group (A), 1-scrape group (B), and 6-scrape group (C). (A) ROI box I draws focus to appearance of a
healthy AF structure present in sham animals. All animals exhibited endplate degeneration as highlighted
by the arrowhead in ROI box II. (B) ROI box III focuses on the hypocellularity and disruption of the AF
in 1-scrape animals. Arrowhead points to hypertrophic cells in the AF. ROI box IV highlights cellular
infiltrate present around an ongoing NP herniation. Evidence of these herniations were found in injured
discs across both 1-scrape and 6-scrape animals (C) The ROI box V arrowhead points to granulation
tissue present on the ventral margin, between the AF and ventral ligament in 6-scrape animals. ROI box
VI shows the hypocellularity of degenerated NP tissue and the arrowhead points to a group of NP cells
sequestered in a lacuna. Disc image scale bar = 1 mm. ROI box scale bar = 250 μm. (D) Summary of the
H&E scores broken down by individual criteria. 1-scrape and 6-scrape scores were significantly higher
compared to sham in all categories except end plate. 6-scrape injury resulted in 50% higher average H&E
scores compared to 1-scrape, but this failed to reach significance (p < .09) (E) Summed averages of the
individual H&E scores. 1-scrape and 6-scrape scores were significantly higher than sham. The bimodal
distribution of scores in the 1-scrape animal group was accounted for by partial healing of the injury
defect in three of the 1-scrape animals. Data is shown as mean with standard deviation (n = 10-12 per
group). * = p < 0.05 sham vs. 6-scrape. [3]

Injury results in disc hypocellularity
Another important aspect of human disc degeneration is disc hypocellularity
[298]. As a proxy for cells, nuclei were counted using an automated analysis of DAPI
staining. The NP areas in sham animal sections were densely packed with cells and the
AF displayed bands of cells consistent with the lamellar structure (Fig. 15A). Conversely,
injured animal sections exhibited sparce cellularity in the AF, particularly around the site
of needle insertion (Fig. 15B-IV & Fig. 15C-VI). The NP of 6-scrape and 1-scrape
sections contained nuclei sequestered to lacunae as noted by the arrowheads in boxes III
and V (Fig. 15B&C). Granulation tissue, dense with cells, was present in almost all
injured animals and can be seen at the arrowhead in box VI (Fig. 15C). To quantitatively
assess differences, nuclei number was counted using the same region scheme as the nerve
IHC analysis. Compared to sham animals, 1-scrape disc tissue was significantly less
cellular in the ventral AF but was more cellular in the ventral ligament (Fig. 15D). 6scrape animals displayed significantly higher cellularity in both ligaments but
significantly lower cellularity in all regions of the disc compared to sham animals (Fig.
15D). The average cellular density of the ventral AF, NP and dorsal AF was also
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computed, and both injured groups exhibited significantly lower cell density compared to
sham (Fig. 15E). This cellularity analysis confirmed the 1-scrape and 6-scrape injury
created a disc environment incompatible with cell survival, like that observed in humans.

Figure 15. Degenerated disc are hypocellular
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Figure. 15. Degenerated discs are hypocellular. Representative cellularity (DAPI) images from the
sham group (A), 1-scrape group (B), and 6-scrape group (C). (A) Sham animals exhibited dense
cellularity in the NP and AF as shown in ROI boxes I & II. (B) 1-scrape animals displayed NP
hypocellularity with cells predominantly isolated to lacunae (arrowhead), box III. Box IV highlights the
AF hypocellularity. (C) 6-scrape animals exhibited widespread hypocellularity. Box V focuses on the loss
of cells in the NP and highlights the isolation of remaining cells to lacunae (arrowheads) like box III in
1-scrape animals. Finally, box VI emphasizes the hypocellularity of the AF around the needle tract and
the presence of thick granulation tissue (arrowhead) between the ligament and ventral AF. Whole disc
image scale bar = 1 mm. ROI box scale bar = 250 μm. (D) Summary of the cellularity scores broken down
by zones. 6-scrape ligamentous tissue was hypercellular compared to sham. All disc zones in 6-scrape
animals were hypocellular compared to sham. 1-scrape sections exhibited hypocellularity in the ventral
AF and hypercellularity in the ventral ligament. (E) Average of the NP and AF cellularity averages. Disc
tissue from 1-scrape and 6-scrape animals was significantly more hypocellular than sham tissue. Data is
shown as mean with standard deviation. Two animals from the 1-scrape were excluded due to a lack of
usable sections (n = 9-12 per group). Significant differences between groups were assessed using a oneway ANOVA. # = p < 0.05 sham vs. 1-scrape. * = p < 0.05 sham vs. 6-scrape. [3]

Injury increases nerve sprouting into the disc
To assess if aberrant nerve sprouting coincided with disc degeneration, like in
humans, motion segment sections were processed using immunohistochemistry (IHC) to
visualize PGP9.5 (pan neuronal marker), the heavy chain of neurofilament (NF-H), and
peripherin (small diameter fiber marker). NF-H and peripherin were included to
differentiate nerve fibers, but after processing and validation in DRG sections, it was
discovered that unphosphorylated NF-H is expressed across most fiber types in rats
limiting its ability to differentiate fibers, and this phenomenon was further suggested by
neurobiology research [299-302]. Expectedly, all animals exhibited consistent
immunopositivity in the dorsal and ventral ligaments as these structures require
innervation for proprioception [303]. Sham animal sections displayed little
immunopositivity for any neuronal marker within the disc, but when present, nerves were
predominantly in the outer layers of the dorsal AF as noted by an arrowhead (Fig. 16A).
In contrast to sham animals, 1-scrape and 6-scrape animal sections exhibited positivity in
all regions of the disc, especially in the dorsal and ventral outer one third AF (Fig.
16B&C). Unlike 1-scrape sections, nerve fibers in 6-scrape scrape samples were
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commonly observed deep in the tissue along the border of the NP (Fig. 16C).
Advancement of nerves fibers into the interior disc structures in this model directly
parallels human data in which nerves are observed to penetrate from the peripheral AF
into the disc interior [116, 118]. Significantly higher nerve scores were present between
injured and sham animals in all regions apart from the ligamentous tissue. Summation of
disc only nerve scores, i.e., ventral AF, NP, and dorsal AF, affirmed an overall increase
in innervation of injured discs compared to healthy discs (Fig. 16E). The observations
and quantifications made from nerve IHC data strongly suggest the 1-scrape and 6-scrape
injury along with subsequent degeneration created a neuro-permissive environment
throughout the disc, allowing aberrant nerve sprouting into all disc regions.
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Figure 16. Nerves sprout into degenerated discs.
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Figure. 16. Nerves sprout into degenerated discs. Representative nerve (PGP 9.5) images from the
sham group (A), 1-scrape group (B), and 6-scrape group (C). Arrowheads point to nerve fibers. PGP9.5
immunopositivity in the ligamentous tissue was used as ground truth for nerve fiber quantification. (A)
Box I highlights the presence of nerve fibers located in the ventral ligament of a sham section in sham
animals. Very rarely were nerve fibers observed in the discs of sham animals as shown in box II. (B) Box
III shows a handful of fibers located in the dorsal ligament of 1-scrape animals. Box IV highlights the
presence of a nerve fiber in the ventral AF of a 1-scrape animal. (C) Box V highlights multiple nerve
fibers found in the dorsal AF of a 6-scrape section. Box VI exhibits a multitude of nerve fibers in the
ventral AF of a 6-scrape animal. Whole disc image scale bar = 1 mm. ROI scale bar = 250 μm. (D)
Evaluation of nerve fibers by location and treatment. 1-scrape and 6-scrape animals contained
significantly more nerves than sham animals. (E) Summation of the NP and AF nerve scores. Both 1scrape and 6-scrape nerve scores were significantly greater than sham. Data is shown as mean with
standard deviation. One animal from the 1-scrape was excluded due to a lack of usable sections (n = 1012 per group). The ventral ligamentous tissue in all animals contained 4+ nerves resulting in a standard
deviation of zero. # = p < 0.05 sham vs. 1-scrape. * = p < 0.05 sham vs. 6-scrape. [3]

Injury results in disc cell TNF-a expression
Increased inflammation is consistently observed in disc samples from patients
suffering LBP suggesting it is a contributing factor to disc-associated pain [280, 304,
305]. To assess inflammation in this model, TNF-α was visualized in disc sections using
immunohistochemistry and TNF-α+ cells were counted. 1-scrape and 6-scrape disc cells
exhibited immunopositivity for TNF-α especially in the ventral AF and granulation tissue
(Fig. 17B-IV & Fig. 17C-VI). Significantly increased cellular inflammation was observed
in the ventral AF and ventral ligament of 6-scrape animals compared to sham (Fig. 17D).
The dorsal and ventral AF tissue values were then summated to get a total disc
approximation of TNF-α positivity (Fig. 17E). The NP was excluded from this sum due
to the abnormal staining pattern which is discussed later. 6-scrape AF tissue contained
significantly more TNF-α positive cells than sham discs. In conclusion, these data
confirmed the injury and subsequent degeneration promoted production of TNF-α,
indicative of inflammation, but further work is needed to validate these results and to
determine the inflammatory state of healthy NP.
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Figure 17. Degenerated disc cells express TNF-α

86
Figure. 17. Degenerated disc cells express TNF-α. Representative TNF-α images from the sham group
(A), 1-scrape group (B), and 6-scrape group (C). (A) Sham animal NPs stained extensively with TNF-α
although it remains unclear if this is true immunopositivity. Sparce immunopositivity was observed in
the dorsal and ventral AF of sham animals as seen in box I & II respectively. (B) 1-scrape sections
contained immunopositive cells predominantly in the ventral AF, box IV, although some immunopositive
cells were observed in the dorsal AF, box III. 1-scrape and 6-scrape NPs contained immunopositive areas,
but this staining was fainter than sham NPs. (C) Boxes V & VI highlights immunopositivity in the dorsal
and ventral AF tissue of 6-scrape animals. Arrowheads in both (B) and (C) point to cells which were
strongly immunoreactive for TNF-α. Whole disc image scale bar = 1 mm. ROI scale bar = 100 μm. (D)
Summary of the TNF-α cellular quantification broken down by zones. Significantly more TNF-α+ cells
were found in 6-scrape ventral AF and ligamentous tissue. (E) Disc total averages, excluding NP, of TNFα+ cell scores. Disc cellular TNF-α was significantly higher in 6-scrape animals compared to sham. Data
is shown as mean with standard deviation. Two animals from the 1-scrape group were excluded due to a
lack of usable sections (n = 9-12 per group). Significant differences between groups were assessed using
a one-way ANOVA. # = p < 0.05 sham vs. 1-scrape. * = p < 0.05 sham vs. 6-scrape. [3]

Pain-like behavior was significantly correlated with post-processing outcomes
A Pearson correlation analysis in GraphPad Prism 9 was performed to determine
how disc volume, grip strength, von Frey, pressure algometry, distance traveled, H&E,
disc nerves, ligament cellularity, disc cellularity, and disc inflammation were associated
with one another at 18-weeks. Semi-quantitative and ordinal data sets were included in
this analysis because for each semi-quantitative or ordinal data point, nine measurements
were averaged making all the data semi-continuous and thus useful for comparison.
Twenty significant correlations were revealed among the ten selected assessment
outcomes (Fig. 18A). The analysis revealed that important facets of disc degeneration
hypothesized to contribute to disc-associated pain in humans, like disc volume loss and
nerve sprouting, were significantly correlated with pain-like behavior. The relationship
between the average of the final two collections of grip strength and nerve score was
highly significant (p <.0004) with a moderate correlation of -0.59 (Fig. 18B). A principal
component analysis was also performed in GraphPad Prism 9 to impute factors
contributing the most variability in the model’s 18-week data set. Because this analysis is
agnostic to treatment status, it was able to provide insight into what factors most strongly
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contribute to data point distribution in a blinded manner. Principal component 1
accounted for 42% of variability across all selected data sets. Assessments which were
successful in detecting robust differences between injured and sham animals split along
principal component 1 suggesting this component is related to injury (Fig. 18C). The
correlation and principal component analysis provided crucial insight into how nerve
sprouting was tied to disc-associated pain-like behavior and confirmed most assessments
were accurate in detecting differences due to injury. Further, the highly significant
correlation between grip strength and nerve sprouting implies this model was successful
in producing a degenerative disc pain-like phenotype.
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Figure 18. Relationships between data sets.

Figure. 18. Relationships between data sets. (A) Correlation matrix of various behavioral and postprocessing analyses. Strong correlations were found between grip strength and disc nerve score and
among various post-processing outcomes. (B) Association between nerve score and the average grip
strength in the final 2-weeks. This relationship was highly significant and moderate in strength. (C) PCA
loadings of the top two principal components. H&E, inflammation, nerve score, and ligament cellularity
skewed negative along PC1. Disc volume, grip strength and disc cellularity skewed positive along PC1.
Pressure algometry, Von Frey, and distance traveled skewed negative along PC2. PC1 was assumed to
be injury due to the distribution of assessments which were metrics of degeneration along this axis.
Significant correlations between groups were assessed using a correlation analysis in Prism 9. * = p <
0.05. [3]
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5.4 Discussion
This work provides the basis of an animal model of disc-associated pain that
accurately approximates the human condition. The chronic pain-like behavior, which was
correlated with disc degeneration and nerve fiber sprouting, presents strong evidence this
model was successful in creating a pain-like phenotype that resulted from pathological
shifts in the disc. Additionally, four important characteristics of human degenerative
discs, namely, ECM breakdown, hypocellularity, inflammation and aberrant nerve
sprouting were manifested in our model, demonstrating comprehensive model validity.
Special consideration was given at the beginning of this study to develop a
degeneration induction mechanism that replicates a traumatic event. The needle puncture
procedure was refined using sixty rat motion segments (data not shown) to create a
traumatic fissure which perforated the AF and resulted in a degenerative phenotype
highly analogous to the human clinical presentation of a radiating annular tear (Fig. 11C)
[306]. Assessing changes in the disc due to injury using µCT was important as a litmus
test for injury success and to track changes in the disc real-time. At two-weeks postinjury, the volumetric method developed in our lab (under review), detected a highly
significant decrease of disc volume in injured animals compared to controls confirming
successful disc injury.
Provided the knowledge that injury decreased disc volume, the next important
question was if injury and ongoing degeneration resulted in pain-like behavior changes.
Patients suffering LBP experience movement evoked pain, indicating mechanical
agitation of the spine can exacerbate nociception [307, 308]. The highly significant (week
16 & 18 p < .0001) and substantial reduction in grip strength between 6-scrape and sham
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animals across eight time points implied disc injury resulted in hypersensitivity to axial
strain. We believe the grip strength assay was sensitive to degenerative changes because
the L5-L6 motion segment is the most caudal spinal structure with significant degrees of
freedom involved in this assay. The L6-S1 motion segment is relatively translationally
locked because it is fused to the sacrum and iliac, both of which have multiple stabilizing
muscle attachments. The immobility of L6-S1 suggests the axial stress imparted on the
spine by the pulling motion disproportionately affects the L5-L6 motion segment because
musculature is not present to partially distribute the load. Supporting this hypothesis, we
observed a distinct increase in spinal curvature above the L5-L6 motion segment in all
animals during the grip strength assay. Given the abundance of nerves in degenerated
discs and these features, it is likely the axial strain led to increased nociceptor
depolarizations in degenerated discs, causing cognitive or spinal reflex mechanisms to
release the grip plate at a lower threshold compared to sham. Also, the persistent and
progressive decrease in 6-scrape grip strength suggested underlying pathological shifts
due to injury drove hypersensitivity rather than acute effects. To our knowledge, no other
rat model of disc degeneration has measured increased axial hypersensitivity to this
extent longitudinally. Pressure algometry was performed to provide another metric of
evoked pain-like behavior. Unlike grip strength, this assay provoked the disc through
shear and axial strain. Similar to a prior model of repeated disc puncture [200], pressure
algometry detected differences between sham and injured animals at multiple time points,
implying nociceptors in the degenerative tissue were activated by shear strain albeit less
so compared to axial strain. In difference to well established models of disc degeneration
[139], we failed to detect signs of referred hypersensitivity measured by the von Frey
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assay. The presupposition behind this assay was that dichotomizing neurons innervating
both the hind paw and the degenerated disc could be phenotypically altered by the
inflammation present in the degenerated disc giving rise to hind paw referred
hypersensitivity. Despite sham exhibiting higher thresholds than injured animals at all
time points except week 2, these differences failed to reach significance suggesting
referred hypersensitivity was not strongly present. The discrepancy between our model
and other models could be due to sex differences in pain, degree of injury, pain masking
and innervation especially considering another study witnessed similar results with von
Frey characterization on female rats after disc injury [2]. Further, sham animals exhibited
higher withdraw thresholds compared to injured animals at all time points, indicating we
may have lacked sufficient statistical power to detect differences. The final method used
to gauge pain-like behavior was the open field test which did not measure any significant
difference.
The disc volume and behavior data suggested injury resulted in pathological disc
changes, but these pathologies were unknown. To elucidate the factors underpinning the
behavioral changes, we quantified four key aspects of degeneration found in disc samples
from LBP patients: ECM breakdown, hypocellularity, aberrant nerve sprouting, and
inflammation. The first assessment employed was H&E analysis which is the gold
standard for measuring disc degeneration and incorporates multiple metrics of ECM
breakdown. End plate ossification present in all animals was consistent with previous
literature which observed endplate calcification in 94% of sand rats at the equivalent
spinal level and age [309]. Unexpectedly, all healthy NP lacunae stained with eosin
(pink) which can be seen in Figure 4A-II, albeit slightly masked by dark hematoxylin
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(purple) staining. This unexpected staining indicates that NP lacunae in rats are different
in charge and composition than the surrounding ECM. Additional insight was provided
by H&E concerning the radial expansion and volume increase of degenerated discs noted
in µCT. For healthy discs, the vertebral bodies always terminated in line with the ventral
AF. However, depending on the severity of degeneration, granulation tissue up to 500 µm
thick was present between the outer edge of the AF and the ventral ligament in injured
discs, paralleling granulation tissue found in human degenerated discs [310]. In all cases,
the granulation tissue was flanked caudal and cranial and sometimes further ventrolateral
by bony deposition suggesting it was load bearing. Gradual deposition of this granulation
tissue may have been the factor that drove disc volume increase following injury.
Similar to human data, degenerated discs in our model were hypocellular with
large swaths of the ventral AF in injured animals completely devoid of nuclei.
Hypocellular tissue predominantly expanded around the site of needle puncture in the
AF, indicating secondary aspects of the tissue defect inhibited cellular survival. One
possible explanation for this hypocellularity is that matrix catabolism resulted in
deleterious loading patterns, causing apoptosis through the MAPK pathway [311-313].
Also like human degeneration, there was cellularized granulation tissue around the
ventral surface of the disc [314]. We presume the increased cellularity in the ligamentous
tissue of injured animals was a result of infiltrating fibroblasts into the granulation zone.
Nerves in the disc were quantified because aberrant nerve sprouting is
hypothesized as a source of painful disc degeneration. In our model, nerve sprouting was
ubiquitous across degenerated discs. Because three sections were analyzed for each
animal, some nerve fibers could be visualized passing between sections, confirming with
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high certainty the immunopositivity was indicative of nerve fibers. When present in
degenerated discs, nerves were enriched around annular fissures and in areas of clear
tissue disruption which directly compliments human data [116, 118, 120, 315]. This bias
in locality may be accounted for by cytokines like NGF, which is known to be produced
by degenerating disc cells and stimulates neuronal ingrowth [316]. The proximity of
nerves to the disrupted tissue may have predisposed them to activation during mechanical
aggravation.
Inflammation proved to be the most difficult to analyze in our model. Strong
staining of the NP with TNF-α contradicted literature that has quantified this cytokine in
degenerated and healthy discs [304]. Of note, the areas of healthy NP that were
immunoreactive with the TNF-α antibody precisely aligned with the areas of healthy NP
that unexpectedly stained with eosin in H&E suggesting electrostatic interactions may
have driven false-positivity [317]. Abnormal IHC staining of the NP has been observed in
rodents previously suggesting this staining is a false positive [291]. We also witnessed
this phenomenon infrequently with other antibody targets but failed to see this
phenomenon with secondary only controls. Despite these obstacles, we believe counting
TNF-α+ cells was sufficient to gather an approximation of discal inflammation.
After analysis of individual data sets, we then evaluated how week 18 and postprocessing data sets related to one another and how well our assessments measured
differences due to injury. To answer these questions, we performed a correlation and
principal component analysis to impute relationships between data sets and contributors
of variance respectively. The correlation value of 0.88 between nerve score and H&E
suggested disc breakdown was intrinsically tied to the production of a neuropermissive
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environment. The notion that disc volume can serve as a proxy of degeneration was
validated by the significant correlation of -0.40 between H&E and disc volume. Greatly
important to the validity of this work was the significant correlation of -0.59 between
nerve score and grip strength. This moderate relationship provides evidence that nerve
presence could be the basis for disc-associated pain. This relationship was limited by the
contribution of nociceptive fibers in the granulation and ligamentous tissue, as well as
changes in the facet joints, end plates, and paraspinal muscles which were not a part of
the nerve score but could have contributed to overall axial hypersensitivity. The role of
nerve infiltration in pain development could be further elucidated in the future by
assessing this relationship longitudinally. The principal component analysis revealed PC1
accounted for 42% of variability across all data sets used in the correlation analysis. The
Eigenvector of this component was more than double that of PC2, suggesting it was an
overwhelming contributor to assay variance. Assays which measured differences due to
treatment tended to cluster on each end of the PC1 axis, indicating this component was
related to treatment.
This work has a few limitations in addition to those already mentioned. First, only
female animals were employed making it unclear how sexual dimorphism may relate to
the onset of disc degeneration and pain. Further, animals were housed randomly
implicating affect contagion as a possible confounding factor in behavioral data [318].
Finally, predictive validity was not measured to verify that the pain could be alleviated
via treatments which have efficacy in humans. Work is ongoing to address these
limitations in future use of this model.
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In summary, construct validity was intrinsic to this model because degeneration
induction mimicked an annular radiating tear, which occurs in 50% of human discs by
age 35 [306]. Face validity was robustly upheld by significant increases in axial
hypersensitivity, deep pressure hypersensitivity, disc degeneration, inflammation,
hypocellularity and aberrant innervation. Therapies with known effects, like opioids,
must be tested in the future to verify predictive validity. We hope this model will provide
utility for the advancement of translatable therapeutics and basic science around LBP
which is an immense problem that plagues modern society.

The work described in Chapter 5, constitutes a scientific paper which was published in
the Journal of Orthopedic Research Spine [3].
Lillyman, D. J., Lee, F. S., Barnett, E. C., Miller, T. J., Alvaro, M. L., Drvol, H. C., &
Wachs, R. A. (2022). Axial hypersensitivity is associated with aberrant nerve sprouting in
a novel model of disc degeneration in female Sprague Dawley rats. JOR Spine, e1212.
https://doi.org/10.1002/jsp2.1212
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CHAPTER 6: Extracellular matrix hydrogel derived from
porcine nucleus pulposus restores disc volume and alleviates
axial hypersensitivity
6.1 Introduction
Low back pain (LBP) is the leading contributor to disability worldwide [253]. The
majority of those who suffer an episode of LBP recover, but for some, the pain persists
and becomes debilitating [254]. Chronic LBP imposes a tremendous socioeconomic
burden on the world by increasing risk of unemployment, depression, insomnia, suicide,
and healthcare expenditures [255-257]. The predominant etiology for this condition is
pain arising from the intervertebral disc (IVD), termed disc-associated pain [22]. Patients
suffering disc-associated low back pain exhibit pathological changes in their IVDs,
including, hypermobility, inflammation, and innervation [103, 118, 319]. Despite the
understanding of these fundamental aspects of disc-associated pain, more than half of
patients fail to achieve remission after treatment [131, 133-135, 254, 277, 320]. For select
patients, IVD fusion and stabilization therapies can be effective short term in reducing
pain and disability [60, 61, 133, 276, 321, 322]. The remission these patients experience
suggests IVD mechanics may be a key therapeutic target for disc-associated pain. Herein
we describe a novel biomaterial which increases injured IVD rheological properties in
vitro and restores disc volume and alleviates axial hypersensitivity in female Sprague
Dawley rats, in vivo.
The IVD is a cartilaginous tissue that acts as a joint between vertebral bodies of
the spine and is predominantly aneural [79]. Due to age, injury, environment and/or
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genetics, cells of the IVD can become stressed, upending tissue homeostasis into
catabolism [102, 103]. IVD catabolism is defined by a pro-inflammatory milieu
consisting of cytokines, chemokines and enzymes such as TNF-α, IL-1β, IL-6, CCL2,
CCL5, MMPs and ADAMTs [114, 280, 323, 324]. These factors recruit and activate
immune cells and break down the extracellular matrix, resulting in inflammatory
persistence and biomechanical decline [325]. Coinciding degeneration, a loss of
neuroinhibitory proteoglycans and formation of annular fissures creates a neuropermissive environment, allowing nerves to aberrantly penetrate the IVD [79]. While the
presence of nerves within degenerated IVD is the basis for pain, there is considerable
evidence that altered biomechanics drives nociception, poising hypermobility as the
primary causative agent in disc-associated pain [319, 326]. In fact, spinal destabilization
alone can produce disc-associated pain-like phenotypes in animals [140, 191, 326-328].
Further, patients treated with IVD stabilizing treatments like surgical fusion, which
rotationally and translationally lock the IVD, or spinal stability exercises which impart
stronger musculature control over spinal movements, often report pain remission in the
short term [60, 61, 132, 133].
We have recently described an animal model of disc-associated low back pain in
rats that exhibits overt IVD degeneration and pain-like hypersensitivity. Pain-like
behavior in this model is detected during actions which apply strain on the degenerated
IVD implying mechanical perturbation as a driver of pain-like behavior. Further, analysis
of degenerated IVD morphology revealed the presence of radiating annular tears
suggesting degeneration in our model compromises IVD mechanics and macrostructure
like what is observed in humans [76, 101, 154, 329]. This knowledge provided the
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impetus to engineer a therapeutic that restores IVD tissue mechanical properties to
improve pain-like behavior.
The objective of this work was to create a biomaterial capable of annealing macro
and microscopic defects in the degenerated IVD tissue in hopes of stabilizing degenerated
IVD and in turn lessening disc-associated low back pain. Our lab has developed a novel
biomaterial, decellularized nucleus pulposus hydrogel (dNP), derived from decellularized
healthy IVD material, that is spontaneously fibrillogenic, cytocompatible, and
neuroinhibitory. We modified the constituent concentrations of this biomaterial and
added a collagen crosslinker, genipin, to create a robust hydrogel capable of integrating
with degenerated IVD tissue. Herein, we demonstrate this biomaterial, dNP+, is
cytocompatibility, and is effective at restoring IVD volume, disc mechanics, and
alleviating axial hypersensitivity when administered 8-weeks after degeneration is
initiated.

6.2 Materials and Methods
Whole disc decellularization: Whole disc decellularization was accomplished using a
previously established protocol [235]. In short, cervical spines from commercial line
Landrace/Yorkshire/Duroc young female pigs (~200 days of age) were aseptically
collected and frozen (-80 °C) following humane slaughter at the United States Meat
Animal Research Center Abattoir (Clay Center, NE, USA; USDA Material Transfer
Agreement). The spines were then cleaned aseptically and the NPs of the C2-C7
intervertebral discs were surgically removed. NPs were decellularized using a series of
detergent and buffer washes as outlined before. Finally, decellularized NPs were
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lyophilized (FreeZone 4.5 L Freeze Dryer (7750020, Labconco)) and stored at -80 °C
until use.
Digestion and preparation of dNP: The creation of the dNP followed a previously
described method with a few exceptions. First, lyophilized decellularized NP was
comminuted via cryogenic pulverization using a steel mortar and pestle and liquid
nitrogen. 20 mg/mL of comminuted dNP was digested using 1 mg/mL of pepsin (P6887,
Sigma-Aldrich) in 0.05 N HCl for 44 hours at 300 rpm using a magnetic stir bar.
Following digestion, all steps for making dNPs were performed on ice, until incubation at
37 °C. 10X PBS was added first to the preparation to ensure a final concentration of 1X
PBS after following component additions. Next, volumes to ensure 6 mg/mL dNP digest
and 6 mg/mL collagen I (Ibidi, 50201) were added to the 10X PBS. The digest was then
neutralized with 5 M NaOH to pH ~7.4. Finally, genipin (TCI Chemicals, G0458-25MG)
at a stock concentration of 400 mg/mL in DMSO was added to the neutralized dNP
solution to yield concentrations ranging from 0 mM to 20 mM. The final formulation
used in vivo consisted of: 1X PBS, 6 mg/mL collagen, 6 mg/mL dNP and 2.5 mM
genipin. Throughout this manuscript, this final formulation is referred to as dNP+.
Gelation kinetics: The rate at which the dNPs achieved complete fibrillogenesis and
were cross-linked by genipin was assessed using an absorbance assay. Collagen
fibrillogenesis was measured using absorbance at 405 nm as previously described [235].
Genipin cross-linking was measured using absorbance at 610 nm. This wavelength was
chosen because genipin produces genipin blue, which has high absorbance at 610 nm, as
part of the cross-linking process [249]. To measure these two absorbances longitudinally,
50 µL of dNPs with genipin concentrations of 0, 0.1, 0.5, 1, 2.5, 5, 10, and 20 mM were
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prepared and pipetted in duplicate into a 96 well plate. The plate was then placed into a
microplate reader, pre-heated to 37 °C and the absorbance was read once every two
minutes for 12 hours at 405 and 610 nm. A total of n = 3 different preparations were
evaluated with two technical replicates in each preparation.
Gel rheological characterization: Rheological analysis of dNPs was performed to
evaluate how genipin crosslinking affected mechanical properties. Rheology testing was
performed on gels using an Anton Paar MCR 302 with sand blasted plates. Briefly, dNP
gels were formed by pipetting 100 uL of the gel solutions into 8-mm diameter silicone
molds (666305, Grace Bio-Labs). The gels were sandwiched between glass slides within
the molds to prevent desiccation and incubated at 37 °C for 24 hours to allow for
complete fibrillogenesis and cross-linking. After gelation, the gels were soaked in 1X
PBS for 30 minutes to reach a replicable osmotic equilibrium. An amplitude sweep was
conducted to determine the storage and loss modulus across strains analogous to human
movement [330]. This characterization entailed measuring the storage and loss moduli
across a strain range from 0.1-1.66% at an angular frequency of 5 Hz. This angular
frequency was chosen because it is analogous to the compressive cycling frequency
during movement [170, 331]. The average storage and loss modulus from 0.137-0.477%
strain was computed as the storage and loss modulus for each gel. Gels were fabricated
and tested in duplicate, and this process was repeated three times (n = 3).
Motion segment rheological characterization: Rheological analysis of rat motion
segments was performed to evaluate how treatment with dNP+ affects disc mechanics
after injury in an ex vivo setting and 8-weeks after administration in the animal model.
Rheological assessment was performed on motion segments using an Anton Paar MCR
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302 rheometer with sand blasted plates. Briefly, motion segments were excised from
cadavers and potted in custom 3D printed pots using Loctite 401. For the ex vivo work,
L4-L5, L5-L6, and L6-S1 motion segments were used. After pot fixation, motion
segments were allowed to equilibrate overnight in 1X PBS at 4 °C. To analyze, motion
segments were brought to room temperature and attached to the rheometer base plate and
probe using labeling tape. An amplitude sweep was then conducted to determine the
storage and loss modulus across strains analogous to human movement [330]. This
characterization entailed measuring the storage and loss moduli across a strain range from
0.1-1.66% at an angular frequency of 5 Hz. The average storage and loss modulus from
0.137-0.477% strain was computed as the storage and loss modulus for each motion
segment. For the ex vivo work, PBS and dNP+ motion segments were then injured using
the six-scrape injury method described in the injury surgery methods. These motion
segments were equilibrated again overnight and mechanically assessed the following day
using an amplitude sweep with the previously described parameters. Once the post-injury
values were collected, the PBS and dNP+ motion segments were injected with 1X PBS or
dNP+ respectively. All motion segments were placed in a humidified incubator for 8
hours at 37 °C followed by overnight equilibration in 1X PBS at 4 °C. All motion
segment rheology was assessed a final time and all values were normalized against
baseline. Non-injured motion segments were included in the ex vivo work as additional
controls.
Cytotoxic Assessment of dNP+: To evaluate the cytotoxicity of dNP+ in vitro, human
NP cells were cultured on top of dNP+ gels. In brief, P3 human NP cells (4800,
ScienCell) were cultured in a T75 flask (CLS430641U, Sigma Aldrich) coated with 15

102

µg of Poly-L-Lysine (0413, ScienCell) using Complete Nucleus Pulposus Cell Media
(4801, ScienCell) till confluent to prepare NP cells for treatment plating. 48-well plates
were prepared for treatment culture by coating with either nothing (PS) or with 10 µL of
6 mg/mL collagen gel, 6 mg/mL collagen + 6 mg/mL dNP gel, or 6 mg/mL collagen + 6
mg/mL dNP + 2.5 mM (dNP+) genipin gel. The coatings were gelled for 8 hours at 37 °C
in a humidified incubator and then equilibrated for 12 hours in 1X PBS. NP cells were
plated on top of the treatments at a density of 7,500 cells/cm2 and cultured for 48 hours in
phenol free Complete Nucleus Pulposus Cell Media (4801-prf, ScienCell). After the 48
hours expired, each well was washed three times with 1X PBS and incubated with 200
µL 2 µM Calcein AM (ThermoFisher C3100MP) and 4 µM Eth-1 (ThermoFisher E1169)
in 1X PBS for 30 minutes. A kill well was included for each donor as a positive control
for Eth-1 staining. The cells were then washed three times with 1X PBS and imaged on a
Cytation 5 (BioTek) at 10X. Imaging parameters were uniform across all samples and
four images were taken from each well, deconvoluted, and analyzed using Gen 5
software to evaluate cell number and size in each channel. Viability was calculated using
the following calculation: (# Calcein+ objects / (# Calcein+ objects + # Eth-1+ objects) x
100. Cytocompatibility was evaluated using three unique human NP cells donors, n = 3,
with three technical replicated each.
Animals: All animal procedures and assays were in accordance with the National
Institute of Health guidelines following PHS Policy on Humane Care and Use of
Laboratory Animals and approved by the Institutional Animal Care and Use Committee
and the University of Nebraska – Lincoln. Thirty-six female, 15-week-old, Sprague
Dawley rats were purchased from Envigo and housed with a 12-hour light/dark cycle and
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ad libitum access to food and water. On the day of surgery, the animals were split into
three groups of equal size (n = 12): sham, PBS, and dNP+. After surgery, all animals
were weighed and assessed on a weekly basis for overall health. After injury surgery, one
sham animal had to be terminated due to surgical complications. After treatment surgery,
one dNP+ animal was excluded due to incorrect treatment injection.
Injury Surgery: Animals were injured according to a previously described method. In
brief, on the day of injury surgery, rats were anesthetized, and the lumbar spine was
approached ventrally by dissecting through the abdominal cavity and retroperitoneum.
For sham animals, the L5-L6 was visualized only, and the surgical site was closed in the
same manner as injured animals outlined below. For PBS and dNP+ animals, the L5-L6
lumbar disc was punctured bilaterally with a strong point dissecting needle (Roboz, RS6066) with an O.D. of 0.5 mm set to a length of 2.75 mm. The exact needle length was
predetermined based on µCT data to ensure that the needle length did not exceed the
diameter of the smallest L5-L6 disc in all animals. While the needle was within the disc,
it was swept back and forth along a 90o arc six times in the transverse plane. A simple
continuous and subcutaneous suture pattern were used to close the abdominal wall and
the skin respectively. Buprenorphine SR (.75 mg/kg) was administered once post-op for
pain and animals were rested for two weeks following surgery to enable healing. All
animals displayed mild pica behavior, i.e., bedding consumption, after surgery but this
behavior resolved within 72 hours.
Treatment Surgery: On the day of surgery, rats were anesthetized, and the L5-L6 disc
was approached using the same method as the injury surgery. For sham animals, the L5L6 was visualized only, and the surgical site was closed in the same manner as treated
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animals. For PBS and dNP+ animals, the L5-L6 lumbar disc was injected through the
midline using a 30-gauge needle (BD, 305106) with a rubber stopper (WidgetCo, 7R0000000-EPDM-RS) fixed at 2 mm attached to a 10 µL microsyringe (Hamilton,
80001). PBS animals were injected with 2.5 µL of 1X PBS and dNP+ animals were
injected with 2.5 µL dNP+. The needle length was predetermined based on µCT data to
increase the probability that the therapeutic was delivered to the NP space. The injection
site was sealed with Vetbond (3M, 1469c). A simple continuous and subcutaneous suture
pattern were used to close the abdominal wall and the skin respectively. Buprenorphine
SR (.75 mg/kg) was administered once post-op for pain and animals were rested for two
weeks following surgery to enable healing. All animals displayed mild pica behavior, i.e.,
bedding consumption, after surgery but this behavior resolved within 72 hours.
Disc volume: The L5-L6 disc volume was quantified using the Quantum GX2 µCT
Imaging System and Analyze 13.0 (Analyze Direct). In short, the rat lumbar spine was
radiographed by placing anesthetized animals in the supine position and scanning for 2minutes with 90 kV power, 88 µA tube current, 72 mm FOV, 144 µm voxel size, and a
Cu .06 + Al .05 X-ray filter. VOX files were then removed from the µCT computer and
analyzed in Analyze 13.0. To begin processing, raw VOX files from the µCT scans were
filtered using a high pass threshold of 700 Hounsfield units to remove all non-bony
signal. After the scans were reduced to only bony tissue using the software filter, the
intervertebral disc space was colored in every coronal plane where the adjacent vertebral
bodies were present using a manual draw tool. The slices of colored intervertebral disc
space between the L5 and L6 vertebral bodies were then concatenated, smoothed using a
built-in function and saved as an object map. The volume of the object map of these
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concatenated colored planes was quantified using a built-in software analysis. This
quantification was based on a previously established method developed in our lab.
Behavioral tests: For all behavioral tests, animals were acclimated prior to the study
commencement to the assay apparatuses and experimenters over the course of three
weeks with at least two hours of acclimation to each assay apparatus prior to any data
collection. All assays were performed under red light to minimize animal stress. Two sets
of baseline behavior measurement were collected and averaged to obtain a better estimate
of the mean with particular consideration that all measurements after baseline would be
normalized to the baseline values. Three experimenters performed behavioral tests, and
all were blinded to animal treatment. All animals were randomly assigned to treatment
groups.
Grip strength axial hypersensitivity: Hypersensitivity to axial strain was quantified
using a grip strength apparatus (Columbus Instruments, 1027SR). All animals were
allowed to acclimate to the testing room for 15 minutes prior to testing. Animals were
picked up by grasping the hind quarter and then allowed to grip a metal wire mesh
attached to the grip strength force sensor. The experimenter’s grip was then transitioned
to the base of the tail and the animal was gently pulled backward until it released the
metal wire mesh. This process was repeated three times and the average max force (N)
was used as the grip strength. All withdraw grip strength thresholds were log transformed
to achieve normality and then normalized to baseline to reduce variability.
Pressure algometry deep tissue hypersensitivity: Hypersensitivity around the L5-L6
motion segment was measured using an electronic von Frey aesthesiometer (IITC, 2391)
with a blunt tip applied to the skin superficial the L5-L6 IVD. All animals were allowed
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to acclimate to the testing room for 15 minutes prior to testing. Each animal was
sequentially hooded inside a clean cotton t-shirt such that the entire animal was covered.
The animal was then loosely constrained by one experimenter while another
experimenter applied the blunt probe to the dorsal L5-L6 skin and slowly increased the
pressure until the animal exhibited a nocifensive response. The L5-L6 skin area was
ascertained by palpating along the caudal spinal curvature to locate the area of skin
directly superficial to the spinous processes just caudal of the iliac crest. Positive
responses included rolling, rapid movement, and vocalization. Two measurements were
collected for each animal and the average was used as the deep tissue pressure threshold.
All animal thresholds were normalized to baselines to reduce variability.
Open field test: Spontaneous pain-like behavior was evaluated using the open field test
with custom built acrylic 2’x2’x2’ black, opaque arenas. All animals were allowed to
acclimate to the testing room for 15 minutes prior to testing. Animals were individually
placed in arenas illuminated by overhead red lighting and allowed to explore for 30
minutes while recorded by an overhead low-light camera (ALPCAM). The middle 20
minutes of each video was analyzed using Ethovision (Noldus) for total distance traveled,
time spent rearing unsupported, time spent rearing supported, time spent grooming, max
velocity, average turn angle, and max turn angle. All data were normalized to baselines to
reduce variability.
Diclofenac treatment: Diclofenac was administered to all animals at 15-weeks to
validate pain-like behavior could be alleviated via analgesic mechanisms used in humans.
To accomplish this, diclofenac (MilliporeSigma, 1188800-200MG) was dissolved in 1X
PBS at 5 mg/mL and administered intraperitoneally at 10 mg/kg. Diclofenac was
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administered by an unblinded observer that did not participate in behavioral
quantification. Grip strength was performed thirty minutes after the administration of
diclofenac. No signs of toxicity were observed in any animal.
Statistical analysis: All data is presented as mean ± 95% CI. Data were analyzed using
GraphPad Prism 9. Normality was assessed using a Shapiro-Wilk test. Cytotoxicity, cell
area, and cell count were assessed using a one-way ANOVA with Tukey’s post hoc.
Behavioral and disc volume data were analyzed using a two-way ANOVA with
Dunnett’s post hoc. Motion segment rheology was evaluated using a student’s t-test.
Results were considered statistically different when p < 0.05.

6.3 Results
Study overview
The central proposition of this work was that a painful degenerated disc could be
transitioned to a painless state using a hydrogel fabricated from decellularized tissue (Fig
19A). The success of this proposition hinged upon delivery and maintenance of the
hydrogel within the degenerated disc. This criterion motivated the inclusion of a tissue
crosslinker, genipin, to form inter-collagenous covalent bonds between the hydrogel and
the degenerated disc tissue. The first arm of this work focused on engineering a genipin
crosslinked hydrogel derived from decellularized NP tissue and collagen type I (Fig
19B). To accomplish this, cervical NPs were dissected, decellularized, comminuted,
digested, neutralized, and supplemented with 6 mg/mL collagen to form a dNP gel.
Additionally, dNP gels were supplemented with 0 – 20 mM genipin to measure the
variable effects of genipin crosslinking on select outcomes. These outcomes consisted of
gelation kinetics, rheological properties, cytotoxicity, and ex vivo capacity to augment
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disc mechanics. Work done in this first arm suggested a 6.0 mg/mL dNP + 6.0 mg/mL
collagen I + 2.5 mM genipin hydrogel, termed dNP+, was the best candidate for in vivo
evaluation. To test the therapeutic in vivo, disc degeneration was induced in female
Sprague Dawley rats and progressed for 8-weeks (Fig 19C). At 9-weeks, injured animals
were treated with dNP+ or 1X PBS, and pain-like alleviation was measured over the
following 6 weeks.

Figure 19. Study overview

Fig. 19. Study overview. (A) The central proposal of this work was that a treatment for disc-associated
pain could be fabricated from a mixture of decellularized healthy porcine NP tissue, collagen and genipin.
This therapeutic would theoretically be tissue integrating, spontaneously fibrillogenic, cytocompatible,
and biomechanically restorative leading to pain-like behavior remission. (B) The first arm of this work
entailed testing decellularized nucleus pulposus gels supplemented with 6.0 mg/mL collagen and genipin
from 0 – 20 mM. Testing of these gels (dNPs) included gelation kinetics, rheology, cytotoxicity, and ex
vivo capacity to restore injured disc mechanics. (C) The outcomes of the first arm determined the optimal
formulation to test in vivo was 6.0 mg/mL dNP + 6.0 mg/mL collagen + 2.5 mM genipin, referred to in
this manuscript as dNP+. To test this therapeutic, disc degeneration was induced in female Sprague
Dawley rats and allowed to progress for 8 weeks. At 9 weeks post-injury, half of injured animals were
treated with dNP+ and the other half with 1X PBS. Throughout the in vivo arm, disc volume and painlike behavioral metrics were collected to monitor effects of disc injury and treatment.
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dNP hydrogels spontaneously gel and crosslink
Considering a core criterion of this therapeutic was to be thermally fibrillogenic
after injection into a ~37 °C tissue, gelation kinetics were first to be determined. When
incubated at 37 °C, all dNP gels completed collagen fibrillogenesis in under 15 minutes
(Fig. 20A&B). The rapid gelation indicated these gels would be suitable for an injection
procedure because fibrillogenesis would complete in the time required for wound closure
and awakening. Crosslinking mediated by genipin took considerably longer than collagen
fibrillogenesis with most formulations hitting 75% max 610 nm absorbance by four hours
(Fig. 20C&D). Of note, the cross-linking process appears relatively stochastic with
higher genipin concentrations beginning crosslink formation earlier than lower
concentrations. Also, higher concentrations of genipin resulted in a greater final
absorbance, indicating increasing degrees of crosslinking occurred with increasing
genipin concentrations. It should also be noted that the asymptotic limit of absorbance
seen at 610 nm for the 10 mM and 20 mM genipin dNP hydrogels could be due to
limitations of the plate reader, true nature of the gel absorbance, or both. All gels were
homogenous in appearance and did not desiccate during the 12-hour collection window
(Fig. 20E). These data showed genipin hydrogels complete fibrillogenesis in under 15
minutes and that the majority of genipin crosslinking activity completed in 4 hours in all
formulations.
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Figure 20. dNP hydrogel spontaneously gel and crosslink

Figure. 20. dNP hydrogels spontaneously gel and crosslink. (A) Absorbance of dNP gels at 405 nm
over 12 hours of incubation at 37 °C. All gels exhibited rapid fibrillogenesis in the first 20 minutes of
incubation as highlighted in (B). The continual increase of absorbance at 405 nm after 2 hours was largely
due to light absorbance by genipin blue, produced during crosslinking. (C) Absorbance of dNP gels at
610 nm over 12 hours of incubation at 37 °C. As part of the crosslinking reaction, genipin forms genipin
blue, which absorbs light at 610 nm. 20 mM genipin dNP gels were the first to exhibit a dramatic increase
in absorbance although all genipin supplemented gels increased in absorbance at 610 nm. The final
absorbance values for 10 mM and 20 mM dNP gels were similar, suggesting all crosslinking sites were
exhausted at around 10 mM genipin. The final absorbance of 2.5 mM genipin was at the midpoint between
20 mM and 0 mM. (D) All gels exhibited genipin crosslinking initiation between 1:30:00 and 3:30:00.
(E) Visual appearance of the dNP hydrogels after 12 hours of incubation at 37 °C. Error bars are left off
for clarity.
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Genipin increases dNP rheological properties
Each dNP formulation was measured using a rheometer for storage and loss
moduli (Fig. 21A). The average storage and loss modulus for 0 mM genipin gels was
709.81 ± 44.0 Pa and 118.19 ± 8.68 Pa respectively (Fig. 21B&C). The addition of
genipin markedly increased storage and loss moduli with 20 mM genipin increasing the
storage modulus more than 10-fold (11271 ± 3248.0 Pa) compared to 0 mM gels (709.81
± 44.0). Despite the remarkable increase of gel mechanics due to genipin, the moduli of
all gels was still several orders of magnitude lower than native disc tissue (5.8 – 42.7
MPa) [332]. The average storage and loss modulus for the 2.5 mM genipin dNP gel were
2244.6 ± 208.60 Pa and 210 ± 30.976 Pa respectively. Interestingly, the dNP hydrogels
suffered increasing variability at genipin concentration of 5 mM and above. It is unclear
what drove this increase in variability as duplicate variability and inter experimental
variability were both present at these higher concentrations. Unlike the gelation kinetic
data, the rheological properties did not reach an asymptotic limit indicating that crosslinking sites were not exhausted at high genipin concentrations. Overall, these data

Figure 21. Genipin increases dNP rheological properties.
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Figure. 21. Genipin increases dNP rheological properties. (A) Image of a dNP hydrogel on the
rheometer. Scale bar = 4 mm. (B) Storage moduli of the dNP with various concentrations of genipin.
These values represent the elastic resistance to torsional strain. The variability increased dramatically
with genipin concentrations greater than 5 mM. (C) Loss moduli of the dNP with various concentrations
of genipin. These values represent the viscous resistance to torsional strain. Like the storage moduli,
variability increased dramatically when genipin concentrations exceeded 5 mM. Data is shown as mean
with standard deviation. Gel fabrication was performed in duplicate in three separate experiments (n =
3).

confirmed genipin increases dNP mechanical properties and that 2.5 mM genipin was the
highest concentration usable to maintain replicable fabrication outcomes.
dNP+ increases injured motion segment rheological properties
Two additional necessities for dNP+ were injectability and capacity to alter disc
mechanics. These two aspects were tested ex vivo using motion segments excised from
female Sprague Dawley rat cadavers (Envigo). The injection process is overviewed on a
potted motion segment in Fig. 22A with the gel dyed green for ease of visualization. To
determine how well dNP+ restores disc mechanics, the rheological properties of potted
motion segments were assessed at baseline, after 6-scrape injury, and after treatment
(Figure 22B&C). Undamaged controls were included at all time points. All data was
normalized to pre-injury baselines so that motion segments from L4 to S1 could be
pooled without dramatically increasing the variability. Injury decreased the storage
modulus of motion segments by around 50% compared to baseline. Treatment with dNP+
significantly restored the modulus by 15% compared to post-injury (p < .05). These data
confirmed dNP+ alone could increase disc mechanical properties after acute injury.
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Figure 22. dNP+ increases injured motion segment rheological properties

Figure. 22. dNP+ increases injured motion segment rheological properties. (A) Overview of the
injection process. In the top image, the 30-gauge needle is shown with a rubber stopper set at 2 mm from
the needle tip. The rubber stopper was fixed to the needle to make injection into the NP space easier. The
middle image shows a potted motion segment injected with dNP gel dyed green. Evidence of injection
can be seen by the faint green dye on the surface of the annulus fibrosus. In the bottom image, an injected
motion segment was transected to display the presence of dyed dNP hydrogel injectate in the disc. (B)
An image of a potted motion segment fixed to the rheometer. (C) Motion segment storage moduli from
undamaged, injured, and dNP+ treated motion segments. The average storage modulus of undamaged
control motion segments did not change over the course of the experiment. Injury decreased the average
storage modulus by 50%. Treatment with dNP+ significantly rescued the storage modulus by 15%
compared to post-injury. Data is shown as mean with standard deviation (n = 3 per group). Significance
is denoted by * = p < 0.05

dNP+ is cytocompatible
To understand if the dNP+ hydrogel was cytotoxic, human NP cells were cultured
on top of dNP+ for 48 hours and viability was determined using Calcein AM and Eth-1.
Polystyrene, collagen, and collagen + dNP substrates were included as controls (Fig.
23A-C). All treatments exhibited minimal cell death as noted by the absence of Eth-1
fluorescence (Fig. 23A-D). When quantified, the viability for polystyrene, collagen,
collagen + dNP, and dNP+ treatments was 96.37 ± 1.91%, 96.54 ± 1.66%, 96.15 ± .91%,
and 94.75 ± 5.61% respectively (Fig. 23E). Cell size was also quantified to assess how
each substrate impacted cellular morphology (Fig. 23F). The collagen + dNP control
which represented a less stiff substrate compared to polystyrene caused the cells to adopt
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significantly smaller morphology compared to polystyrene. However, this effect was
partially reversed with the addition of 2.5 mM genipin in the dNP+ treatment.
Rheological data indicated 2.5 mM genipin made the hydrogel stiffer which likely caused
the cells to adopt a more elongated morphology. Finally, total cell count was measured to
understand if dNP+ had a negative effect on cellular proliferation (Fig. 23G). Analysis of
the cell counts indicated dNP+ did not significantly decrease cellular proliferation
compared to collagen + dNP although the difference narrowly missed significance (p <
.052). These results demonstrated that dNP+ is not cytotoxic to human NP cells but the
trend toward decreased cellular proliferation suggested concentrations of genipin above
2.5 mM might be harmful to cell growth and perhaps viability.
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Figure 23. dNP+ is not cytotoxic.
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Figure. 23. dNP+ is not cytotoxic. Representative images from the NP cell viability experiments (A-D).
NP cells exhibited a more elongated morphology on polystyrene compared to collagen, collagen + dNP,
and dNP+ substrates. (E) Quantification of treatment cytotoxicity. All treatments exhibited minimal
cytotoxicity with the lowest average viability occurring in the dNP+ treatment at 94.75%. (F)
Quantification of cell size. Cells plated on polystyrene had significantly larger average area than those
plated on collagen + dNP. (G) Quantification of total cell proliferation over the 48 hours of culture. No
significant differences were detected between any treatment group. The average dNP+ treatment cell
count was 66% that of collagen + dNP but this difference narrowly missed significance (p < .052). Data
is shown as mean with standard deviation. Experiments consisted of three unique donors plated in
triplicate (n = 3). Significance is denoted by * = p < 0.05

Animal study overview
Previously, we have described a rat model of disc-associated pain that develops
robust axial hypersensitivity after disc injury [3]. This model was employed to evaluate
the efficacy of dNP+ as a rescue treatment for disc-associated low back pain. This arm
entailed three weeks of acclimation, injury surgery, eight weeks of data collection,
treatment surgery, six weeks of data collection, and post-processing (Fig. 24A). For the
study, 36, female Sprague Dawley rats were split into three groups of equal size: sham –
12, PBS – 12, dNP+ - 12. One sham animal was euthanized prematurely due to surgical
complications and one dNP+ animal was excluded due to incorrect treatment injection
(Fig. 24B). Animal pain-like development was assessed using two evoked pain-like
behavior assays, grip strength and pressure algometry, and one spontaneous pain-like
behavior assay, the open field test (Fig 24C). Disc degeneration was induced at week 0 in
PBS and dNP+ animals and involved mechanical injury of the L5-L6 IVD using a ventral
approach (Fig. 24D). Sham discs were visualized only. The treatment surgery followed
the same steps as the injury surgery to visualize the disc (Fig. 24E). PBS and dNP+
animals discs were injected with 1X PBS or dNP+ respectively (Fig. 24F). Sham discs
were visualized only.
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Figure 24. Animal study overview.

Figure. 24. Animal study overview. (A) Timeline of the in vivo assessment of dNP+. Animals were
acclimated for three weeks before a week of baseline behavior and uCT measurements. Injury surgery
was performed on week 0 and disc degeneration was allowed to progress for 8 weeks before treatment
surgery on week 9. Following treatment surgery, behavior and uCT measurements were collected for 6
weeks. (B) For this study, 36, 18-week-old, female Sprague Dawley rats were split into three groups:
sham, PBS and dNP+. One sham animal was terminated due to surgical complications and one dNP+
animal was excluded due to incorrect treatment injection. Final animal numbers are shown in bold in
parenthesis. (C) Three assays were employed to measure the development and alleviated of pain-like
behavior during the study. The open field test measured spontaneous pain-like behavior and grip strength
and pressure algometry measured evoked pain-like behavior. (D) Graphical depiction of the injury
surgery. The L5-L6 IVD was approached ventrally and injured using a microdissecting needle. (E)
During treatment surgery, the L5-L6 disc was visualized in all animal groups. The disc can be seen at the
tip of the black arrowhead. (F) Animals in the PBS group were injected with 1X PBS and animals in the
dNP+ group were injected with dNP+.
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dNP+ restores disc volume
Intervertebral disc volume was quantified at eight time points as a real time
measurement of disc degeneration (Fig. 25A&B). From weeks 2 to 8, both PBS and
dNP+ groups exhibited significantly decreased disc volume compared to sham animals.
After treatment, dNP+ disc volume returned to baseline and was not significantly
different from sham at any time point from week 11 till study conclusion. Conversely,
IVDs injected with 1X PBS remained at a sub baseline volume and were significantly
different from sham and dNP+ at all time points. These data demonstrated dNP+
treatment restored disc volume 9 weeks after degeneration was initiated.

Figure 25. dNP+ restores disc volume.

Figure. 25. dNP+ restores disc volume. (A) 3D rendering of a rat spine from L5 to S1. The L5-L6 IVD
is colored in blue. (B) L5-L6 intervertebral disc volumes calculated from uCT data. The disc volume in
both dNP+ and PBS animals significantly decreased after injury compared to sham animals. After
treatment surgery, dNP+ treated animal disc volumes returned to baseline and were no longer significantly
different from sham. Data is shown as mean with standard deviation (n = 11-12 per group). # = p < 0.05
sham vs. dNP+. * = p < 0.05 sham vs. PBS. & = p < 0.05 dNP+ vs. PBS.
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dNP+ and diclofenac alleviate axial hypersensitivity
Evoked and spontaneous pain-like behavior were measured during the study to
assess how pain-like behavior developed after injury and how dNP+ treatment affected
pain-like behavior. Grip strength specifically measured hypersensitivity to axial strain,
i.e., axial hypersensitivity (Fig. 26A). From week 6 to 8, both PBS and dNP+ animal
groups exhibited significantly decreased grip strength compared to sham animals. After
treatment surgery, this decrease was ameliorated in animals injected with dNP+ whereas
grip strength continued to decline in animals injected with 1X PBS. At weeks 13 and 15,
dNP+ animals displayed significantly increased grip strengths compared to PBS animals
and were not significantly different from sham. The grip strength data demonstrated the
dNP+ treatment alleviated axial hypersensitivity and was effective for at least 6 weeks.
Deep pressure hypersensitivity as measured by the pressure algometry assay
failed to detect differences between sham and dNP+ groups at any time point (Fig. 26B).
However, this assay was successful in detecting differences between PBS and sham
animal groups at weeks 4, 8, 13, and 15. Also, animals in the PBS group displayed
significantly decreased thresholds compared to dNP+ animals at week 13, 4 weeks after
treatment surgery. Put together, data from this assay suggests dNP+ may have been
effective in decreasing deep pressure hypersensitivity but the failure of dNP+ animals to
develop deep pressure hypersensitivity prior to treatment, limits the interpretability of this
data set.
The open field test measured changes in spontaneous pain-like behavior (Fig.
26C). The only time point at which significant differences in total distance travel were
observed was at week 11, 2 weeks after treatment surgery. At this point dNP+ animals
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traveled significantly further than both PBS and sham groups. This highly significant
difference, suggested the dNP+ treatment may have alleviated nociception evoked
through movement, causing the animals to roam more.
Finally, an NSAID known to effectively treat acute low back pain in humans,
diclofenac, was administered intraperitoneally to all animals in week 15 to determine if
disc-associated pain could be alleviated in the animal model via drugs used in humans
[46, 333-335] (Fig. 26D). This evaluation was crucial for providing evidence of this
model’s predictive validity. After diclofenac administration, PBS animal grip strengths
returned to baseline and were significantly different from week 15 pre-treatment
evaluation. These data confirmed pain-like hypersensitivity in this model could be
alleviated via approaches used in humans and that the increase in grip strength observed
after treatment with dNP+ was likely due an alleviation of nociception in the degenerated
disc tissue.
Altogether these pain-like measurements indicate dNP+ was effective at
alleviating pain-like hypersensitivity and the effect of dNP+ was sustained for 6 weeks
after treatment.
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Figure 26. dNP+ and diclofenac alleviate axial hypersensitivity.

Figure. 26. dNP+ and diclofenac alleviate axial hypersensitivity. (A) Normalized grip strength data
which measured axial hypersensitivity. Both PBS and dNP+ animals groups exhibited significantly
decreased grip strength in weeks 6 and 8 compared to sham animals. After treatment surgery, grip strength
increased in dNP+ animals and not significantly differ from sham animals for the remainder of the study.
The grip strength of PBS animals continued to decline from week 11 onward and was significantly
different from sham at all time points. PBS animals also exhibited significantly decreased grip strength
compared to dNP+ treated animals at week 13 and 15. (B) Normalized pressure algometry which measure
deep pressure hypersensitivity. PBS animals exhibited decreased pressure thresholds at week 4, 8, 13,
and 15 compared to sham animals. Also, PBS animals exhibited lower thresholds compared to dNP+
animals at week 13. At no point did the dNP+ animal group significantly differ from sham animals. (C)
Normalized distance traveled was a measure of spontaneous pain-like behavior. The only significant
difference measured was at week 11 between dNP+ animals and both PBS and sham animals. (D) 15week grip strength before and after treating with diclofenac. Diclofenac was effective at suppressing axial
hypersensitivity as noted by the highly significant increase in animal grip strength after drug
administration in PBS animals. (n = 11-12 per group). For longitudinal data, significant differences
between groups were assessed using a two-way ANOVA. Drug treatment data was analyzed using a oneway ANOVA. # = p < 0.05 sham vs. dNP+. * = p < 0.05 sham vs. PBS. & = p < 0.05 dNP+ vs. PBS.
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dNP+ alters motion segment rheological properties
At study conclusion, motion segments from six animals in each group were
excised and potted using the same process as described in the ex vivo testing. A total of
five motion segments (sham – 1, PBS – 1, dNP+ - 3), were removed from the sample
pool due to desiccation during the potting process. The remaining motion segments were
tested on a rheometer for storage and loss moduli to determine if segments from PBS or
dNP+ treated animals were significantly different from sham motion segments (Fig. 27).
The storage modulus of PBS motion segments was significantly lower compared to sham.
The loss modulus of PBS motion segments was also significantly lower than sham. These
data indicated that resistance to strain mediated by both viscous and elastic properties
declined due to injury. The moduli of dNP+ treated motion segments were not
significantly different from sham nor PBS groups, but this may have been due to
insufficient statistical power considering only three motion segments were included in the
analysis. These data indicated injury and subsequent degeneration decreased the
rheological properties of motion segments and the treatment with dNP+ resulted in
motion segments that did not significantly differ from sham nor PBS injected motion
segments.
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Figure 27. dNP+ alters motion segments rheological properties.

Figure. 27. dNP+ alters motion segments rheological properties. (A) Storage moduli of L5-L6 motion
segments resected at the conclusion of the in vivo study. The average storage modulus for sham motion
segments was significantly greater than PBS motion segments. (B) Loss moduli of L5-L6 motion
segments resected at the conclusion of the in vivo study. The average loss modulus for sham motion
segments was significantly greater than PBS motion segments. No significant differences were detected
between dNP+ and the other treatment groups. A total of 5 motion segments were discarded due to
desiccation during the potting process (sham: n = 5, PBS n = 5: dNP+: n = 3). Data was analyzed using a
one-way ANOVA. * = p < 0.05

6.4 Discussion
This work provides evidence that a biomaterial composed of decellularized,
healthy porcine NP, collagen, and genipin, could be an effective therapeutic for discassociated low back pain. In our rat model, dNP+ treatment restored degenerated disc
volume to baseline and this effect was maintained at all time points measured after
treatment. Further, animals treated with dNP+ displayed remarkably diminished axial
hypersensitivity which was maintained at all time points after the treatment surgery.
Finally, motion segments resected at study conclusion from animals in the PBS group
exhibited significantly lowered storage and loss moduli compared to sham. There was no

124

significant differences between sham and dNP+ motion segments nor PBS and dNP+
motion segments indicating the treatment was effective at augmenting mechanical
properties.
Motivation to engineer the dNP+ therapeutic arose from observations made in our
rodent model of disc degeneration. In this prior work, degenerated disc tissue routinely
contained large fissures which radiated through the disc tissue. In most injured animals,
these fissures presented as large swaths of annulus fibrosus tissue with no
interconnection. Additionally, aberrant nerve sprouting localized around the fissures,
implicating mechanical agitation as a potential source of nociception. Together, these
observations strongly suggested that a therapeutic capable of annealing collagenous
fissures and other microdefects could decrease deleterious loading patterns within the
disc and decrease nociception, thereby alleviating pain. Based on prior work in our lab
and published data[214, 336-340], we determined a hydrogel could be effective in
treating disc degeneration and could potentially impact pain-like behavior as well[201,
341]. It was reasoned an injectable hydrogel could percolate into the tissue defects prior
to completing fibrillogenesis. Moreover, the minimally invasive injection procedure
would minimize surgical complications and facilitate delivery of the hydrogel to regions
of the disc which could expand to accommodate the extra volume, like fissures.
To date, numerous research groups have treated disc degeneration in rodent
models with varying degrees of success. These treatments have included cell
transplantation, in situ gene therapy, and bioactive factors [202, 211-218]. However, the
vast majority of models are limited by the administration of treatments prophylactic or
concomitant with the initiation of degeneration. Further, the majority of publications that
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evaluate treatments for disc degeneration fail to quantify pain-like behavior [219].
Clinically, patients do not seek treatment for disc degeneration unless the degeneration
causes pain. This simple fact brings into question the validity of prior work because
treatments are administered prior to pain-like manifestation which does not replicate how
human patients are treated. As of 2021, no treatment in over 100 animal model
publications has achieved FDA approval for the treatment of degenerative disc disease
providing strong evidence that the prophylactic and concomitant treatment paradigms are
inadequate [219]. With this knowledge, we decided that treating animals after disc
degeneration and pain-like behavior had sufficiently developed would provide predictive
validity far greater than the majority of prior work.
The hydrogel engineering process began by trialing different chemical
crosslinking agents. It was hypothesized that a therapeutic would have greater potential to
stabilize the disc if it covalently bound to the local tissue. In the past, covalent bonding of
biomaterials doped with crosslinking agents has been studied as part of the development
of bioadhesives likes GRF glue [240]. Lysyl oxidase, transglutaminase, and genipin were
all tested but only genipin provided a dramatic increase in mechanical properties
suggesting it had the greatest crosslinking capacity (data not shown). Having selected
genipin as the crosslinker, experimentation to determine the optimal concentration
commenced.
The first analysis assessed if the addition of genipin along with the changes to the
dNP and collagen concentrations changed dNP gelation kinetics compared to prior work
[235]. As part of this analysis, the time at which different concentrations of genipin began
and completed crosslinking was also determined. It was revealed that the new

126

concentration of collagen and dNP and the addition of genipin did not dramatically
change the onset time of collagen fibrillogenesis. From this data, 15 minutes was
conservatively estimated as the time to fibrillogenesis completion in vivo fibrillogenesis.
These data aligned with previously existing literature and indicated this process would
occur during surgical recovery in the animal model [249].
With the inclusion of a chemical crosslinking agent, another major criterion was
to avoid cellular cytotoxicity [245]. Work done by the Iatridis lab has suggested free
genipin, rather than genipin bound in crosslinks, is responsible for cellular cytotoxicity
[250]. Knowing lysine residues on collagen fibrils were the main target of genipin
activity and that genipin transforms into genipin blue after becoming a crosslink, it was
reasoned the absorbance assay could determine the genipin concentration at which all
crosslinking sites were saturated. Unfortunately, at 610 nm absorbance, gels above 10
mM genipin reached absorbances above the linear response range of the plate reader.
However, an absorbance greater than 1.0 was not reached at 405 nm and these values
suggested there was diminishing return of genipin activity above 5 mM genipin. These
data indicated that 2.5 mM genipin was a conservative concentration to use to avoid the
presence of free genipin and in turn cytotoxicity.
All concentrations of genipin imparted an increase of storage and loss moduli to
the hydrogels. Unexpectedly, the hydrogels suffered increasing variability at genipin
concentrations of 5 mM and above. Experimental variability did not account for this
change as duplicate gels were also variable. At 5 mM and above, the rheological
properties increased at a faster rate than lower concentration suggesting the underlying
crosslinking mechanisms were fundamentally different. Plotting concentration vs. storage
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modulus revealed a non-linear relationship implying the mechanism of genipin
crosslinking is not strictly stochastic and emergent aspects may come into play (data not
shown). More work must be performed to discover why the hydrogels suffered this
increased variability and why the rate of modulus increase changed at genipin
concentrations of 5 mM and above.
Overall, the kinetic and rheological data indicated that 2.5 mM was the optimal
concentration of genipin to achieve a rapidly gelling, cytocompatible, and consistent dNP
hydrogel. This formulation was given the name dNP+.
As a proof of concept, motion segments excised from rat cadavers were treated
with dNP+ after injury to establish that the hydrogel could be used as an injectable,
mechanically enhancing, therapeutic. Motion segments treated with dNP+ exhibited
significantly increased mechanical properties compared to pre-treatment values. The 15%
increase in storage modulus represented around a 200,000 Pa increase, which was
multiple orders of magnitude greater than the dNP+ gel alone. This increase may have
resulted from the combinatorial effect of genipin on the existing tissue and annealing of
the injury defect by dNP+. This analysis showed that dNP+ could be injected into a rat
IVD and could increase IVD mechanical properties following injury.
DNP+ was further characterized by quantifying cellular cytotoxicity using a
standard LIVE/DEAD assay. In this assay, dNP+ proved cytocompatible with primary
human NP cells. This data complimented prior work done in our lab with dNP and
collagen gels [235]. In this prior work, total cellular metabolic activity was greatest in
collagen + dNP gels which parallels the high proliferation witnessed in our work. The
fact that cellular proliferation in dNP+ narrowly avoided significance when compared to
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collagen + dNP (p < 0.052) suggested any further increase of genipin would have
significantly impacted cellular proliferation. Extrapolated further, higher concentrations
might also have affected cell viability. This assay was limited by the equilibration step
needed to ensure the gels were completely hydrated and at a uniform osmotic equilibrium
prior to cell seeding. This step was limiting because it may have removed any free
genipin from the gels, which could have increased cellular viability across the board.
Having collected this data, we concluded 2.5 mM genipin represented the maximum
concentration of genipin usable to guarantee minimal cytotoxicity.
Having chosen a 2.5 mM genipin, 6.0 mg/mL dNP and, 6.0 mg/mL collagen
hydrogel as the best therapeutic candidate, work transitioned to testing in vivo. This arm
entailed acquiring 36 animals, injuring 24, allowing degeneration to progress for 8 weeks
and then treating 12 injured animals with 1X PBS and the other 12 with dNP+. Of all the
work described in this manuscript the most time-consuming step was determining a
method that ensured a consistent volume of liquid dNP+ precursor solution was injected
into the disc. After trialing microinjectors, insulin syringes, and syringe pumps, it was
found that microliter syringes manufactured for gas chromatography were ideal. The
downside of these syringes was that they could not create sufficient back pressure to draw
up the hydrogel solution. To solve this, each syringe was attached to a needle and the
plunger was removed so that dNP+ could be filled from the back of the syringe. This
technique also ensured that there was no dead volume in the needle hub. Further, rubber
stoppers were affixed to the needle 2 mm from the needle tip to prevent overpenetration
and increase the odds dNP+ was delivered to the NP space. Finally, the injection speed
was limited to 5 uL/minute because it was discovered that IVDs could not handle rapid
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volume injection and quick administration would force the gel to exude around the needle
hub.
Disc volume was measured throughout the course of the study as a proxy for
degeneration. Directly after surgery, the IVD volume of injured animals dramatically
declined. After treatment surgery, dNP+ IVD volumes returned to baseline while PBS
treated IVDs remained significantly lower than sham and dNP+ treated IVD volumes.
This data provided compelling evidence that dNP+ successfully entered and remained in
the IVD. The gradual increase of disc volume in all injured animals was due to radial
expansion as noted in prior work. Interestingly, after treatment, dNP+ IVD volumes no
longer exhibited this gradual increase indicating bony deposition caused by aberrant
loading patterns may have been alleviated. Presuming that aberrant loading drives painlike behavior, this indication was further supported by the behavioral data.
Similar to prior work, injured animals displayed a gradual decline in grip strength
from week 2 to week 8 [291, 292]. For PBS treated animals, grip strength continued to
decline after treatment surgery. Conversely, dNP+ treated animal grip strength increased
after treatment surgery suggesting the treatment alleviated axial hypersensitivity. This
axial analgesia reached significance compared to PBS animals at week 13 and 15. At
week 15, the dNP+ grip strength was 26% higher than PBS treated animals. This
difference is more than double the minimal clinically important difference (MCID) that
has been recommended for low back pain treatment outcome measures [342]. The grip
strength data provided strong evidence that dNP+ could be an effective treatment for
axial pain caused by disc degeneration.
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The pressure algometry data proved more difficult to interpret. At no time point
did dNP+ animals significantly differ from sham animals. The failure to develop deep
pressure hypersensitivity prior to the treatment surgery limited our understanding of the
effect of dNP+ on deep pressure hypersensitivity. On the contrary, PBS animal thresholds
were significantly lower than sham at multiple time points before and after surgery. Also
at week 13, PBS thresholds were 16% lower than dNP+ animals which exceeded the
MCID. This data indicated injury does produce deep pressure hypersensitivity but the
variability of the assay, especially in dNP+ animals, limited our interpretation of the
treatment effect.
The spontaneous pain-like behavior, as measured in the open field test, provided
additional evidence that dNP+ treatment had an analgesic effect. This effect was
manifested at week 11. This time point was 2-weeks after treatment surgery. Similar to
week 2, which was 2 weeks after injury surgery, sham and PBS animals traveled less
distance due to post-surgical effects like pain. Intriguingly, dNP+ animals traveled
significantly more than both PBS and sham animals and this effect was highly significant
(p < .0029 dNP+ vs. sham, p < .0006 dNP+ vs. PBS). We reason that dNP+ may have
provided an analgesic effect that was greater than the inhibitory action of post-surgical
effects causing the animals to roam more. Regardless of the cause, the increase in
distance traveled did not continue into weeks 13 and 15. This data mirrors clinical
interventions in humans for disc-associated low back where pain relief, as measured by
the visual analog scale (VAS), is highest immediately after surgery and lessens as time
goes on [343]. The open field test confirmed the dNP+ had an effect on spontaneous
pain-like behavior but this effect was not significantly maintained.
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Diclofenac was administered at week 15 primarily to verify the predictive validity
of this model. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that acts as
an analgesic by inhibiting cyclooxygenase 1 and 2 (COX-1 and COX-2) [333]. This drug
has proven efficacious in humans suffering acute episodes of low back pain and in
animals model which exhibit mechanical hypersensitivity and decreased motor ability
[334, 335, 344]. Similarly, diclofenac effectively reduced axial hypersensitivity in our
model. This outcome confirmed that disc-associated pain in our model could be
alleviated via mechanistic approaches applied in humans and indicated our model
maintains a high degree of predictive validity.
In summary, these pain-like behavior assays determined dNP+ was effective at
alleviating axial hypersensitivity and clearly augmented deep pressure hypersensitivity
and spontaneous pain-like behavior.
The final data set collected in this study was motion segment rheological data.
This was collected to evaluate if dNP+ treatment had an effect on disc mechanics as
mechanics were hypothesized to contribute to disc-associated pain. Both storage and loss
moduli of PBS animal motion segments were significantly lower than sham motion
segments. The moduli of dNP+ segments did not differ from either PBS or sham.
Looking at the dNP+ and sham storage modulus 95% confidence intervals, it was found
that 82% of the intervals overlapped. This overlap in suggested the dNP+ and sham
moduli were fairly equivalent.
This work has a few limitations additional to those already mentioned. First, only
female animals were used, disallowing any insight into the role of sexual dimorphism on
treatment effects. Second, an analysis of disc morphology and nerve sprouting was not
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assessed leaving questions of how pain-like behavior was alleviated mechanistically.
Work is ongoing to include male animals in treatment evaluation and to measure motion
segments from this model concerning overall degeneration via hematoxylin and eosin
staining and the presence and localization of nerves via immunohistochemistry.
Chronic low back pain is a tremendous burden on modern society. There is a great
need for therapeutics which address the fundamental cause of pain. It has become
increasingly clear in recent years that a reliance on central or systemic medicines like
opioids and NSAIDs has only increased the societal burden of chronic low back pain. To
this end, we have engineered a non-invasive, spontaneously assembling, therapeutic
derived from healthy disc tissue that remarkably decreases pain-like behavior in animals
suffering disc-associated low back pain. We hope this work will provide the basis of a
next generation therapy for low back pain and will assist other research groups in
developing similar treatments.

The work described in Chapter 6 will constitute a scientific paper. This paper will
be titled “Extracellular Matrix Hydrogel Derived from Porcine Nucleus Pulposus
Restores Disc Volume and Alleviates Axial Hypersensitivity” with authors DJ. Lillyman,
KE. Ney, SM. Caparaso, E. Barnett, AL. Redwine, F. Lee, and RA. Wachs.
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CHAPTER 7: Discussion and Future Directions
7.1 Chapter 4 Discussion and Future Directions
The first objective of this dissertation was to create a method to quantify the
degenerative state of IVDs real-time in rats. The current gold standard for gauging
degeneration real-time is the DHI
method which entails measuring the

Figure 29. Overview of the DHI method

IVD space and adjacent vertebral
bone lengths using X-ray
radiographs (Fig. 28) [158, 199,
203]. While this method seems

Figure 28. Overview of the DHI method [1]

straightforward in writing, X-ray images force the observer to make decisions about
where a measurement stops and ends that are highly subjective. The reason for this
subjectivity is because X-ray radiographs represent a projection of all dense objects in a
sample onto a single plane. This projection creates many imaging artifacts especially
around boney objects with complex
structure, like the spinal column
(Fig. 29). Further, X-ray machines

Figure 28. X-ray radiograph of a rat lumbar spine

lack sufficient spatial resolution to
make precise measurements

Figure 29. X-ray radiograph of a rat lumbar spine [2]

necessary for quantifying aspects of small structures like IVD height.
At the time DHI was being trialed, the Life Science Annex at UNL aqcuired a
state of the art μCT (Quantum GX). Unlike X-ray imaging, μCT employs a rotating Xray source and collector, permitting three dimensional scans. Additionally, the μCT

134

machine purchased was built for small animals, and thus had high spatial resolution, ideal
for measuring a small structure like the disc.
Along with the μCT, post-processing software was included that allowed removal
of soft tissue, creation of tissue density thresholds, and creation of unique objects within
scans. For object maps, the software provided readouts like, average intensity, entropy,
number of voxels, and volume. It was determined these object maps could be created for
the IVD to approximate IVD volume. This rationale was enhanced by the fact that the
IVD sits between bone, making the edges of segmentation straightforward.
In 2019, we performed a pilot
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Figure 30. Normalized L5-L6 disc volume from
the 2019 pilot study of disc degeneration

volume over the course of 21 weeks (Fig. 30). Unfortunately, no differences between
sham and injured animals were observed because the injury method did not induce disc
degeneration. Despite this downside, it was abundantly clear the μCT method was highly
precise because sham and injured animals were consistently equal with one another.
Conversely, both sham and injured averages deviated from baseline, indicating this
method might suffer low accuracy due to inter-experimental variabiltiy, i.e., the day
animals were scanned influenced the outcomes. Initially, it was suspected the time of day
and disc hydration state might explain this variation, but after testing a single threshold
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across multiple time points, it was determined that the post-processing imaging
parameters were the source of inter-experimental variability. To remedy this source of
error, imaging thresholds were standardized and kept consistent between imaging days.
Having established universal imaging thresholds, this final method was delineated
in the methods paper described in Chapter 4. When compared to the DHI method, the
disc volume method is superior in all ways except for time spent to analyze the data (Fig.
9). The inclusion of multiple slice planes in the final measurement dramatically decreased
the opportunity for observer bias to be introduced. Further, multiple slices also increased
the quantity of data involved in the final measurement, increasing the precision of the
estimate.
There are several factors that could improve the work described in Chapter 4.
First, the scans gathered to calculate the disc volume collect a larger field of view (FOV)
than necessary. Current scans include the lumbar region of the rat torsoe from L4 to S1.
Because only the L5-L6 is injured and of interest, the current method includes a fair
amount of extraneous data. Reducing the FOV would allow for greater spatial resolution
and could further enhance the precision of the method. Additionally, an increased spatial
resolution may permit alternate analyses pertinent to disc degeneration like degree of
osteophyte formation, schmorl’s node formation, etc. [345]. Furthermore, reducing the
FOV could impart a sufficient increase in image quality that scan times could be reduced
from two minutes to 18 seconds, which would dramatically decrease the X-ray dosing. In
both animal models described in this dissertation, at least one animal developed a large
tumor. Although tumor formation is part of the genetic predisposition of female Sprague
Dawley rats, decreasing X-ray dosing stands to decrease the likelihood of tumor
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formation [346]. In the future, the FOV can be reduced from 72 mm to 45 mm, which
will decrease the voxel size from 144 μm to 90 μm. The smaller voxel size will allow for
greater image resolution, and more precise disc volumes.
The disc volume method could also be validated to improve it’s acceptability as a
scientifically robust measure of IVD volume. This work would entail comparing the
calculated disc volumes with volumes calculated using an alternate method. Because the
disc is irregular in shape and elastic, it would be difficult to take physical measurements
to approximate volume. One method to approximate the disc volume would be to collect
its mass, and place it in liquids with linearly increasing densities to ascertain neutral
bouyancy and in turn overall tissue density. Knowing the mass and density of the disc,
the volume would be a trivial calculation.
In summary, Chapter 4 outlined a method for quantifying disc degeneration realttime and non-invasively. Given the profound accuracy, precision, and consistency of this
method, we believe it was an overhwelming success. Further work could be done to
improve the method and validate the outcomes.

7.2 Chapter 5 Discussion and Future Directions
The second objective of this dissertation was to create an animal model of discassociated pain. This objective was motivated by a lack of valid animal models of pure
disc-associated pain and the desire to establish an in-house model for therapeutic testing.
The first animal study occurred in 2019, but failed to induce disc degeneration and
manifest a pain-like phenotype. However, this study was tremendously useful to
acclimate experimenters to animal procedures and assays. Furthermore, this pilot study
assisted in cementing assays, like the open field test, used in later studies.
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In 2020, the COVID-19 pandemic allowed ample time to re-develop the animal
model from first principles. During this time, a thorough investigation of rat
neuroanatomy revealed rat IVD innervation is complex, un-intuitive, and involves DRG
projections from multiple levels [180, 295]. It was discovered the dorsal side of the rat
IVD is innervated by nerve fibers originating in adjacent DRGs, wherease the ventral side
of the IVD is innervated by nerve fibers originating in DRGs multiple spinal levels
higher. This neuroanatomy implied the location of
injury and subsequent degeneration could affect the
pain-like phenotype which emerges because distinct
DRG were implicated in ventral and dorsal focused
damage. In fact, the dichotomous innervation may
explain the disparity in the results across all rat models
of disc degeneration as some models induce more
comprehensive degeneration than others [199, 200].

Figure 31. Overview of the
injury refinement

Provided the knowledge of IVD and rat whole
body innervation, an injury procedure was created that
would result in comprehensive, IVD-wide, tissue
disruption. To accomplish this, an array of injury
procedures were trialed on rat cadavers, starting with
syringe puncture and progressing to puncture and
scrape with a dissecting needle (Fig. 31). The

Figure 31. Overview of the injury
refinement. (A) Undamaged IVD.
(B) Over damaged IVD. (C) Ideally
damaged IVD. Scale bar = 3 mm.

refinement process entailed damaging 85 motion
segments to various degrees using needles of various diameter and mechanical agitation.
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The outcomes from this process were evaluated using a semi-quantitative measurement
scheme for total disc damage. The semi-quantitative analysis measured aspects of the
injury like, NP damage, ventral AF damage, dorsal AF, damage, and end plate damage to
determine a procedure that minimized
Normalized Disc Volume

damage to the end plate and maintained

of this process, the 1-scrape and 6scrape methods were chosen because
they caused comprehensive tissue
damage, did not core the tissue, and
posed little risk to errantly damage the
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damage to the NP and AF. At the end
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Figure 32. Normalized disc volume
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Figure 32. Normalized disc volume from the model of
disc-associated pain before and after injury surgery

end plates. Confirming this choice, the 1-scrape and 6-scrape injury were highly effective
in the animal model at inducing disc degeneration, with all injured animals exhibiting a
dramatic loss of disc volume after surgery (Fig. 32).
Concommitant with the initiation of this 2020 animal study, alternate assays of
measuring pain-like behavior were considered to increase the chance that pain-like
differences could be detected. Evidence in the literature in mouse models of spontaneous
and induced disc-associated pain suggested grip strength could be useful [291, 292].
Thus, this assay was added as an additional pain-like assay to those employed in the 2019
pilot study. Complimenting the prior work in mice, the grip strength assay proved highly
sensitive at detecting axial hypersensitivity due to disc degeneration in rats in our model
(Fig. 33). Intuitively, it may not be clear how IVD degeneration results in decreased
forelimp grip strength. However, its reasonable to assume that increasing axial strain on
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the IVD causes mechanically
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sensitive nociceptors to depolarize.

inhibitory effects on the maximum
grip strength an animal is willing to
endure, causing them to release the
grip plate at a lower force. To our
knowledge, this work was the first to
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Figure 33. Raw grip strength from the model of discassociated pain before injury surgery and 18-weeks after

describe persistent increased axial hypersensitivity in rats caused by disc injury and
degeneration. It could be valuable in the future to also collect hindlimb grip strength
considering the hindlimps are closer to the level of degeneration, however, this may
prove more difficult as rats are less apt to reliably grip the plate in this manner [347].
Another major goal of this 2020 animal study was to measure degenerative
changes in the disc. Two important assessments were the analysis of nerve sprouting and
macrophage infiltration in the degenerated IVD tissue. Existing literature indicated there
would be nerve sprouting in degenerated tissue but the quality of this prior evidence and
a lack of consensus suggested there was value in confirming nerve sprouting in our model
[71, 79, 118, 348]. Complimenting prior literature, widespread nerve sprouting was
visualized in degenerated tissue, especially around the site of needle insertion [310].
Furthermore, a significant correlation between axial hypersensitivity, as measured by the
grip strength assay, and the degree of nerve sprouting, was imputed, suggesting nerve
sprouting plays a causal role in the manifestation of disc-associated pain. Evidence in the
literature also implied that macrophages would be abundant in degenerated disc tissue
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[349-351]. Suprisingly, little evidence of macrophages was found in degenerated IVD
tissue despite using multiple antibody targets and concentrations. However, macrophages
were visualized in skin tissue which indicated the antibodies worked. These observations
indicated there were indeed no macrophages in degenerated disc tissue at the terminal
timepoint in our study, however, macrophages may have been present at earlier time
points and diminished over the 18-week post injury. This finding was of personal interest
because early work in this Ph.D. had been spent trying to modulate macrophage
phenotype using decellularized tissue with the end goal of using decellularized tissue to
treat macrophages implicated in disc degeneration. This discovery caused a realization of
three things. First, scientific literature is not always correct and the most robust data is
that which has been replicated across multiple groups. Second, in vitro analyses do not
always replicate how processes unfold in vivo. Third, macrophages do not play a large
role in late stage disc degeneration in our model, and thus, do not represent a therapeutic
target for disc-associated pain at chronic time points.
There are several aspects of this animal model that could be expanded or
improved in future work. First, spontaneous pain-like behavior assays could be improved
and more could be included. Because we only detected differences in evoked pain-like
behavior, there is still a strong need for a spontaneous measure of pain-like behavior.
Data from the Open Field Test was highly variable, limiting the power to detect
differences, if there were any. One source of error noted in the first animal study, was
uneven overhead lighting cause by imperfect alignment of the arenas’ centerpoint with
the overhead light source. The uneven overhead lighting caused asymmetric lighting
among the four arenas which animals were placed. In half of the arenas, a large portion of
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the floor was dark, causing the animals to preferentially reside in this area replicating a
light-box dark-box experiment. Because this phenomenon only occurred in two of the
four arenas, bias was introduced into the outcome. However, this factor was removed in
the treatment study. Another source of error that could be removed in future studies from
the open field test is the presence of human observers in the room during data collection.
Due to the allocation of a single room, all behavior had to be performed in one location.
For this reason, animals in the open field test were exposed to human talking, human
smells, doors closing, and other animal vocalizations during data collection. These factors
may have had a larger impact on animal spontaneous behavior than the pain caused by
disc degeneration.
In future work, additional measures of spontaneous pain-like behavior like gait,
grimace, and operant conditioning could be included [141]. If these methods are pursued,
the power analysis used to determined n size should be computed using the assay with the
largest standard deviation to improve the likelihood that significant differences can be
detected.
Another aspect of pain-like data that should be addressed involves error in evoked
assays. Evoked pain-like behavior assays are imperfect in animal studies because they
involve an experimenter which subjects outcomes to unintentional bias. An interesting
aspect in the collection of evoked pain-like behavior is the balance between experimenter
empathy and apathy. Experimenter empathy is required because animals perform best
under relaxed conditions [352]. For this reason, an experimenters ability to appraise
animal affect, and treat the animal gently to minimize stress is imperative for behavioral
data collection. Conversely, experimenters are also asked to subject animals to chronic
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pain and disallow the pain-like suffering in animals from biasing how an animal is
treated. Maintaining unbiased measurements of animals can be particularly difficult,
especially when animals display overt signs of distress. For example, some animals
during the grip strength assay, especially those which are injured, exhibit heightened fear
responses to the assay apparatus. This manifests as erratic, energetic, and desparate
avoidance of the grip plate. However, a grip strength must be collected so these animals
are subjected repeatedly to the grip plate, further amplifying the stress. This forced
reapplication of animals, despite overt signs of suffering, requires apathy from the
experimenter to complete. It stands to reason that differences between animals which
willingly grip the force plate and animals which exhibit aversive behavior are amplified
due to the experimenters empathetic desire to minimize animal suffering. Furthermore,
over the course of any animal study, experimenters become familiar with invididual
animals, and may develop individualized relationships. However, at study conclusion,
experimenters may be asked to personally euthanize these animals and treat them as a
biological sample, resulting in cognitive dissonance. The requirement for experimenters
to exhibit both empathy and apathy, which are diametric, necessitates further use of
spontaneous pain-like assays in animal models.
Analysis of degenerated IVD tissue sections could also be expanded in the future
to greatly benefit our understanding of pathomechanisms of disc degeneration. The
preponderance of cellularized granulation tissue along the degenerated IVD’s perimeter
raises questions as to the cell type, inflammatory state, and function of this tissue.
Additionally, IHC processing or more careful analysis in H&E could shed more light on
these unknowns. Further, modes of nociception could be revealed by determining the
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type of nerve fiber present in the disc using markers specific for fiber types, like IB4,
CGRP, SP, etc [79]. Furthermore, the origin of these nerve fibers, i.e., whether some
might be extensions of the sympathetic nervous system, could be determined by staining
for tyrosine hydroxylase [353]. Finally, it would be useful to understand if the
hypocellularity of the disc is a result of necrosis, apoptosis or a combination. This could
be accomplished using IHC, to measure markers of apotosis and necrosis like Annexin V
and receptor-interacting serine/threonine-protein kinase 3 (RIPK3), respectively [354,
355]. Understanding this aspect of degeneration would provide insights into whether
deleterious loading or nutrient deficiency plays the predominant role in driving cell death.
In summary, Chapter 5 outlines a robust model of disc-associated cLBP. This
model came to fruition through lessons learned in a failed pilot study, evidence in
literature, and understanding of rat neuroanatomy. The manifestation of overt disc
degeneration, chronic pain-like behavior, and nerve sprouting cements this as a leading
model. As always, more could be done to improve the model’s readouts and to explore
more pathomechanisms of disc-associated pain.

7.3 Chapter 6 Discussion and Future Directions
The final Chapter of this dissertation described the engineering of a therapeutic
for low back pain in vitro and its capacity to alleviate disc-associated pain in vivo. This
final study represented the culmination of all the work completed from the start of the
Ph.D. to the end. Critical motivation for this work arose from observations made during
the establishment of the disc-associated pain model. After staining and imaging with
H&E, it became clear that degeneration resulted in widespread loss of tissue integrity
(Fig. 34). Because we witnessed consistent staining of nerve fibers around annular
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fissures and other
tissue disruptions,
we hypothesized

Figure 34. H&E stained section of an injured IVD from
our rat model of disc-associated pain

altered
biomechanics
may drive

Figure 34. H&E stained section of an injured IVD from the rat model of discassociated pain. Notice the loss of tissue integrity on the right side (ventral AF).

nociception and in turn pain. The basis for this hypothesis was that mechanically
sensitive nerve fibers located in sites of tissue integrity loss, may be subjected to
deleterious loading, resulting in depolarization and nociception. Supporting this
hypothesis, grip strength, which indirectly strained the disc and may have imparted
deleterious loading, was the most sensitive measure of pain-like behavior.
At the conclusion of the disc-associated model study, our lab also published data
on a biomaterial derived from decellularized healthy NP tissue. In this paper, the
biomaterial was amenable to injection, not cytotoxic, and partially neuroinhibitory [235].
Establishing the methods for fabricating this biomaterial and measuring its properties
comprised the first two years of my Ph.D. Having worked with this biomaterial
extensively, and knowing mechanics might be at the core of disc-associated pain, it was
decided to re-engineer this biomaterial specifically for tissue integration and IVD
stabalization.
In early work, it was realized that fabricating a hydrogel soley from decellularized
tissue was not feasible, with early formulations unable to form a complete hydrogel.
Collagen was added to the formulation to amplify fibrillogenesis and mechanical
properties. An iteration of dNP supplemented with collagen comprised what was
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described in the biomaterial paper we published. However, this biomaterial was deemed
suboptimal for treating disc-associated pain in vivo because it would not robustly
integrate with existing tissue, decreasing its capacity to augment deleterious loading. To
resolve this limitation, the dNP biomaterial was supplemented with a crosslinking agent
to promote integration.
The first crosslinking agent tested was lysyl oxidase (LOX), an endogenous
enzyme known to crosslink collagen [244]. This enzyme is known to play a key role in
tissue sclerotization, and therefore seemed a great candidate for integrating the
biomaterial and rigidifying the IVD. Unfortunately, LOX only increased the mechanical
properties of dNP hydrogel by around 30% after prolonged exposure, indicating the
cross-linking activity was either too low or not rapid enough to ensure biomaterial
integration. Genipin was next to be evaluated and exhibited a remarkable capacity to
increase dNP mechanical properties (Fig. 35) [251]. Further, genipin completed 90% of
its crosslinking in under 12 hours
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genipin, exhibited cytocompatibility, and still dramatically increased dNP mechanical
properties suggesting there was a high degree of crosslinking activity.
Having chosen the final formulation, dNP+, the next problem solved was the
injection procedure. This process was refined using trial and error on rat cadavers and
involved insulin syringes, syringe pumps, microinjectors, and gas chromatography
microliter syringes. Insulin syringes could not adequately control the small injection
volume, syringe pumps were too wasteful because of hydrogel lost in the pump line and
the microinjector was not feasible because of it’s size and requirement for a new syringe
for each injection. With these limitations, the gas chromotography syringe represented
the only viable option for controlled, minimally wasteful, injections. However, dNP+ was
too viscous to be drawn up by these syringes making them unusable. A solution was
found by removing the syringe plunger and injecting the gel from the back end of the
syringe. Next, to ensure the dNP+ was delivered to the middle of the disc, and did not
overpenetrate, the syringe needles used for injection were affixed with a rubber stopper
on the needle to control the injection depth. Initially, this final system did not reliably
adminster dNP+ to the disc but rather leaked dNP+ around the needle hub. After more
trial and error, we realized that the injection speed had to be slowed to allow time for the
disc to expand and accommodate the gel. In future work, air-tight syringes with luerlocking hubs may further decrease the risk of injectate extrusion around the needle hub
and provide more consistent injectate volumes.
Another major decision concerned the time at which degenerated IVDs would be
treated in vivo. DNP+ was viewed as a treatment that might be used for humans suffering
chronic disc-associated pain. Therefore, we reasoned the only permissible time to treat
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IVDs with dNP+ would be at a chronic time point, after pain-like behavior had
developed. In our model, this occurred by week 8, so treatment was administered at week
9. This treatment strategy contrasted nearly all work that has been done in animal models
of chronic low back pain where most treatments occur concomittant or shortly after
degeneration induction [221].
Given all the work developing the biomaterial and refining the injection
procedure, it appeared dNP+ might be capable of treating disc-associated pain despite the
overwhelming majority of treatments from other groups failing in animal models.
Confirming this outlook, the treatment worked, restoring disc volume and alleviating
axial hypersensitivity at all time points after administration. Further, at study conclusion,
mechanics of dNP+ treated discs did not significantly differ from sham discs while sham
discs did significantly differ from discs treated with PBS. Currently, it is not clear what
caused this increase in mechanical properties because dNP+ was orders of magnitude
weaker than disc tissue meaning that the addition of dNP+ alone could not have increased
disc mechanics dramatically. The current hypothesis is that dNP+ reconnected tissue
disruptions, permitting migration and localization of cells like fibroblasts to these sites
which deposited new matrix to stabalize the disc. The dNP+ treatment may have also
worked through an immunomodulatory capacity to promote tissue anabolism considering
it is derived from healthy, decellularized tissue [226-229]. An alternative explaination is
that genipin diffused from the hydrogel and crosslinked existing, degenerated tissue,
stabalizing it. Overall, this process may have resolved deleterious loading and
transformed the disc from unstable catabolism to stable, fibrotic, homeostasis. These
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results indicated that mechanics may have underpinned the decrease in axial
hypersensitivity.
This study has several areas that could be expanded or refined in future work.
First, the cytocompatibility assessment in vitro did not entirely evaluate the effect of free
genipin released from dNP+ hydrogels. Because dNP+ required eight hours to complete
crosslinking, it was not feasible to plate cells on top of it prior to gelation completion.
Additionally, during the incubation window there was some concern the gels could
partially dry, resulting in erroneous outcomes. These two factors made it so the plates had
to be coated with gels, incubated for 8 hours and then equilibrated with 1X PBS
overnight prior to cell seeding. The 1X PBS equilibration step may have removed a
significant fraction of free genipin, if there was any. In the future, cells could be cultured
in proximity of dNP+ gels made separately or the dNP+ coated wells could be
equilibrated with 1X PBS containing 2.5 mM genipin to address this limitation.
Another process that could be refined is the potting and mechanical evaluation of
rat motion segments. For all mechanics, we simply measured motion segments using an
amplitude sweep which measured the resistance to an increasing torsional strain. This
method does not answer questions involving the neutral zone, stress-relaxation, nor creep
behavior of the motion segments. Considering there is evidence in the literature that these
aspects of motion segments change with degeneration, they represent valuable,
quantifiable metrics of motion segement mechanics [75, 156, 168, 174]. In the future,
tension displacement curves could be collected on a rheometer and analyzed to determine
torsional stiffness, torque range, tosional hysteresis, and neutral zone [2, 325]. These data
could provide insight into functional changes which coincide IVD degeneration and
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provide targets for treatments. Furthermore, the potting process could be refined by
making uniform cuts in the vertebral bone, a preset distance away from the IVD.
Uniformity in this process would ensure that all motion segments are potted in a similar
manner and that they are all of equal length. In the treatment study, a significant portion
of the motion segments had to be discarded because the vertebral bodies were cut far
from the IVD, making them unstable during the potting process. This instability caused
these motion segments to detach from the pot, prolonging the potting process, eventually
leading to tissue dessication which made collecting mechanical properties not feasible.
Finally, considerable work must yet be done processing motion segments into
tissue sections to evaluate morphological and other aspects of degenerated and sham
IVDs in this study. The first and foremost of the next steps should be H&E analysis.
H&E will provide invaluable insight about the location of dNP+ within the degenerated
tissue and may shed light on the effects dNP+ had on tissue necrosis and granulation
deposition. IHC for nerve fibers may also be pursued to determine if dNP+ maintained
neuroinhibitory capacity in vivo and prevented further nerve sprouting, or in best case,
caused dieback of nerve sprouts.
In conclusion, this final chapter, explored the utility of a decellularized
biomaterial, doped with collagen and genipin, as a treatment for disc-associated pain in
an animal model. After thorough engineering, the dNP+ therapeutic proved viable as an
injectable treatment that was spontaneously fibrillogenic and not cytotoxic. When applied
to animals suffering disc-associated pain, dNP+ restored disc volume and alleviated axial
hypersensitivity. These observations indicate that dNP+ is an effective treatment for disc-
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associated cLBP in an animal model, but further work must be completed prior to
disseminating these results or pursuring further animal trials.
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CHAPTER 8: Personal Summary
Taken together, the chapters of this dissertation represent the distillation of five
years of failure, learning, and success. Chapter 4 was the first exploration into animal
models and animal data. From this I learned how to understand animals, work with
variability inherent with in vivo data, and how to refine processes to provide maximum
utility. Chapter 5 built upon the experience gathered in Chapter 4 and facilitated growth
in managing timelines, groups of people, and complex, time-constrained, procedures.
Chapter 5 also marked the turning point of my Ph.D., where I took on the projects
personally, and the burden of success or failure became my own. Chapter 6 was the
culmination of all that was learned throughout the pursuit of a Ph.D. This final work
blended all the experience I had gathered into one task. Without all the past success,
failures, and learning experiences, I would not have been equipped to attempt, much less
succeed, in this final Chapter. I am grateful to have collected this experience and
knowledge over the course of this Ph.D. I hope the work accomplished in and outside of
this dissertation has expanded the frontier of understanding and will provide utility for
future scientific work.
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CHAPTER 9: Conclusion
The primary goal of this dissertation was to engineer a therapeutic for discassociated low back pain. To do this, a method for quantifying disc degeneration realtime and a model of disc-associated pain were established in female Sprague Dawley rats.
After this foundational work, a biomaterial, derived from decellularized porcine IVD
tissue, was created and tested in vitro and in vivo.
Chapter 4 described a method for processing three-dimensional µCT data to
create three-dimensional renderings of intervertebral discs. This method was extremely
sensitive in detecting changes of the IVD and provided a state of the art means to monitor
disc degeneration real time.
Chapter 5 established a novel and robust model of disc-associated pain. This
model manifested consistent and increasing chronic axial hypersensitivity and deep
pressure hypersensitivity at the L5-L6 level. Furthermore, this was the first rat model to
demonstrate nerve fibers penetrating deep into degenerated disc tissue and the first to
positively associate nerve sprouting with pain-like hypersensitivity. The presence of painlike behavior across two assays in concert with aberrant nerve sprouting solidified this
model as a leader in the field of biomedical research.
Chapter 6 outlined the creation of a biomaterial derived from decellularized,
healthy NP tissue, supplemented with collagen and genipin. In our animal model, this
novel biomaterial treatment increased exploratory behavior in the open field test,
decreased axial hypersensitivity, and prevented the development of deep pressure
hypersensitivity. Additionally, immediately after treatment, disc volumes in treated
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animals returned to baseline and remained at baseline for the remainder of the study,
suggesting complete tissue-biomaterial integration.
In sum, this dissertation outlines a platform for evaluating therapeutics and
provides a strong treatment candidate for disc-associated pain.
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